Identification and characterization of phage displayed, SC binding peptides, with potential for use in pIgR mediated mucosal targeting by Sandvik, Anders
 1
 
 
 
 
 
 
Identification and characterization 
of phage displayed, SC binding peptides, 
with potential for use in pIgR mediated mucosal targeting 
 
 
Anders Sandvik 
 
 
Thesis for the degree of Cand.scient in Molecular Cell Biology 
 
Division of Cell and Molecular Biology, 
Department of Molecular Bioscience, 
University of Oslo 
2003 
 2
CONTENTS 
PREFACE 5 
ACKNOWLEDGEMENT 6 
ABBREVIATIONS 7 
GENERAL OUTLINE OF THE IMMUNE SYSTEM 8 
INNATE IMMUNITY 8 
CELLS AND CELLULAR EFFECTOR MECHANISMS OF THE INNATE IMMUNE SYSTEM 9 
THE COMPLEMENT SYSTEM: AN OVERVIEW 11 
ADAPTIVE IMMUNITY 15 
LYMPHOID TISSUE; BIRTH PLACE AND PLAYGROUND OF LYMPHOCYTES 15 
MHC-MOLECULES; A BRIEF INTRODUCTION TO ANTIGEN PRESENTING TOOLS 17 
T-LYMPHOCYTES; DEVELOPMENT, ANTIGEN RECOGNITION AND EFFECTOR FUNCTIONS 19 
B-LYMPHOCYTES; DEVELOPMENT AND IMMUNOGLOBULINS 22 
ANTIBODY STRUCTURE AND FUNCTION; A BRIEF INTRODUCTION 24 
FC RECEPTORS; ANTIBODY DOCKING STATIONS, TRANSPORTERS AND MAINTAINERS 27 
CATALYTIC ACTIVITY OF ANTIBODIES; NOVEL EFFECTOR FUNCTIONS 27 
REFERENCES 29 
ANTIBODY ENGINEERING 31 
INTACT ANTIBODIES; POTENTIAL AND CHALLENGES 31 
GENETICALLY MODIFIED AB FRAGMENTS; HARMLESS TARGET BINDERS? 32 
FUNCTIONAL ANTIBODY FRAGMENTS: TARGET RECOGNITION AND ELIMINATION 33 
ENGINEERED ABS IN VACCINE DEVELOPMENT: RIGHT ON TARGET WITH TROYBODIES 34 
REFERENCES 35 
INTRODUCTION 36 
1. MUCOSAL IMMUNITY 36 
1.1 INNATE MUCOSAL IMMUNITY; PHYSICAL AND CHEMICAL BARRIERS 36 
1.2 ADAPTIVE MUCOSAL IMMUNITY 37 
2. FILAMENTOUS BACTERIOPHAGE AND PEPTIDE DISPLAY LIBRARIES 42 
2.1 FILAMENTOUS BACTERIOPHAGE: STRUCTURE AND BIOLOGY 43 
2.2 PHAGE DISPLAY IN THE FUSE5 SYSTEM 44 
2.3 AFFINITY SELECTION; FINDING THE NEEDLE IN A MOLECULAR HAYSTACK 45 
3. TARGETING PIGR: SPECIFIC DELIVERY TO EPITHELIA AND MUCOSA 48 
REFERENCES 49 
 
 
 
 3
MANUSCRIPT 52 
ABBREVIATIONS 53 
1.  ABSTRACT 54 
2.  INTRODUCTION 55 
3. MATERIALS AND METHODS 58 
3.1 PHAGE DISPLAY LIBRARIES, PHAGE CLONES, PLASMIDS AND BACTERIAL STRAINS 58 
3.2 PREPARATION AND TRANSFORMATION OF ELECTROCOMPETENT E.COLI CELLS 58 
3.3 PHAGE TITRATION, AMPLIFICATION AND PROPAGATION OF SINGLE CLONES 59 
3.4 AFFINITY SELECTION FOR SC BINDING, PEPTIDE DISPLAYING, PHAGES 61 
3.5 PHAGE ELISA 62 
3.6 PHAGE ELUTION-TITRATION STUDY 62 
3.7 PHAGE SEQUENCING 63 
3.8 INHIBITION OF PHAGE BINDING TO SC 64 
3.9 TRANSCYTOSIS OF PHAGE ACROSS PIGR TRANSFECTED MDCK CELLS 65 
3.10 AMINO ACID SUBSTITUTION MUTATION ANALYSIS 65 
3.10.1 PRODUCTION OF INSERTS ENCODING AMINO ACID SUBSTITUTED PEPTIDES 65 
3.10.2 GENERATION OF PHAGE EXPRESSING AMINO ACID SUBSTITUTED PEPTIDES 67 
3.10.3 EFFECT OF AMINO ACID SUBSTITUTIONS ON SC BINDING CAPACITY 68 
3.11 CONSTRUCTION OF GFP FUSION PROTEINS 69 
3.11.1 PRODUCTION OF GFP-FUSION ENCODING INSERTS 69 
3.11.2 LIGATION INTO PET21D, AND TRANSFORMATION OF E.COLI BL21DE 71 
3.11.3 PLASMID ISOLATION, RESTRICTION ANALYSIS AND SEQUENCING 72 
3.11.4 CORRECTION OF DELETION IN PEPTIDE DIMER FUSION TO GFP 72 
3.12 BACTERIAL EXPRESSION OF GFP FUSION PROTEINS 72 
3.12.1 BACTERIAL CELL GROWTH AND INDUCTION OF PROTEIN EXPRESSION 73 
3.12.2 FLUORESCENCE MICROSCOPY AND CELL LYSIS 73 
3.12.3 SDS PAGE 73 
3.12.4 WESTERN BLOTTING 74 
3.12.5 AMMONIUM SULPHATE PRECIPITATION 74 
3.13 TARGET BINDING CAPACITY OF GFP FUSION PROTEINS 74 
3.13.1 TARGET BINDING DETERMINED BY FLUORESCENCE MEASUREMENT 75 
3.13.2 TARGET BINDING DETERMINED BY ELISA 75 
4.  RESULTS 76 
4.1 AFFINITY SELECTION 76 
4.1.1 SCREENING THE AMPLIFIED ELUATES FOR SC BINDING PHAGES BY ELISA 78 
4.2 SCREENING FOR SINGLE CLONES DISPLAYING SC BINDING PEPTIDES 79 
4.2.1 INITIAL HIGH THROUGHPUT SCREENING FOR SC BINDING SINGLE CLONE PHAGES 79 
4.2.2 SCREENING OF SELECTED POSITIVE INDIVIDUAL CLONES IN A CONFIRMATIVE ELISA 80 
4.2.3 SEQUENCING OF SELECTED SC BINDING PHAGE 82 
4.3 INHIBITION OF PHAGE BINDING TO SC BY PIGA, PIGM AND SPSA FRAGMENTS 83 
4.4 TRANSCYTOSIS OF SC BINDING PHAGE ACROSS PIGR TRANSFECTED MDCK CELLS 84 
4.5 DETERMINATION OF THE CONTRIBUTION OF EACH C9-4 AMINO ACID ON SC BINDING 85 
4.5.1 SEQUENCING OF ALANINE/SERINE SUBSTITUTION MUTATED C9-4 86 
4.5.2 EFFECT OF AMINO ACID SUBSTITUTIONS ON BINDING TO SC AS DETERMINED BY ELISA 86 
4.5.3 EFFECT OF AMINO ACID SUBSTITUTION ON SC BINDING, DETERMINED BY ELUTION-TITRATION  87 
 4
4.6 CONSTRUCTION AND EXPRESSION OF GFP FUSION PROTEINS  89 
4.6.1 CONFIRMATION OF FUSION PEPTIDE SEQUENCES 89 
4.6.2 PROKARYOTIC EXPRESSION OF GFP FUSION PROTEINS 90 
4.6.3 AMMONIUM SULPHATE PRECIPITATION OF GFP LYSATE 92 
 
4.7 TARGET BINDING CAPACITY OF GFP FUSION PROTEINS 93 
4.7.1 STANDARDIZATION OF LYSATE FLUORESCENCE INTENSITY 93 
4.7.2 BINDING TO SC AS DETERMINED BY ELISA AND FLUORESCENCE MEASUREMENT 94 
4.7.3 BINDING TO C1Q AS DETERMINED BY ELISA AND FLUORESCENCE MEASUREMENT 95 
5. DISCUSSION 97 
6. REFERENCES 107 
7.  APPENDIX 111 
 
 
 
 
 5
Preface 
 
This thesis attempts to communicate basic knowledge about the immune system and how it can be 
modulated for potential use in modern medicine.  Furthermore, based on that introduction, the 
thesis presents recent research related to mucosal immunology.  The thesis comprises four 
separate, though interrelated parts: 
• General outline of the Immune system 
• Antibody engineering 
• Introduction 
• Manuscript 
 
Part I, General outline of the Immune system, gives a brief introduction to the components, the 
organization, and effector mechanisms of the immune system.  This part is intended for readers 
without training in immunology.  My aim is to provide the reader with basic insight in the 
importance of the immune system and the prospective of capitalizing on our native defence 
systems in modern medicine.  An introduction to immunological terminology and basic 
comprehension of the immune-biology is clearly essential for efficient communication of the 
ideas, results and discussion presented in this thesis.      
 
Part II, Antibody engineering, gives an introduction to promising technology based on 
engineering and alternative production of antibodies.  Recombinant antibodies and fragments of 
such show immense potential in therapeutic and diagnostic applications and as research tools.  
The available technology, prospects for the future and the limitations of this technology is given 
some attention as the research group, from which this work originates, has its focus on antibody 
modulation.  Thus, a brief introduction to this exciting topic facilitates the communication and 
understanding of the work presented herein.    
 
Part III, Introduction, gives a focused introduction to mucosal immunity, the use of phage 
display libraries in general and fUSE5 based systems in particular.  Furthermore targeting of 
mucosal sites via the polymeric Ig-receptor is discussed.  The theoretical basis for the work 
presented in the enclosed manuscript is dealt with in some detail in this section.   
 
These three sections are based largely on recent review articles.  Interested readers are referred to 
these for further background information and links to original work. 
 
Part IV, Manuscript, concludes this thesis.  ”Identification and characterization of phage 
displayed, SC binding peptides, with potential for use in pIgR mediated mucosal targeting”, 
presents the work I have conducted for the academic degree of Cand.scient.   
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Abbreviations  
 
Aa, Amino acid  
Ab(s), Antibody (ies) 
ADCC, Antibody-dependent cell-mediated 
cytotoxicity 
APC(s), Antigen presenting cell(s)  
BALT, Bronchial-associated lymphoid tissue 
BCR(s), B-lymphocyte receptor(s) 
BPI, Bacterial permeability inducing protein 
C, Constant region 
CD, Clusters of differentiation  
CDR(s), Complementarity-determining region(s) 
CH, Heavy chain constant region  
CL, Light chain constant region 
CR(s), Complement receptor(s)  
C-terminal, COOH-terminal 
CTL(s), Cytotoxic effector T-lymphocyte(s) 
D, Diversity region 
DC(s), Dendritic cell(s) 
DH, Heavy chain diversity region 
Fab, Fragment antigen binding 
FcγRs, IgG Fc receptors 
Fc, Fragment crystallisable      
FcRn, Neonatal Fc receptor 
FcRs, Fc receptors 
Ff, F-pilus dependent filamentous phages  
fSC, Free SC  
Fv, Fragment variable 
GALT, Gut-associated lymphoid tissue  
HLA, Human leukocyte-associated antigens 
Ig(s), Immunoglobulin(s) 
IL(s), Interleukin(s) 
ITAM(s), Immunoreceptor tyrosine-based 
activation motif(s) 
 
J, Joining segment 
JH, Heavy chain joining segment 
JL, Light chain joining segment 
mAbs, Monoclonal Abs 
MAC, Membrane attack complex 
MALT, Mucosa associated lymphoid tissue 
MASP(s), MBL-associated serine protease(s) 
MBL, Mannan-binding lectin  
MC(s), Mast cell(s)  
MDCK, Madin-Darby canine kidney 
MHC, Major histocompatibility complex  
NK cell(s), Natural Killer cell(s) 
N-terminal, NH2-terminal 
PALS, Periarteriolar lymphoid sheath 
PAMP(s), Pathogen associated molecular 
pattern(s)   
PCR, Polymerase chain reaction 
pIgA, Polymeric IgA  
pIgR, Polymeric immunoglobulin receptor 
pIgs, Polymeric Igs 
RF, Replication form 
sAbs, Secretory Abs 
SC, Secretory component  
scFv, Single chain Fv 
sIgA, Secretory IgA  
sIgM, Secretory IgM 
ssDNA, Single stranded DNA  
TBR, Target binding region   
TCR(s), T-lymphocyte receptor(s) 
TLR(s), Toll-like receptors  
V, Variable region 
VH, Heavy chain variable region 
VL, Light chain variable region  
 
 8
General outline of the Immune system 
Our body is facing a constant challenge against disease causing agents, collectively known as 
pathogens.  Four broad categories of pathogens are now recognized.  These are viruses, 
bacteria, pathogenic fungi, and other relatively large and complex eukaryotic organisms 
collectively termed parasites.  Every second we exist; some opportunistic invader (bacteria, 
virus, fungi or parasites) is trying to make a meal or breading ground of our body.  If properly 
functioning, our immune system keeps these relentless invaders at bay with its incredible 
array of weapons.  Distributed throughout the body, the immune system represents our 
"armed forces."   
 
The immune system is a complex network of lymphoid tissue, cells, humoral factors and 
cytokines that interact to eliminate foreign invaders, pathogens and altered self, i.e. cancer.  
Host defence against the broad variety pathogens constantly present in our environment, 
requires dramatically different responses, depending on the character of the pathogen and on 
the tissue under attack.  Central to the immune system's ability to mobilize a response to an 
invading pathogen is its sophisticated biologic ability to distinguish self from non-self and 
altered-self.  We have evolved both innate and adaptive mechanisms to respond to and 
eliminate pathogens.  Both of these branches of the immune system, further discussed in the 
next sections, rely on self-, non-self discrimination.  A key feature of the adaptive response is 
that it produces long lived cells that can, upon re-challenge with the antigen, re-express 
effector mechanisms.  This immunological memory provides the host with a specific and 
efficient defence when it encounters the pathogen a second time.  It is of critical importance, 
that the powerful, destructive effector mechanisms of the immune system are not attacking the 
host’s own cells.  Avoidance of destruction of self-tissues is referred to as self tolerance.  The 
broad class of autoimmune diseases are caused by failure of self-tolerance.    
 
Innate immunity  
The term innate immunity encompasses granulocytes, monocytes, macrophages, dendritic 
cells, mast cell, natural killer cells, complement, cytokines and acute phase proteins.  Physical 
barriers such as epithelial cell layers and mucosal surfaces in the gut, respiratory- and 
urogenital tract are also sometimes considered part of the innate immune system.   
 9
Chemical- and antimicrobial barriers are also included in some definitions of innate 
immunity.  These highly conserved defensive measurements of the immune system have 
evolved in even the simplest animals. 
Cells and cellular effector mechanisms of the innate immune system  
The innate immune response lacks specificity, it is rapid and is considered to be the first line 
of defence.  Immune responses depend largely upon the activities of white blood cells, or 
leukocytes.  All leukocytes derive ultimately from the same hematopoietic stem cells.  The 
different leucocytes are classified both by morphology and by surface phenotype as 
determined by registered differentiation antigens known as clusters of differentiation (CD).   
Innate immunity largely involves cells derived from myeloid progenitors.   
 
Granulocytes, also called polymorphonuclear leukocytes, are a diverse collection of white 
blood cells including the phagocytic neutrophils.  Neutrophils, short-lived, migrating and 
well-armoured cells are possibly the most important cellular, component of the innate immune 
system.  They detect the presence of pathogens through germ-line encoded receptors that 
recognize pathogen associated molecular patterns (PAMPs).  In vertebrates, the best 
characterized class of these receptors are Toll-like Receptors (TLRs) (reviewed in Takeda et 
al., 2003; Underhill, 2003).  Interaction between PAMPs and the surface receptors of the 
phagocytic cells triggers the cells to engulf the pathogen they have encountered.  
Phagocytosis by neutrophils involves additional important receptor classes:  Fcγ receptors 
(FcγRIIA /CD32, and FcγRIIIB/CD16) and complement receptors (CR1 /CD35 and 
CR3/CD11b/CD18 integrin).  Neutrophils hold an impressive arsenal of antibiotic enzymes, 
such as acidic hydrolases, myelo peroxidase and lysozyme and antibacterial proteins such as 
defensin and bacterial permeability inducing (BPI) protein.  They also possess membrane 
bound compartments containing highly reactive, cytotoxic oxygen species, such as hydrogen 
peroxide and singlet oxygen used to fight invaders.  Neutrophils are both a target and a source 
of various cytokines, chemokines, and growth factors (Witko-Sarsat et al., 2000, review).  
Cytokines are secreted proteins that affect the behaviour of other cells that bears receptors for 
them. Cytokines produced by white blood cells mainly work on other leucocytes and are 
collectively called interleukins (ILs).  Chemokines are chemo attractants that recruit cells with 
chemokine receptors.   
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Circulating monocytes differentiate to become macrophages when they leave the blood and 
migrate towards sites of infection or inflammation.  Macrophages are widely distributed, 
mononuclear, phagocytic cells.  They are equipped with Fc Receptors, complement receptors 
and TLRs that enable them to recognize and engulf pathogens.  Macrophages show 
microbicidal activity much like neutrophils.  In addition they produce cytotoxic amounts of 
nitric oxide (Panaro et al., 2003).  Early after an infection or tissue damage, activated 
macrophages release cytokines and chemokines, giving them an immuno-modulating and 
regulatory role in adaptive immune responses.     
 
Dendritic cells (DCs) are a third phagocytic cell type.  They are bone marrow-derived 
migratory cells that are present in virtually all organs of the body.  Their major role is to 
sample micro environmental antigens, and then to migrate to regional lymph nodes where 
they present processed antigenic peptides to T-cells and initiate adaptive immunity.  DCs 
produce, release and respond to cytokines.  Microbial antigens can stimulate myeloid DCs to 
induce either Th1 or Th2 immune responses (reviewed in Upham, 2003).  The phagocytes of 
the innate immune system provide a first line of defence against many common micro-
organisms, they are essential for the control of common bacterial infections and go on to 
initiate and orchestrate later adaptive responses.  Phagocytosis and killing of pathogens is 
greatly enhanced if the particle to be eliminated is first opsonised.  That is if the pathogen is 
marked for destruction by bound antibodies (Abs) or surface bound soluble proteins such as 
the ones comprising the complement system.  Phagocytosis of opsonised pathogens is 
mediated by Fc-receptors or complement receptors on the surface of the phagocytic cells.   
 
Mast cells (MCs), most widely studied in the context of allergic disease and hypersensitivity 
reactions, differentiate in tissue and are mainly located near small blood vessels.  When 
activated, they release substances that affect vascular permeability and induce inflammation 
(e.g. histamine, serotonine, leucotrienes and prostaglandins).  MCs play a critical role in host 
defence against bacterial infection.  They recognize the products of bacterial infection through 
several surface receptors.  In addition to its protective role, mast cells have homeostatic 
functions.  The cytokines and chemokines produced by mast cells in response to pathogens 
are known to profoundly alter the nature of the innate immune response and its effectiveness 
in eliminating infection facilitate subsequent tissue repair (reviewed in Boyce, 2003; Marshall 
et al., 2003).   
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Basophils, found in circulation, are morphologically and functionally similar to mast cells.  
Like mast cells they posses high affinity receptors for IgE (FcεRI).  Cross-linking of the 
receptors leads to degranulation and release of preformed effector molecules.   
 
Eosinophils mediate host protection against larger parasites, such as nematodes, that can not 
be phagocytosed.  Eosinophils express low affinity receptors (FcεRII) that interact with 
pathogens opsonised with IgE.  Binding to IgE leads to degranulation and release of cytotoxic 
substances onto the pathogen surface.   
 
Natural Killer cells (NK cells) a lineage of lymphoid cells that lack antigen specific 
receptors are part of the innate immune system. These cells circulate in the blood as large 
lymphocytes with distinctive cytotoxic granules.  NK cells scan the host’s cells and 
extracellular environment for abnormalities by means of both inhibiting- and activating 
surface receptors.  Their cytotoxic activity is inhibited by binding to self- MHC I molecules 
on the host’s cell surface.  Down regulated or missing MHC I on the host’s cells, i.e. caused 
by viral infection, trigger the NK cells to kill the target by inducing apoptosis in the infected 
self-cell.  This selection mechanism known as “missing self” activation, allows for NK cells 
to recognize and kill abnormal cells, for example some tumour cells and virus-infected cells 
(Karre, 1981; Karre, 2002, review).  NK cells also hold immunoglobulin receptors (FcRs).  
Binding of Ab coated antigens mediates NK-cells to induce antibody-dependent cellular 
cytotoxicity.  NK cells are thought to be important in the innate immune defence against 
intracellular pathogens and altered self (reviewed in Middleton et al., 2002).    
The complement system: an overview 
Complement was initially discovered as heat-sensitive components of normal plasma that 
enhanced antibody killing of some bacteria. This activity was said to 'complement' the 
antibacterial activity of antibodies, hence the name.  Although first discovered as an arm of 
adaptive immune responses, complement can be activated early in infection independent of 
the presence of antibodies. It is now evident that complement first evolved as part of the 
innate immune system, where it still plays an important role (Nonaka, 2001, review).  The 
complement system (see figure 1) is composed of more than 30 plasma and cell surface 
proteins.  The main goals of complement activation is; firstly to mark targets permanently for 
destruction. Secondly, to recruit other proteins and cells that facilitates target destruction.   
 
 12
Thirdly, to participate directly in destroying pathogens by formation of the membrane attack 
complexes (MAC) on the target, thereby inducing osmotic lysis.  The initiation of the 
complement system triggers a cascade of reactions.  The early components of the cascade are 
serine protease pro-enzymes, also known as zymogens that are sequentially activated by 
limited proteolytic cleavage, thereby amplifying the initial signal.  The cascade can be 
initiated via three known pathways. These pathways depend on different molecules for 
activation, but they converge to generate the same set of effector molecules. 
 
Immune-complexes formed on the pathogen surface by binding of antibodies (IgM and IgG) 
to antigen surfaces initiates the classical pathway.  Binding of multiple Fc-regions to the 
globular heads of C1q, a subcomponent of C1, a component of the complement system, 
initiates a cascade of reactions.  Sequential activation of complement components C1, C4 and 
C2 leads to the generation of the key enzyme C3 convertase.  C3 convertase, the enzyme that 
cleaves C3 to C3a and C3b, is the common denominator of all three pathways that 
subsequently goes on to activate the later steps of the cascade.  Host cells express protein 
regulators of complement activation (RCA), which inhibit the complement cascade at the 
C3/C5 convertase step.  On foreign surfaces on the other hand, the C3 convertase is free to 
catalyse substrate cleavage.  C3b bound to the C3 convertase forms a C5 convertase.   C5b 
fragments bind C6 and C7, to form hydrophobic C5b67 complexes that attract C8 molecules 
and insert into the cell membrane.  Finally, further recruitment of C9 molecules leads to 
membrane lesion and cell lysis by formation of a self assembling pore-forming complex 
known as the membrane attack complex (MAC).  During complement activation, fragments 
that act as opsonins and chemo attractants are generated. C4b and C3b, deposited on the 
cascade triggering agent, function as opsonins by binding the complement receptor 1 (CR1) 
on phagocytic neutrophils, monocytes and macrophages, leading to enhanced phagocytosis 
and clearance of pathogens.  Inflammatory molecules, such as C3a, C4a and C5a induce 
smooth muscle contraction and increased vascular permeability, which recruit Abs and 
complement molecules to the infection site. In addition, C5a functions as a chemoattractant 
that directs the migration of phagocytotic cells towards inflammatory tissue.   
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The alternative pathway is initiated by interaction 
between complement inhibitors and microbial 
antigens that cancel out the inhibitory signals.  This 
allows for auto activation of the cascade at the C3 
level to occur. C3 interacts with factor B and factor D 
to generate the alternative pathway C3 convertase. 
 
 The early events of all three pathways involve a series 
of cleavage reactions that culminate in the formation 
of a C3 convertase.  Generation of C3 convertase is 
the point at which the three pathways converge and 
the main effector functions of the complement system 
are generated.  
 
All three C3 convertases cleave component C3 to 
form C3a and the larger C3b.  C3a increase vascular 
permeability allowing proteins, such as Abs, and 
migrating phagocytes to penetrate the tissue.  It also 
works as a chemo attractant.  C3b is deposited on the 
activating pathogenic surface or immune complex.  
This opsonizes the activating antigen for enhanced 
phagocytosis and initiates the formation of a 
membrane-attack complex (MAC).   
 
C5a and C5b are generated by cleavage of C5 by a C5 
convertase formed by C3b bound to the C3 convertase 
(not shown in this simplified diagram). C5a, like C3a, 
is a powerful peptide mediator of inflammation.  
 
Formation of C5b triggers the late events in which the 
terminal components of complement, C6, C7, C8 and 
C9 spontaneously assemble into a membrane-attack 
complex.   MAC forms a pore structure that damages 
the membrane of certain pathogens and there by kill 
them by osmotic lysis.   
 
C4a, generated by the cleavage of C4, prior to the 
formation of C3 convertase, during the early events of 
the classical pathway, hence the *; it is a relatively 
weak peptide mediator of inflammation. Similarly, 
C4b, the large cleavage fragment of C4 (not shown in 
this simplified diagram), is a weak opsonin.  
 
The diagram is based on figure 2.8 in Immunobiology, 
5th ed, Janeway, et al. 
Figure 1.  Overview of the main components  
and effector functions of the complement system.   
 
The classical pathway is initiated by the formation of 
immune complexes on the pathogens surface.  Multimeric 
binding of antibody Fc regions to the globular heads of 
subcomponent C1q activates proteolysis of C1.  C1 
subsequently cleaves C4 and C2 to form the classical C3 
convertase.   
 
The mannose binding lectin pathway (MBL) is activated 
through contact between mannan-containing microbes and 
MBL.  This interaction activates mannan-binding lectin-
associated serine protease 1 and 2 (MASP-1, 2) leading to 
C2 and C4 cleavage.  Once again, C3 convertase is 
formed.  
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The alternative pathway is independent of Abs and is activated by microbial surface 
structures that counterbalance inhibitors of spontaneous complement activation.  The 
alternative pathway is initiated by spontaneous hydrolysis of the internal thioester bond within 
plasma C3, also known as the C3 'tick over' mechanism.  The larger cleavage product C3i, a 
structural and functional analogue of C3b, associates with a protein of the alternative pathway 
called factor B.  Factor D, another protein of the alternative pathway, cleaves the C3b-factor 
B complex to generate the alternative pathway C3 convertase, that subsequently goes on to 
activate later steps in the cascade.  The alternative pathway also amplifies the classical 
pathway of complement activation.  The spontaneously activated complement products 
indiscriminately bind both host and foreign surfaces and may form lytic membrane attack 
complexes.  As mentioned shortly above, host cells are protected from complement lysis by 
membrane bound and soluble proteins that inhibit MAC formation, whereas pathogens lack 
this protection.   
 
The so called lectin pathway is triggered by microbial cell wall components containing 
mannans and other related carbohydrates.  The interaction between pathogenic mannan and 
serum mannan-binding lectin (MBL), a molecule that resembles C1q, activates pro-enzymes 
known as MBL-associated serine protease 1 and 2 (MASP-1, MASP-2).  MASP-1and 2 form 
a protease analogous to the activated C1 protease found in the classical pathway that goes on 
to activate the rest of the complement cascade (reviewed in Walport, 2001a; Walport, 2001b). 
 
Phagocytic cells also play an important role in adaptive immune response by taking up 
pathogens, processing them with proteolytic enzymes and eventually displaying pathogenic 
peptide fragments that can activate T-cell responses.  Additional related cells, including 
Langerhans cells of epidermis, Kupfer cells in liver, Microglial cells in the central nervous 
system and a broad class of DC’s, do all express MHC I and MHC II surface molecules that 
permit them to display internalized and processed pathogenic peptide-digests to T-cell 
receptors (TCRs) on T-lymphocytes (T-cells are discussed in further detail later on).   
DC’s appear to be the most effective antigen presenting cells (APCs).  However, all MHC 
expressing cells are potential APCs if stimulated appropriately.  The innate immune response 
makes a crucial contribution to the activation of adaptive immunity.  The inflammatory 
response and release of molecular signals caused by complement activation, increases the 
flow of lymph containing antigen and antigen-bearing cells into secondary lymphoid tissue,  
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while complement fragments on microbial surfaces and induced changes in cells that have 
taken up pathogens provide signals that synergize in activating lymphocytes whose receptors 
bind to microbial antigens (reviewed in Cole and Morgan, 2003; Nielsen and Leslie, 2002). 
Antigen recognition, presentation and the details of effector mechanisms of adaptive 
immunity, is discussed in greater detail in the next section. 
 
Adaptive immunity 
Unlike the innate mechanisms, the adaptive reaction is highly specific for its target antigens.   
However, the adaptive mechanisms typically need several days before they become ready for 
combat.  The adaptive responses are based on the antigen specific receptors expressed on the 
surface of T- and B-lymphocytes.  The ability to recognize infinite numbers of antigens is 
enabled by somatic rearrangement of genes that encode T-cell receptors (TCRs) and 
immunoglobulins (Igs), as well as by the requirement for T cells to recognize antigens in the 
context of presentation by MHC molecules encoded within the major histocompatibility 
complex. 
Lymphoid tissue; birth place and playground of lymphocytes  
The lymphoid organs are organized tissues containing large numbers of lymphocytes in a 
framework of non-lymphoid cells.  Lymphoid tissue can be divided into primary lymphoid 
organs, where lymphocytes are generated, and secondary lymphoid organs, where adaptive 
immune responses are initiated and where lymphocytes are maintained.   
 
The primary lymphoid organs are the bone marrow and the thymus.  The leucocytes of 
adaptive responses are derived from the same lymphoid progenitor cells in the bone marrow.  
Two major types of lymphocyte exists: B lymphocytes (B cells) and T lymphocytes (T cells 
or Thymocytes).  B cells mature in the bone marrow, whereas T cells migrate to the thymus to 
mature.  Upon maturation, the lymphocytes enter the bloodstream, from which they migrate to 
the secondary lymphoid organs.   
 
Secondary lymphoid tissues include the lymph nodes, the spleen, and mucosa associated 
lymphoid tissue.  The primary role of secondary lymphoid tissue is to facilitate interactions 
between antigens, antigen charged APCs or immune complexes and recycling lymphocytes.   
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Lymph nodes are highly organized structures located at the points of convergence of vessels 
of the lymphatic system, an extensive system of vessels that collects extracellular fluid from 
the tissues and returns it to the blood.  This extracellular fluid, called lymph is produced 
continuously by filtration from the blood. It is transported in vessels known as lymphatic 
vessels.  The lymphatic vessels collect fluid from the tissues and the lymph also carry antigen-
bearing cells and antigens from infected tissues to the lymph nodes where they are trapped.  B 
and T lymphocytes are segregated in the lymph nodes.  B-cells are organized in follicles, 
surrounded by more diffusely distributed T-cells in what is referred to as T-cell zones.   
 
The spleen collects antigen from the blood.  Lymphocytes surround the arterioles entering the 
organ, forming areas known as white pulp.  This inner region is divided into the periarteriolar 
lymphoid sheath (PALS), containing mainly T cells, and a flanking B-cell corona (reviewed 
in Chadburn, 2000).   
 
Mucosa associated secondary lymphoid tissue (MALT) are frequently subdivided in to gut-
associated lymphoid tissues (GALT) and bronchial-associated lymphoid tissue (BALT).  
GALT which include the tonsils, adenoids, and appendix, and specialized structures called 
Peyer's patches in the small intestine, collect antigen from the epithelial surfaces of the 
gastrointestinal tract.  In Peyer's patches, the most important and highly organized of these 
tissues, antigen is collected by specialized epithelial cells known as M cells.  In Peyer's 
patches lymphocytes form a follicle consisting of a large central dome of B-cells surrounded 
by T lymphocytes.  Similar but more diffuse aggregates of lymphocytes protect the 
respiratory epithelium, where they are known as BALT.  Lymphoid tissue is also found in the 
genitourinary tracts.  Mucosal immunity is discussed in further detail in the Introduction part, 
section 1. 
 
Although very different in morphology, the lymph nodes, spleen, and mucosal-associated 
lymphoid tissues all share the same basic architecture.  Each of these tissues operates on the 
same principle; trapping antigen from sites of infection and presenting it to migratory small 
lymphocytes, thus inducing adaptive immune responses.   
The secondary lymphoid tissues also provide signals to the lymphocytes that do not encounter 
their specific antigen, so that they continue to survive and re-circulate until they encounter an 
antigen with adequate specificity.  This is of immense importance in the maintenance of the 
correct amount of circulating T- and B- lymphocytes.   
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It also ensures that only lymphocytes with the potential to respond to foreign antigen are 
sustained.  B- and T-lymphocytes that have matured in the primary lymphoid tissue, but have 
not yet encountered antigen that match their specificity, are referred to as naive lymphocytes.  
These cells circulate continually from the blood into the peripheral lymphoid tissues, by 
squeezing between the cells of capillary walls.  They are then returned to the blood via the 
lymphatic vessels or, in the case of the spleen, returned directly to the blood.   
 
Pathogens can enter the body by numerous routes and set up an infection practically 
anywhere.  However, antigen and lymphocytes will eventually encounter each other in the 
peripheral lymphoid organs. Circulating T- and B-cells continuously passes through 
secondary lymphoid tissue, to which antigen is also carried from sites of infection, primarily 
within macrophages and dendritic cells.  In the lymph nodes, these antigen-presenting cells 
display the antigen to T-cells, which they also help to activate.  B-cells that encounter antigen 
as they tour the lymphatic system are also arrested and activated in the lymph node.   
In the event of an infection antigen-specific lymphocytes, that have recognized an infectious 
agent, are arrested in the secondary lymphoid tissue.  There they proliferate and differentiate 
into effector cells capable of combating the infection. 
MHC-molecules; a brief introduction to antigen presenting tools 
Majorhistocompatibility-molecules (MHC), also known as human leukocyte-associated 
(HLA) antigens, are a cluster of cell surface glycoproteins (figure 2). Class I MHC molecules 
are expressed on virtually all nucleated cells, whereas class II molecules, are normally 
confined to specialized cells, such as B cells, macrophages, DC’s and other antigen-presenting 
cells.   
Figure 2.  MHC class I and II proteins.  
(A, left) Schematic presentation of MHC class I with its three 
extracellular domains (α1,α2 and α3) non-covalently associated 
with a β2 microglobuline. While β2 microglobuline is invariant, the 
α-chain is extremely polymorphic, especially in the α1 and α2 
domains. 
(B, right) In MHC class II molecules both chains (α and β) are 
polymorphic.  The α1and β1 domains comprise most of the 
variation.  Thus there are striking similarities between MHC class I 
and class II proteins. In both, the two outermost domains (shaded in 
blue ) interact to form a groove that binds foreign antigen and 
presents it to T cells.  
Figure obtained from; Molecular Biology of the Cell, 3rd ed. 
Alberts et al. Fig. 23-43. 
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MHC-class I are membrane bound heterodimers composed of a ~44kD α-chain and a 12kD 
β2- microglobulin.   The α-chain gene encodes three extracellular domains (α1, α2 and α3), a 
trans-membrane domain and an intra cellular domain that anchors the molecule to the 
membrane surface.  α1 and α2 combine to form a groove, in which antigenic peptides can bind.   
MHC-class I mainly bind and display peptide fragments and proteins that have been 
synthesized within the host cell such as viral antigens or tumour specific proteins (figure 3).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MHC-class II molecules, like class I, are composed of two polypeptide chains.  Both chains, 
designated α (33-35 kD) and β (25-30 kD) are transmembrane proteins.  The α-chain has two 
extracellular domains (α1and α2) and so does the β-chain (β1 β2).  The α1- and β1 chains 
combines to form a groove similar to the one found in MHC-class I.  MHC-class II primarily 
binds and display antigens that have been ingested and proteolytically processed, such as 
bacterial antigens engulfed by phagocytic cells (see figure 4).  
 
The composite structure of self-MHC and antigenic peptide is the target for T-cell receptors 
(TCRs).   
 
Figure 3.   
The MHC class I antigen presentation 
pathway.  (1) Endogenous antigens (i.e. viral 
proteins, intracellular bacteria, tumour antigens 
and self-antigens) are proteolytically processed in 
the cytosol by the proteasome. (2) Peptides 
generated by the proteasome are translocated into 
the ER lumen by TAP. (3) MHC class I 
molecules fold and assemble in the ER lumen 
with the aid of the ER chaperones calnexin, 
calreticulum and ERP57. (4) The MHC class I 
molecule in a complex with calreticulum and 
ERP57 associates with TAP and tapasin 
facilitates peptide binding. (5) Peptide loaded 
MHC class I molecules dissociate from TAP and 
are transported through the secretory pathway to 
the plasma membrane.  Here, the MHC-I/peptide 
complexes can be recognized by CD8+ T-cells 
with complementary TCRs. 
 
Obtained from Hewitt, (2003). 
 19
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T-lymphocytes; development, antigen recognition and effector functions 
T-cells are defined by expression of the heterodimeric αβ T-cell surface receptor (figure 5) 
and specific co-receptor expression.  TCR α- and β chains are transmembrane polypeptides 
with extracellular, immunoglobulin like, variable domains (VαVβ) and a constant domains 
(CαCβ).     
 
 
 
 
 
 
 
 
 
 
Figure 5.  Structure of the TCR 
The hetrodimeric T-cell receptor is composed of α and β 
polypeptide chains. They are transmembrane, glycosylated 
chains with an extracellular part that is folded into two Ig-
like domains, the membrane distal variable (V) and the 
constant (C) domains.  
An interchain disulfide bond links the two polypeptides.   
The antigen-binding site, that recognizes self-MHC-peptide 
complexes, is formed by the Vα and Vβ domain (shaded in 
blue).   
 
Figure obtained from; Molecular Biology of the Cell, 3rd ed. 
Alberts et al. Figure 23-42. 
Figure 4. Transport and antigen pressentation of MHC class II molecules 
Class II αβ dimers (black pincers) associate with Ii trimers (white snakes) in the ER (bottom left of the figure) and the 
resulting αβ Ii complexes are transported through the Golgi apparatus. In the TGN, αβ Ii complexes are then diverted 
from the constitutive secretory pathway into the endocytic pathway. Transport of these complexes to antigen-
processing compartments can occur following a direct pathway from the TGN to lysosomes (Pathway 1), indirectly 
after transit through to the cell surface and endosomes (Pathway 2), or indirectly following a pathway of TGN-to-
endosome transport (Pathway 3). Ii is degraded in antigen-processing compartments and class II complexes are 
loaded with peptide epitopes from exogenous antigens (i.e. bacteria, free viruses, yeasts, protozoa, and toxins) 
(different peptides are depicted using different colors).  Antigenic peptides and αβ–peptide complexes are 
subsequently sent to the cell surface (thick pink arrow).  Pre-existing surface αβ–peptide complexes can also 
internalize and recycle through endosomes, where peptides can be exchanged (Pathway 4, thin pink arrows).  At the 
plasma membrane, the peptide and MHC-II complexes are presented for CD4+ T-cells with complementary TCRs.    
 
Figure obtained from Hiltbold, (2002). 
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The variable domains of the TCRs include hyper variable loops, or complementarity-
determining regions (CDRs) 1, 2, and 3.  Each T-cell bears TCRs with a single specificity.  
The huge receptor repertoire is enabled by the variation found within the CDRs and 
rearrangement of the elements therein.   
 
Selection for fully functional T-cells occurs in the thymus where the T-cells mature.   
T-lymphocytes that undergo positive selection receive survival signals through interaction 
with self-MHC-peptide complexes and other ligands and are actively rescued from apoptosis.  
Negative selection refers to the deletion or inactivation of potentially auto reactive T-cells.  
These cells do not receive protective signals and are sentenced to “death by neglect”.  Cells 
that fail any of these, positive and negative, selection criteria are removed by apoptosis.  It has 
been calculated that fewer than 5% of the developing T-lymphocytes escape the well guarded 
control gates of the thymus to enter circulation (reviewed in Sprent and Kishimoto, 2001).     
 
During their maturation in thymus, T-cells differentiate into discrete subpopulations with 
defined effector functions.  Two major categories are defined by selective expression of CD4 
or CD8.  CD4+ T-lymphocytes are generally known as T-Helper cells (Th) and CD8+ T-cells 
are known as cytotoxic T-cells.  
 
As mentioned briefly above TCRs recognize antigens only in the context of self-MHC 
molecules with antigenic peptide displayed in its groove.  The TCR interacts both with the 
presented peptide and with the flanking α-helixes of the MHC-groove.  This concept, known 
as MHC restriction, allows the T-cells to ignore free, extracellular antigens, thereby enabling 
them to focus their effort towards infected cells.  The MHC/peptide/TCR complex is known 
as the immunological synapse.   
 
Conventional antigen presentation by MHC molecules is limited to protein antigens.  
Alternative presentation mechanisms for pathogenic lipid- and polysaccharide antigens have 
evolved.  CD1 molecules, structurally related to MHC, displays antigens to T-cells with the 
common αβ-TCR or to lymphocytes expressing an alternative γδ-TCR.   
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CD4+ T-cells only recognize antigen presented on MHC-class II molecules, whereas CD8+ 
T-cells needs to see the antigen in a MHC-class I context.  CD8 and CD4 serve as co-
receptors for MHCI/peptide and MHCII/peptide recognition, respectively (Gao et al., 2002, 
review).  The α- and β-chains of the TCR associate with invariant accessory molecules, 
collectively known as the CD3 complex, that serves as a signal transducer.   
 
Interaction between the TCR/CD3 complex and the MHC/peptide complex, does not provide 
sufficient signals for proper T-cell activation.  Adequate activation requires additional co-
stimulatory signals.  CD28 on T-cells and CD 80/B7.1 or CD86/B7.2 on the APC provides 
these signals.  Properly activated ITAMs (immunoreceptor tyrosine-based activation motifs) 
in the cytoplasmic parts of the CD3 complex initiates a cascade of enzymatic reactions, 
leading to activation of genes that control lymphocyte proliferation, differentiation and 
survival (Sommers et al., 2000).   
 
Both CD4+ and CD8+ cells differentiate to distinct, effector cells upon activation by antigen.  
Activation of CD4+ T-helper cells (Th) causes production and release of IL-2.  At this stage 
the cells are designated Th0.  The Th-cells continue to respond to the activating signals and 
goes on to diverge into Th1- and / or Th2-cells, distinguished by the cytokine signature they 
produce.  Th1 cells mainly leave an IL-2, Interferon-γ, TNFβ signature, which induces T-cell 
proliferation and T-cell cytotoxisity, activate macrophages and induces NK- cytotoxisity.  
This gives them an important role in cell-mediated immune responses.  Th2 cells are 
characterized by IL-4, IL-5, IL-6, IL-10, IL-13 secretion.  They play an important role in B-
cell maturation and antibody production (discussed in detail in the next section).  Most 
immune responses will show elements of both Th1 and Th2 differentiation.   
 
Naïve CD8+ T-lymphocytes are activated by peptides carried by self-MHC class I molecules.  
Most cells presents peptides derived from endogenous proteins on MHC class I molecules.   
Thus, by doing so, they become targets of the effector function of CD8+ T cells.  Professional 
APCs, primarily DCs, have been demonstrated to load peptides derived from internalized 
antigens onto MHC class I molecules.  This process, known as cross presentation, and the 
subsequent activation of immune responses, called cross-priming, consequently leads to 
cytotoxic immune responses against exogenous antigens presented in the context of MHC 
class I (Amigorena, 2003; Norbury and Sigal, 2003, review).   
 22
Activated CD8+ T-lymphocytes proliferate and differentiate to become cytotoxic effector 
lymphocytes (CTLs).  CTLs develop exocytic granules containing perforin and granzymes 
upon activation.  They also produce and secrete cytokines.  When re-challenged with antigen, 
the CTLs direct their lethal load towards the site of target-contact and release their effector 
molecules to induce target cell death.  This pathway is crucially important for the ability of 
CTLs to induce target cell death in many biologically important scenarios, including allogenic 
rejection, tumour cell killing, and the clearance of some viruses.   
The cytotoxic CD8+ T-cells kills via yet another mechanism, known as the Fas-FasLigand 
induced apoptosis.  Killing of the target cell is mediated by surface molecule interaction 
between apoptosis triggering Fas on the target cell and Fas-Ligand on the CTL (Russell and 
Ley, 2002, review). 
 
A key feature of adaptive immunology is the defence’s ability to remember the antigens it has 
previously encountered.  This is called immunological memory.  Both CD4+ and CD8+ T-cell 
develop into memory cells.  Upon antigen re-challenge they are induced to rapidly synthesize 
large quantities cytokines and they expand rapidly.  Memory cells require lower levels of Ag 
and co-stimulation than naive T cells to be activated.  Moreover, they are recruited more 
rapidly to sites of inflammation than are naïve T-cells (reviewed in Swain, 2003).    
B-lymphocytes; development and immunoglobulins  
B-lymphocytes originate from bone marrow stroma stem cells.  During IL-7 dependent 
maturation in the bone marrow, B-cells develop to express membrane bound antigen receptors 
(BCR).  The antigen receptors found on B-cells are immunoglobulins (Igs).  Ig molecules are 
composed of two identical heavy chains and two identical light chains.  The amino terminal 
domains of the heavy and the light chain are designated variable-heavy (VH) and variable-
light (VL) respectively.  The variable domains of Igs, like TCRs, contain three hyper variable 
regions, also known as complementarity-determining regions (CDRs).  Four gene segments; 
variable (V), diversity (D) (heavy chains only), joining (J) and constant (C) segments are 
involved in the formation of the receptor repertoire.  Rearranged VL and JL genes are coupled 
with CL genes to produce light chains.  Light chains come in to versions known as κ and λ 
respectively.  Heavy chains contain VHDHJH genes coupled to CH genes.  Additional variation 
is introduced to the receptor repertoire by inaccurate splicing, frame shift and introduction of 
additional nucleotides.  
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Heavy chain constant genes contain exons that encode different constant regions that 
determine classes and subclasses of immunoglobulins.  Combination of VH and VL domains 
produces the antigen binding site on the receptor, thus each Ig contains two identical antigen 
binding sites.  The C-terminal, constant domains of the two heavy chains pairs to form the Fc-
domain of the Ig-molecule that is responsible for the effector functions mediated by Igs.  Like 
TCRs, the BCR is dependent on invariant transmembrane proteins for signal transduction.  
Igα and Igβ (CD79 a, b), both containing ITAM domains, communicate intracellular signals 
initiated by BCR-antigen interaction.   
 
Naïve, developing B-cells initially express membrane bound receptors with µ-heavy chains 
known as isotype IgM.  Later in lymphocyte development the same VHDHJH genes are 
coupled with δ heavy chains to produce isotype IgD receptors.  B-cells produce receptors with 
only one antigen specificity.  This is ensured through the process of allelic exclusion.  Mature 
naïve B-cells, expressing IgM and IgD, leaves the bone marrow, enters circulation and 
migrate to secondary lymphoid tissue.  In the lymphoid tissue B-cells encounter antigens.   
 
Antigens are recognized by the membrane bound receptor, internalized, processed and re-
expressed on the B-cells MHC class II molecules.  T-cells that recognize the B-cell presented 
MCH-peptide complex may become activated and start to produce cytokines that stimulate 
the antigen presenting B-cell to proliferate and differentiate to antibody producing plasma 
cells.  This B-cell activation pathway, in which B-cells act as APCs, is known as a T-cell 
dependent response.   
 
Supplementary T-lymphocyte interaction, particularly the binding of CD40 on B-cells to 
CD40-ligand on T-cells, induces an important event known as class switching.  This process, 
dependent on the cytokine profile released by the Th-cell, shifts the initial IgM response 
towards immune responses dominated by antibodies of other isotypes.  However, the antigen 
specificity remains the same as the VJD-genes are not rearranged outside of the bone marrow.  
B-cell activation occurs mainly in the germinal centres of secondary lymphoid tissue.   
 
As B-cells undergo class switching in the germinal centres, an active process introduces 
mutations in the variable domains of the light and heavy chains.  This may lead to loss of 
affinity for the triggering antigen, in which case the B-cell looses receptor mediated growth 
signals necessary for life.   
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On the other hand, if the somatic mutations lead to increased affinity for the antigen, the 
antibody producing cell get a propagating advantage, and grow to outnumber the other 
responding cells.  This process is known as affinity maturation.  Recent investigations indicate 
that a protein expressed specifically in activated B cells, activation-induced deaminase (AID), 
causes deamination of cytosine residues within the immunoglobulin loci, thereby triggering 
major programs of antibody gene diversification.  It is now apparent that programmed 
introduction of uracil into DNA by targeted cytosine deamination is used by the adaptive 
immune system as a means of triggering multiple pathways for somatic modification of 
antibody genes (reviewed in Neuberger et al., 2003). 
 
Plasma cells leave the lymphoid tissue to secret antibodies with specificity corresponding to 
the specificity of the membrane bound Ig.   
 
Following class switching, some of the activated B-lymphocytes go on to become memory B-
cells.  These react rapidly with a characteristic IgG response to antigen re-challenge.  B-cell 
memory is of critical importance to the success of vaccination.   
 
B-cells may also be activated independent of T-cells.  In the absence of T-cell co-stimulatory 
protein signals, monomeric antigens are unable to trigger B-cell activation.  However, 
polymeric antigens, such as certain pathogenic polysaccharides, lipids and proteins with 
repetitive structures, are able to cross-link and cluster membrane IgMs, thereby activate the 
receptor bearing cell.  Class shifting, somatic hyper mutation and generation of memory does 
not occur in T-cell independent B-cell activation.  Such activation ultimately leads to an IgM 
limited response of poor specificity and of limited duration. 
 
Antibody structure and function; a brief introduction 
Antibodies (Abs) are central molecules in the immune system.  They play a crucial role in 
recognition and elimination of infectious agents. 
 
The general structure of an antibody comprises two identical heavy- and two identical light- 
Ig-chains.  They combine to generate a bifunctional molecule, comprising two highly diverse 
N-terminal antigen-binding sites and conserved effector mediating sites in the C-terminal end 
(figure 6).   
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The infinite diversity of binding specificities found in the variable (VL and VH) domains is 
created by imprecise recombination and somatic mutations as described above.  The Ab 
molecule is frequently divided into substructures; VL and VH linked to CL and CH1 
respectively constitute the Fab part, whereas the effector functions of the Abs are mediated by 
the carboxy-terminal CH domains, the Fc portion of the Ab.  In addition a flexible part of the 
heavy chain, containing disulfide bridges, is known as the hinge region.  Two Fab fragments 
linked by parts of the hinge is known as F(ab’)2.  The minimum fragment for antigen binding, 
VL and VH, is known as fragment of variation or just Fv.  
 
 
 
 
 
 
 
 
 
 
 
 
 
There are five different human Ab classes, namely IgA, IgD, IgE, IgG and IgM.  The 
characteristics of each class, with focus on human Igs, will be discussed below.  As 
mentioned in the previous section, immunoglobulin classes are distinguished by their heavy 
chains, denoted by the corresponding lower case Greek letter; α, δ, ε, γ and µ respectively.   
There are only two different light chains; the λ- and κ chains.   
 
Ig heavy and light chains have common structural domains, called immunoglobulin folds. 
They are characterised as a sandwich of two extended β-sheets of three and four anti-parallel 
β-strands in constant domains, and four and five anti-parallel β-strands in the variable 
domains, linked together by disulphide bridges.  The β-strands are connected by inter sheet- 
and intra sheet loops of variable length and amino acid sequence.  Three loops of the variable 
domain of Abs, CDR1, CDR2 and CDR3, determine the antigen specificity of the antibody.  
Figure 6. The basic structure of antibodies; 
represented by IgG 
The antibody molecule is made up of two identical light- 
(purple) and heavy- (green) chains of immunoglobulin 
domains.  The molecule is commonly divided into the 
following sub structures; The Fc-fragment which 
consists of CH2 and CH3; The Fv fragment that consists 
of VH and VL domains; Fab fragments which consist of 
one light chain (VL-CL) and a part of the heavy chain 
(VH-CH1) and the hinge region, a flexible region of 
heavy chain. Note that all domains of IgG pair closely, 
except for the CH2 domains. The CH2 domains are 
separated by carbohydrate residues, marked as black 
spots in this simplified diagram.   
 
Note: The hinge region has been oversimplified and is 
not to scale with the rest of the molecule.  
Fv 
F(ab`)2 
Fc
C-terminal 
Fab 
The hinge region 
N-terminal 
CH3 
CH2 
CH1 CL 
VH VL 
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IgG is the most studied among the Igs and consists of a heavy chain of the structure VH-CH1-
hinge-CH2-CH3 and a light chain of the structure VL-CL.  The heavy chain and light chain are 
linked by a disulphide bond between CH1 and CL and non-covalent interactions between the 
VH/VL and CL/CH1 domains.  The heavy chains are linked by disulphide bonds in the hinge 
region, while the CH2 domains are separated by carbohydrate residues, and non-covalent 
interactions exist between the paired CH3 domains.  IgG comes in four versions; IgG1-4 with 
γ1-4 heavy chains respectively of which IgG1 is dominating in serum.   
 
IgM antibodies have µ heavy chains with four constant Ig-domains.  Unlike the membrane 
bound IgM of B-cells, soluble IgM usually form pentamers.  They contain an additional Ig-
like protein known as the J-chain, lack the classical hinge region found in IgGs and are 
heavily glycosylated.  If the J-chain is not available, hexamers form.  The multimer is held 
together by inter Cµ3 disulphide bonds and disulphide bonds between the 18 amino acid (aa) 
tailpiece.  The pentamer possesses 10 identical antigen binding sites, the hexamer 12.   
 
IgA is secreted by plasma cells as monomers and as dimers (pIgA).  The α- heavy chains, 
comes in two versions (α1 and α2), contain three constant domains (Cα1-3), are glycosylated 
and holds a hinge region very much like the one found in IgG.  pIgA, like pentameric IgM, 
associates with J-chain that connects the two monomers at their C-terminal tailpiece, giving 
the molecule a total of 4 antigen binding sites.  IgA plays a major role in mucosal immunity.  
It is present in secretes as secretory IgA (sIgA) coupled to the secretory component (SC), the 
extracellular part of the polymeric Ig receptor (pIgR) found on epithelial cells.   
 
IgD constitutes only 1% of the total serum Ig content and is known to serve as BCRs when 
membrane bound to B-lymphocytes.  IgD heavy chains contain three δ constant domains 
(Cδ1-3), a short tail piece, and a single disulphide bond in the hinge region.  The soluble form 
is known to be susceptible to spontaneous proteolytic degradation.   
 
The fifth Ig class, IgE, have heavy chains with four constant domains (Cε1-4).  They lack the 
classic hinge region seen in IgG.  Circulating IgE is scarce.  However, it is frequently found 
bound to the Fcε receptor on basofils, eosinophils and mast cells.   
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The role of the Ab molecule is to act as an adaptor molecule.  Thus, they link target antigens 
to effector cells and molecules that mediate elimination of the target.  The effector functions 
of Abs can be divided into two categories: Firstly, those mediated by binding complement 
component C1q, resulting in activation of the classical complement pathway.  Secondly, those 
mediated by binding of Fc-domains to Fc receptors (FcRs) on effector cells.  
Fc receptors; antibody docking stations, transporters and maintainers 
In addition to being the docking point for Abs on immune effector cells, Fc receptors facilitate 
specialized transport of antibody molecules and finally, they are involved in Ig homeostasis.   
 
FcRs for IgA, IgG and IgE are present on the surfaces of several cells of the immune system.  
These receptors FcαRs (FcαRI), FcγRs (FcγRI,II,III) and FcεRs (FcεRI, II) that bind IgA, IgG 
and IgE respectively, interact with antibody-antigen complexes to activate effector responses 
in effector cells such as phagocytes, NK cells, mast cells and cytotoxic T-lymphocytes.  
Binding of Igs to these FcRs triggers biological responses such as phagocytosis and antibody-
dependent cell-mediated cytotoxisity (ADCC), mast cell degranulation, release of mediators 
of inflammation, and the regulation of B cell activation and antibody production.     
 
Neonatal Fc receptor (FcRn) initially discovered to transfer IgG molecules from the mother to 
the fetus or infant, hence the name, binds and release IgG in a pH dependent manner (high 
affinity at slightly acidic pH and low affinity at neutral pH) enabling efficient unidirectional 
transport.  FcRn now appears to be used for transport of IgG in sites other than the intestine, 
and in adults as well as in neonates.  FcRn is also known to be involved in IgG homeostasis.  
The receptor provides the host with a recycling mechanism, leading to increased IgG serum 
life.   
 
Another Ig transporting receptor, the polymeric Ig receptor (pIgR), mediates transport of 
polymeric IgA and IgM across epithelial cell layers. 
Catalytic activity of antibodies; novel effector functions 
Recent work has demonstrated that antibodies have a new effector function independent of 
complement and FcR mediated antigen elimination.  Abs may in fact harbour recognition 
abilities and killing potential within the same molecule.   
 
 28
All antibodies, regardless of antigenic specificity, can catalyse the generation of highly 
reactive and bactericidal oxidants including, hydrogen peroxide (H2O2), dihydrogen trioxide 
(H2O3) and a component with the chemical signature of ozone (O3) from singlet oxygen (1O ) 
and water (H2O).  Neutrophiles have the potential both to produce 1O  and to bind Abs, and 
are likely to be a biological source of O3 (Babior et al., 2003; Wentworth et al., 2002; 
Wentworth et al., 2003). 
 
Concluding remarks: 
This general introduction to the immune system has been included in my thesis to provide the 
non-immunologist reader with crucial background knowledge for better understanding of the 
work presented in the enclosed manuscript.  It is beyond the scope of this thesis, and has not 
been my intention, to write a comprehensive and detailed review of the complex and 
fascinating biology of the immune system.  However, I do hope the reader find my 
presentation interesting and informative.  Interested readers are referred to other excellent 
reviews (Chaplin, 2003; Parkin and Cohen, 2001) and text books (Janeway, 2001; Roitt, 
2001) on the immune system. 
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Antibody engineering 
 
Antibody molecules and derivatives thereof have proved useful in a variety of research, 
diagnostic, and therapeutic applications.  Their ability to recognize and bind specifically to an 
infinite number of targets makes them valuable tools in the lab and the clinic.  According to 
the US Food and Drug Administration (FDA), engineered antibodies now represent more than 
30% of biopharmaceuticals in clinical trials (reviewed in Hudson and Souriau, 2003).  
Intact antibodies; potential and challenges 
Initially, clinical use of Abs in vivo employed monoclonal mouse Abs (mAbs) generated by 
classical hybridoma technology (Kohler and Milstein, 1975).  This often resulted in unwanted 
human-anti-mouse immune responses due to their immunogenicity.  It is evident that the Abs 
designated for clinical use must be as human as possible.  Genetic engineering has allowed for 
development of chimeric, humanized Abs, constructed from murine variable Ig domains and 
humane constant domains.  Mouse complementarity determining region (CDR) grafted on to a 
human Ig framework has also been attempted.   
 
More recently it has become achievable to produce purely human antibodies in transgenic 
animals (Clark, 2000, review).  The use of complete Ab molecules as therapeutical agents has 
some evident advantages.  Intact Abs are divalent, they possess two bindings sites for the 
target of interest, giving them high functional affinity (avidity) for its target.  As described 
earlier, Abs recruits cytotoxic effector mechanisms through its C-terminal Fc domain.  Thus 
intact antibodies comprising Fc domains are powerful tools.  On the down side, however, it 
should be noted that intact mAbs penetrate tissue poorly, they show slow blood clearance 
resulting in significant, potentially toxic exposure to untargeted tissue (reviewed in Batra et 
al., 2002).  In addition mAbs have proven to be extremely expensive to develop and 
manufacture (Torphy, 2002).  Despite these limitations, FDA approved, intact Ab-molecules 
prove successful both in diagnostics and therapy.  Their mode of action in therapy or 
diagnostics is to block receptors on target cells or to operate as conjugates of therapeutic 
payloads or diagnostic reagents (reviewed in Hudson and Souriau, 2003).     
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Genetically modified Ab fragments; harmless target binders?  
Regardless of the shortcomings of mAbs in therapeutics, antibody based pharmaceuticals still 
show an enormous potential (Souriau and Hudson, 2003, review).  This has been the driving 
force in development of alternative antibody based technology.   
 
The domain structure of Abs permits their division into functional subunits, or modules, 
which can be mixed and matched to create novel molecules with a specific subset of 
functional properties.  In some clinical applications, such as receptor blocking, cytokine 
inactivation or viral neutralization, Fc domains are unwanted and can be removed by 
uncomplicated proteolysis of intact antibodies to yield Fab or F(ab’)2 fragments (see figure 6 
and 7).  These antibody subcomponents show increased tissue permeability and higher 
clearance rate in normal tissue than intact Abs from which they originate.   
 
scFvs, constructs of VL and VH Ig domains (see figure 7) genetically linked together by a 
short, flexible, stabilizing inter-domain peptide chain, show even better tissue permeability 
than Fab fragments (reviewed in Batra et al., 2002).  Molecular cloning and bacterial 
expression of antibody fragments, including the variable region genes of Ig, have greatly 
facilitated the generation of engineered antibodies.  Fab and scFv fragments can be readily 
genetically engineered, selected against a target of interest in protein display systems, e.g. 
phage display, and expressed in inexpensive prokaryotic systems (reviewed in Kretzschmar 
and von Ruden, 2002).  Fabs and scFvs are monovalent molecules with reduced functional 
affinity for their target compared to a complete antibody with the same specificity.  This can 
be overcome by in vitro affinity maturation and/or by construction of multivalent molecules, 
to yield excellent bio-distributable targeting fragments (Batra et al., 2002, review).   
 
Fabs and scFvs do not harbour any cytotoxic effector mechanisms, neither can they recruit 
such.  Fc domains, of intact Abs, depend on proper glycocylation to meet the structural 
requirements for effector mechanism activation, thus they can only be synthesised in 
mammalian cells (Krapp et al., 2003).  Like mAbs, monospecific target binding Ab fragments 
may serve as receptor blocking agents or as carriers in toxin-, drug-, prodrug, enzyme-, 
radionuclide- or dye conjugates.  
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Functional antibody fragments: target recognition and elimination  
Bispesific antibody fragments, known as diabodies, linking target recognition  
(i.e. tumour specific antigens) with effector mechanisms (i.e. complement components and 
cytotoxic cells) have been described (Holliger et al., 1996; Kontermann et al., 1997).  
Diabodies (see figure 7) initially comprised two different polypeptide chains that needed to 
undergo proper folding.  This called for labours refolding and purification steps.   
Figure 7.  Selection of genetically engineered antibodies and antibody fragments  
 
- Antibody fragments generated by proteolytic cleavage shown as bivalent F(ab’)2 (1) and monovalent Fab (2).   
- scFv (3); VH and VL linked together by a short polypeptide chain indicated with a black line.   
- scFv- and Fab pepbodies (4) and (5) respectively, bind antigen monovalently through its target binding region (TBR)   
and recruit effector functions via the genetically fused peptide (indicated with red triangle) they display.   
- Troybodies (6), a novel vaccination strategy tool, are Abs with one or more T-cell epitopes inserted in the constant 
domains designed for efficient epitope delivery to APC for which they have specificity.   
- Antibodies (7) or Ab fragments (8) and (9) with specificity for a target of interest can be chemically conjugated to 
effector molecules such as toxins, pro-drugs, enzymes or radionuclides.  
- Single chain constructs of bivalent- (10) and bispecific- (11) diabodies, trivalent- (12) and trispecific- (13) triabodies 
and tetravalent- (14) and tetra specific- (15) tetrabodies.  Colours denote multivalens and multispecificity. 
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More recently this hurdle has been overcome by design of single chain constructs of diabodies 
(dimers), triabodies (trimers) and tetrabodies (tetramers) with multi valence and/or multi 
specificity (reviewed in Kortt et al., 2001; Todorovska et al., 2001) (figure 7).   Mono-chain 
Ab fragments, known as pepbodies, that possess both antigen binding capabilities and effector 
functions have recently been described.  Pepbodies are Fabs or scFvs fused to one or more 
peptides that mimic Fc function by binding one or more effector molecules of the immune 
system (see figure 7).  Peptides that bind C1q, pIgR, FcγRs, including FcRn have been 
selected by means of phage display technology and genetically fused to scFvs and Fabs 
(Lunde et al., 2002).  This promising invention combines advantageous pharmacokinetics, 
prokaryotic expression, antigen recognition and binding, and engagement of the host’s 
cytotoxic mechanisms in one minimally immunogenic molecule.  
Engineered Abs in vaccine development: right on target with Troybodies 
Genetically engineered antibodies are also used in the development of innovative vaccine 
applications.  Critical in vaccine development is the design of immunogens that give a strong 
and specific T-lymphocyte response.  CD4+ T-helper cells are central in adaptive immune 
responses.  Consequently, strategies that modulate them are of great interest.  Troybodies are 
engineered antibodies, containing cryptic T-cell epitopes inserted in the loops of their constant 
domains, with V-genes encoding specificity for antigen presenting cells (Figure 7).  
Troybodies increase the number of T-cell epitopes that reaches the APC, subsequently 
increasing the number of peptide-MHC complexes on the APC that ultimately goes on to 
activate T-helper cells.   This new vaccine strategy is flexible and can be designed to target 
different APCs and induce immunity to numerous T-cell epitopes (Lunde et al., 2001).   
 
Concluding remarks: 
This section aims to present the reader with some of the possibilities and prospects of 
designing, engineering and producing antibody derived drugs, diagnostics and research tools.  
Furthermore this section elucidates the promises of combining knowledge about the structure 
and function of antibodies with the powerful tools of molecular engineering in modern 
medicine.  Current technologies employing in vitro or in vivo selection of fully human 
antibodies, either by combinatorial approaches or by transgenic animals are review by Brekke 
and Løset (2003).  Their recent review also recapitulates recent developments in antibody 
discovery, design and therapeutic applications. 
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Introduction 
1. Mucosal immunity 
Mucosal surfaces cover approximately 400m2 of exposed body surface, more than 200 times 
of that covered by skin.  This vast and vulnerable surface barrier, lining the digestive system, 
the airways and the genitourinary tracts, is protected by innate mechanisms in intimate 
cooperation with adaptive mucosal immunity.  The mucosa is directly exposed to the external 
environment and is under constant bombardment of antigens such as bacteria, viruses, food 
antigens, bacterial toxins and inhaled potentially pathogenic particles.  Because mucosal 
surfaces are ideal portals of entry to most pathogens, mucosal immunity has evolved as a 
discrete system that performs highly regulated novel immunologic tasks.  Mucosa associated 
lymphoid tissue must continually maintain a delicate balance between active immunity, oral 
tolerance, and suppression of immune responses (MacDonald, 2003, review).   
 
1.1 Innate mucosal immunity; physical and chemical barriers 
Mucosa associated innate immune defence includes physical and chemical barriers.  Digestive 
enzymes of the gastrointestinal tract degrade pathogens by proteolytic cleavage to produce 
short non-immunogenic peptides.  Furthermore, enzymatic alteration of carbohydrate residues 
on pathogens may lead to loss of virulence.  The hostile, acidic environment of the gut 
provides the host with further protection.  A key component of the physical barrier is the 
mucine gene products.  Mucine glycoproteins, secreted by goblet cells, line the apical surface 
of epithelial cells.  This sticky, protective layer prevents pathogens in gaining access to the 
underlying epithelial cells.  Captured potential pathogens are removed with the mucus layer 
through peristaltic- or mucocilary transport in the gastrointestinal tract and respiratory tract 
respectively.  This process, known as non-immune exclusion, prevents the epithelial cell layer 
from colonization and invasion.  The epithelial cells layer itself is virtually impermeable to 
macromolecules due to tight junctions both basolaterally and apically.  The normal gut flora 
may provide additional protective activity trough competition against pathogenic bacteria for 
space and nutrients, thereby preventing colonization and invasion of the epithelia (reviewed in 
Mayer, 2003).   
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1.2 Adaptive mucosal immunity 
Adaptive immunological protection of mucous membranes is provided mainly by secretory 
antibodies, predominantly IgA.  B-cell responses that give rise to secretory antibodies are 
triggered mainly in organized lymphoid, epithelial structures where antigens are sampled 
from the mucosal surface.  Gut-associated lymphoid tissue (GALT) constitutes the major part 
of organized mucosa-associated lymphoid tissue (MALT).  Peyer's patches, specialized lymph 
nodes of GALT, are characterized by follicle-associated epithelium with gateway (M) cells 
capable of capturing and transporting antigens from the lumen into the underlying lymphoid 
tissue.   
 
Harmless proteins, components of commensal bacteria or digestive antigens do not only 
stimulate the secretory antibody system, but also activate suppressive mechanisms 
collectively known as oral tolerance when induced via the gut. This hypo-responsiveness 
possibly explains why individuals with intact immune systems show no adverse immune 
reactions to persistent contact with harmless environmental and dietary proteins.  The 
mechanism governing oral tolerance is not completely understood.  However, it is evident that 
antigen presentation in MALT is of importance.  In the absence of inflammation, presentation 
of peptide to T cells by MHC molecules on APCs, occur in the absence of co-stimulation.   
 
Pathogen derived peptides, on the other hand, concomitantly induce inflammatory responses 
in the tissue that stimulate the maturation and expression of co-stimulatory molecules on the 
APC, ultimately leading to a Th1 protective response.  B-cells with potential for J-chain 
expression, that have been activated in MALT (predominantly in Peyer's patches) to produce 
secretory Abs, migrate through lymph and blood to other mucous tissues (i.e. nasal, salivary, 
bronchial surfaces, mammary glands, and the urogenital tract) where they are subjected to 
terminal differentiation and become immunoglobulin secreting plasma cells (Brandtzaeg, 
2003, review). 
   
1.2.1 Secretory immunoglobulins; J-chain in polymerization and receptor binding  
Approximately 80% of all antibody-secreting plasma cells of the body are located in the 
gastrointestinal and respiratory mucosa.  Some 90% of them are dedicated to production of 
immunoglobulin A.  IgA and IgM antibodies have polymerization signals in the carboxy- 
terminal constant heavy domains C3α and C4µ respectively (Braathen et al., 2002).   
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Plasma cells in the lamina propria co-express a 15 kDa polypeptide known as the joining (J) 
chain.  J-chain expression significantly facilitates generation of polymeric IgA (pIgA, 
primarily dimers) and pentameric IgM (figure 8).  J-chain expression may be considered a 
marker for early B-cells derived from MALT as IgD and IgG secreting tissues are positive for 
this peptide.   The J-chain is exclusively incorporated into IgA and IgM multimers.  J-chains 
do not appear to have a biological function in plasma cells expressing other isotypes of 
antibodies, thus it is intracellularly degraded.   
 
 
 
 
 
 
 
 
 
 
 
  
 
Polymerization leads to formation of multivalent Ig-complexes with high functional affinity 
(avidity) for its antigen, making them appropriate tools for agglutinating bacteria, viruses and 
pathogenic particles.  pIgA have little or no complement-activating potential, allowing it 
function in a non-inflammatory fashion.  Furthermore, J-chain-containing pIgs show high 
affinity for the polymeric Ig receptor (pIgR).  This epithelial glycoprotein mediates transfer of 
dimeric IgA and pentameric IgM across the epithelial monolayer to exocrine secretions 
(Johansen et al., 2000). 
 
The extracellular domain of the pIgR, known as the secretory component (SC), remains 
covalently associated with pIgA in secretions.  This complex is known as secretory IgA 
(sIgA).  Pentameric IgM also remain associated with SC, but in a non-covalent manner 
(sIgM).  The polymeric Ig receptor is a prerequisite for the protective potential of pIgA and 
pentameric IgM.  The role of antibodies in mucosal immunity is discussed in section 1.2.2. 
Figure 8.  Model of polymeric IgA and IgM containing a J-chain 
Left: Polymeric IgAs (pIgA) predominantly form dimmers when a J-chain (orange) is co-expressed.   
The glycocylated (black spots) tetra valent complex is the dominating species of Abs in humoral, mucosal immunity.   
Right: polymeric IgM form decavalent  pentamers bound to one J-chain. 
Black lines represent inter-domain disulphide bonds. 
 
Based on figure 4.6, Immunology, 6th ed. Roitt et al. 
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Although antibodies of all classes may be found in secretions, they are generally not 
considered as secretory Igs.  IgG may play a role in immune exclusion in the respiratory tract.  
IgG is likely to be subjected to proteolytic degradation in the harsh environment of the 
digestive system.  sIgA and sIgM, on the other hand, show increased stability due to their 
multimeric structure and their association to SC.  Recently, FcRn has been suggested to be 
responsible for transepithelial transport of IgG to mucosal surfaces (Spiekermann et al., 
2002).  IgGs role in mucosal immunity remains blurred as it activates complement and leads 
to inflammation that ultimately causes increased mucosal permeability and consequently, 
potential antigen penetration.  IgE antibodies may be carried by mast cells to mucous 
membranes and secretions where they cause degranulation and histamine release.  Likewise, 
traces of IgD may be found in secretions, but their biologic significance remains uncertain. 
 
1.2.2 The polymeric Ig receptor: well beyond pIg transport 
The polymeric immunoglobulin receptor (pIgR), also known as the transmembrane secretory 
component, is an epithelial, ~100 kDa glycoprotein of the immunoglobulin supergene family.  
It consists of five Ig like extracellular domains, an extracellular tail with sites susceptible to 
proteolytic cleavage and a cytoplasmic tail (figure 9).   
 
Newly synthesized pIgR is transported to the basolateral surface of epithelial cells.  pIgRs are 
endocytosed constitutively and sorted into vesicles for transport to the apical surface or 
recycled to the basolateral surface.  The cytoplasmic domain of the receptor contains the 
sorting signals that orchestrate endocytosis, transportation and ultimately, exocytosis at the 
apical (luminal) surface of the epithelial monolayer.  This essential, receptor mediated, 
transepithelial transport mechanism, known as transcytosis, is shared by pIgA and pentameric 
IgM.  The J-chain of pIgA and pentameric IgM constitutes an essential part of the pIgR 
binding site of antibodies destined for excretion (reviewed in Kaetzel, 2001).    
 
 
 
 
 
 
 
 
Figure 9.  Structure of the pIgR  
pIgR is a transmembrane receptor with five extracellular Ig 
homologous domains and a long cytoplasmic tail 
containing signals for intracellular sorting and endocytosis.  
Extracellular domains 1, 4 and 5 (yellow) are highly 
conserved among species, and contain signals for non-
covalent and disulfide bonding to polymeric IgA.  
Domains 2 and 3 (blue) are less conserved, and are absent 
in some splice variants of rabbit pIgR.  Cleavage of full-
length pIgR to release the soluble secretory component 
(SC) occurs within the linker connecting domain 5 to the 
transmembrane region.    
Obtained from Kaetzel, (2001). 
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In the further discussion on the role of Abs in mucosal immunity only sIgA will be dealt with 
in detail, since sIgA is by far the dominating Ab class found in conjunction with mucosal 
tissue.   
 
The pIgR is instrumental to mucosal immunity.  The receptor is involved in multiple 
mechanisms providing the host with a multi layer defence at the mucosae (figure 10).  
Receptor-ligand interaction provides two signals sufficient for increased internalization rate 
and directional transport (Luton and Mostov, 1999).  At the apical side of the cell, the 80 kDa 
extracellular domain of the receptor is proteolytically cleaved off and released as the secretory 
component (SC) bound to IgA (Brandtzaeg, 1974).  Thus pIgR devise the local formation of 
secretory Ig at the mucosae (figure 10, route 1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, unoccupied pIgR may be internalized on the basolateral surface of the epithelia 
and released to the lumen by proteolytic cleavage in the same manner as sIgA and sIgM, to 
form free SC (fSC).  Although initially believed to function solely by providing protection 
against proteolytic degradation it is now evident that this cleavage product, identical to Ab-
bound SC, occurs in most secretions where it may contribute to innate mucosal defence 
(figure 10, route 1’).  Free SC has been shown to work as a non-specific scavenger, 
preventing interaction between luminal microbes or toxins and the epithelia (figure 10, route 
5) (de Oliveira et al., 2001).   
Figure 10.   Functions of the polymeric Ig receptor (pIgR) and secretory component (SC)  
Route (1): pIgR ensures transcytosis of polymeric IgA (pIgA), and IgM if present, across the epithelial cell layer, 
leading to the local production of secretory IgA and IgM denoted sIgA and sIgM respectively.  sIgM is not 
shown in this simplified diagram.  Route (1'): Transcytosis of unloaded pIgR and release of free SC occurs 
similarly to route (1), yet with a lesser efficiency.  Route (2): pIgR is able to transcytose pIgA loaded with 
antigens present in the lamina propria suggesting excretion of pathogen-sIgA complexes.  Route (3): Abs, en 
route for luminal secretion, can neutralize invading pathogens by the process of intracellular neutralization.  
Route (4): Immune exclusion, potentially sIgA’s most prominent role, implies neutralization within the lumen, 
with epithelial anchoring of sIgA mediated by bound SC.  Route (5): Free SC might exhibit scavenger function 
by preventing epithelial cell-pathogen interaction. Route (6): Apical recycling of  pIgR may provide pathogens 
with a cell entrance mechanism.  Figure obtained form Phalipon and Corthesy, (2003).
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Dimeric IgA, generated in the lamina propria, may encounter antigens prior to transepithelial 
transfer.  Antigen binding to pIgA and subsequent pIgR mediated transcytosis, consequently 
leads to removal of the antigen.  This excretory pathway (figure 10, route 2) illustrates the 
protective role of pIgA and pIgR in the tissue underlying the epithelial cell layer.  
Furthermore, sIgA may come across intracellular antigens, such as some viruses, en route to 
the apical surface.  sIgA-antigen complexes generated intracellularly are excreted to the 
lumen, thus preventing damage to the epithelium (figure 10, route 3).  These two mechanisms 
can be considered as backup defensive measurements that take care of pathogens that manage 
to penetrate the epithelial barrier.   
 
sIgA, trapped within the mucus, as antiseptic paint, perform immune exclusion.  sIgA is 
directed and anchored to the mucus by glycosylated SC, where it protects the mucosal barriers 
from colonization and invasion by binding pathogens (figure 10, route 4) (reviewed in 
Phalipon and Corthesy, 2003).   
Streptococcus pneumoniae is a bacterial pathogen that causes invasive life-threatening disease 
worldwide.  This organism also commonly colonizes the upper respiratory epithelium in an 
asymptomatic fashion.  To invade, this pathogen must traverse the respiratory epithelial 
barrier, allowing it to cause disease locally or disseminate haematogenously throughout the 
body.  SpsA (also known as CbpA), a surface displayed protein virulence factor of S. 
pneumonia have been shown to bind human pIgR, fSC and sIgA (Hammerschmidt et al., 
1997; Hammerschmidt et al., 2000; Zhang et al., 2000).  This may turn out to be, for both the 
pathogen and host, a double-edged sword.  Uncleaved pIgR, recycling at the apical face of the 
epithelia, provides a mechanism for colonization and invasion of the epithelia (figure 10, 
route 6) (Zhang et al., 2000).  Furthermore, pIgR mediated apical to basolateral transport of S. 
pneumonia has been demonstrated in a model system (Zhang et al., 2000).  However, this 
retrograde pIgR transport is disputed and is argued to be bacterial strain- and cell type 
dependent (Brock et al., 2002).   
Normally, pIgR-mediated internalization of microbes is prevented by cleavage of pIgR from 
the apical surface, the presence of fSC and finally sIgA antibodies in the secretions.  
However, an imbalance in any of these factors, or an overwhelming infection, could tip the 
scales in favour of the pathogen (reviewed in Kaetzel, 2001).   
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Thus, the key components of adaptive mucosal immunity (i.e. pIgR, sAbs and fSC) are able to 
counteract a variety of strategies employed by invading pathogens, consequently promoting 
crucial protection at the multiple layers of the epithelial barrier (lumen, epithelium and lamina 
propria).   
Targeting of pIgR as a mechanism for specific delivery of novel therapeutics and diagnostics 
to epithelial cells and mucosal surfaces is discussed in section 3. 
 
2. Filamentous bacteriophage and peptide display libraries 
Phage display is a technology suitable for elucidating protein interactions, such as receptor-
ligand interactions, studying molecular evolution and for selection of novel peptides such as 
therapeutic candidates.  To understand the molecular mechanism of protein interactions and to 
isolate compounds of therapeutic value, it is essential to identify and isolate the genes 
encoding the proteins of interest.  Phage display is a technique by which foreign peptides are 
expressed on the surface of bacteriophage particles (Smith, 1985).  Thus, the viral particles 
are vehicles that carry within them the nucleotide sequence encoding the surface expressed 
peptide, and also have the capability to replicate in bacterial hosts.  The physical link between 
genotype and phenotype, provided by the phage particle, is the hallmark of all phage display 
technology derivatives.   
 
A phage display library is a heterogeneous mixture of phage clones, carrying foreign DNA 
insertions, thus they display different peptides on their surface.  Libraries of vast molecular 
diversity coding for e.g. peptides or Ab-fragments, expressed as fusions to the coat proteins of 
the bacteriophage, have been constructed.  These libraries, with sequence diversities in the 
million and billion range, can be conveniently screened by affinity selection, thereby isolating 
clones with desired properties.  In addition to screen naturally occurring protein libraries for 
ligands, libraries may be constructed in vitro to develop peptides with random amino acid 
sequences and novel activities (Willats, 2002, review). 
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2.1 Filamentous bacteriophage: structure and biology  
A number of different bacteriophages have successfully been used in phage display; including 
F-pilus dependent filamentous phages (Ff), λ, baculovirus, T4 and T7.  Members of the Ff 
phage family, such as the virtually identical M13, fd and fl, are all excellent cloning vehicles 
due to their tolerance of relatively large DNA insertions.  Foreign DNA sequences inserted 
into their genome is simply accommodated by the assembly of larger phage particles.  In the 
further discussion, filamentous fd-phages will be the focus as they are used experimentally in 
the work described in this thesis.  
 
Filamentous phage (approximately 1µm in length and 6 nm wide, variation between strains 
exists) consists of single stranded DNA (ssDNA) packaged into a coat consisting of thousands 
of copies of the major coat protein gpVIII.  Additional minor coat proteins (gpIII, gpVI, 
gpVII and gpIX) are located at low copy numbers at the ends of the virus (figure 11) 
(reviewed in Marvin, 1998).  All of these surface proteins may serve as fusion partners for 
expressed peptides (Sidhu, 2001, review).  However, most libraries based on filamentous 
phage are constructed as N-terminal gpIII or gpVIII fusions.  
 
The high copy number of gpVIII on a single phage particle offers the opportunity for 
multivalent display.  However, peptides larger than 6-8 amino acids are not tolerated very 
well on gpVIII (Iannolo et al., 1995).  gpIII, expressed in 3-5 copies, accept larger fusions and 
have been preferred for display of larger proteins like Ab variable domains or Fab fragments.  
gpIII display may also provide multivalent display.   
 
 
 
 
 
 
 
 
 
 
 
Figure 11.   
Schematic illustration of phage display 
Filamentous bacteriophage ssDNA (black oval 
line) is enclosed by thousands of copies of the 
major coat protein gpVIII (brown), making up 
most of the virus capsule.  The ends of the 
phage are constructed from, low copy number, 
minor coat proteins gpVII (orange), gpIX 
(green triangles), gpVI (dark green ovals) and 
gpIII (purple).   
 
Left; Display of introduced peptides (red) 
genetically fused to gpIII as indicated by 
corresponding colours in the phage genome 
(purple and red). 
  
Right; Display of a large number of introduced 
peptides (red) genetically fused to gpVIII as 
indicated by corresponding colours in the phage 
genome (brown and red). 
gpVII 
gpIX 
Peptides genetically 
fused to gpVIII 
ssDNA 
gpVIII 
Peptides genetically 
fused to gpIII 
gpIII 
gpVI 
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Multicopy display consequently leads to an increase in the avidity of the phages for the target 
they are panned against, making it difficult to discriminate between phages with minor 
differences in affinity.  When selecting high affinity peptides, monovalent display may be 
advantageous (Lowman et al., 1991).  Use of a phagemide vectors may result in monovalent 
display.  Phagemids, plasmids with phage origin of replication, carry sequences encoding the 
fusion peptides and lack other vital phage genes.   
 
The majority of the bacteriophage genes are provided by a helper phage that is co-infected 
together with the phagemide into the bacterial host.  Thus, secreted viral particles will display 
a mixture of fusion and wild-type protein, resulting in an average of less than one copy of 
fusion protein on the phage surface. 
 
The N-terminal gpIII domain plays a crucial role in host infection.  First, the phage attaches to 
the F pilus of male (F+) Escherichia coli (E.coli) strain as the primary receptor.   
Next, the phage attaches to the carboxy-terminal domain of the periplasmic E.coli protein 
TolA, the co-receptor for phage infection (Riechmann and Holliger, 1997).   
Subsequently, the viral ssDNA enters the cytoplasm.  In the bacterial cytoplasm, the ssDNA 
plus strand is converted by the host’s enzymatic machinery into a double-stranded replication 
form (RF) by the rolling circle mechanism.  The non-lytic propagation mechanism of Ff 
phage requires the newly synthesised ssDNA and coat proteins to be transported through the 
bacterial inner membrane prior to assembly and extrusion.  Other phages, including λ and T7, 
assemble to form new virus particles entirely within the cytoplasm of their host causing lysis 
at time of escape (reviewed in Marvin, 1998; Willats, 2002). 
 
2.2 Phage display in the fUSE5 system 
fUSE5 is a phage display vehicle and library system based on filamentous bacteriophage 
strain fd-tet (Zacher et al., 1980).  The fUSE5 vector, constructed for gpIII display, carries a 
tetracycline resistance gene inserted in a manner that renders the phage defective in minus 
strand synthesis resulting in low levels of RF DNA and low phage copy numbers.  This 
feature is advantageous as it prevents the host from being killed, allowing for the possibility 
of growing the peptide presenting phage and host bacteria for an extended period of time.  
fUSE5 carries a frame shift mutation in gene III, rendering the phages non-infectious.   
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Replacement of the fUSE5 stuffer fragment with a suitable insert, on SfiI restriction sites, 
restores the reading frame and makes the phage infectious.  There are two SfiI restriction sites 
in fUSE5, which have non-identical, non-complementary 3-base 3´ overhangs allowing for 
directional cloning (Scott and Smith, 1990). 
 
2.2.1 fUSE5 random peptide libraries 
Random peptide libraries may be constructed by inserting synthetic oligonucleotides with 
random sequences into the gene encoding the phage coat protein (Scott and Smith, 1990).   
Peptides can be displayed in fUSE5 as linear fusions or constrained (cyclic) fusions to gpIII. 
Constrained peptide libraries are constructed by introduction of two cystein residues flanking 
the random peptide sequences.  The cystein residues are capable of forming a disulphide-
bridge, reducing the conformational flexibility of the peptide.  Thus, they are expected to 
facilitate formation of tertiary structures that leads to enhanced binding affinity compared to 
linear peptides (O'Neil et al., 1992).  The diversity of the library is limited by a number of 
factors.  The non-lytic biology of the fUSE5 phage allows display of peptides that tolerate the 
viral assembly at the host’s membrane only.  Furthermore, peptides that show host 
cytotoxisity are likely to be eliminated from the library.  Moreover, peptides sensitive to 
proteases found within the host bacteria are eradicated, thus reducing the diversity of the 
library displayed on the phage particles.  In addition the proteolytic activity of the host cell, 
may lead to reduced valency.  That is, reduction of the number of displayed peptides per 
phage particle.  
  
2.3 Affinity selection; finding the needle in a molecular haystack  
Random phage display peptide libraries frequently contain as many as 109 different clones.  
Libraries typically hold hundreds of infective copies of each clone, thus the total number of 
functional phage in a library may exceed 1011 particles.  The enormous diversity in the 
primary library population must be reduced to a manageable level through efficient screening 
procedures prior to detailed analysis of selected clones.  Affinity selection, also known as bio-
panning, is the general approach to phage peptide display library screening (figure 12).   
 
The simplest and most widely used approach is to immobilize a target of interest (e.g. your 
favourite receptor) to a supportive surface (i.e. tubes, wells, beads or membranes) and then 
expose the library to the target (see figure 12, left panel).   
 46
Panning may also be performed directly against cell surfaces, tissues and even animals.  
Following interaction between the target and library, non-binders are removed by washing 
(see figure 12, centre panel).  Bound phage clones are subsequently eluted by disruption of the 
target-peptide interaction (e.g. by dramatic changes in pH).  Next, eluted binders are 
propagated by infecting fresh bacterial host cells (see figure 12, right panel).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The amplified population, comprising millions of copies of each clone, can then be subjected 
to further rounds of selection to obtain phages displaying peptides with even higher affinity.   
Additional variation may be introduced to the pool of phages by mutagenesis in between 
successive rounds of panning.   
 
Finally, selected clones are investigated in further detail and the inserted DNA, encoding the 
peptide displayed by the phage particle, is recovered.  This allows for subsequent sequencing 
and cloning in to expression systems yielding free peptides or fusion proteins depending on 
the desired downstream applications.  Further more, synthetic versions of the selected peptide 
may be constructed based on the revealed DNA sequence.    
 
Figure 12.  Affinity selection: the general cycle of phage display 
- Left panel: A phage library displaying an immense variety of peptides or proteins is exposed to immobilized target 
molecules of interest (e.g. receptors) (indicated by red aches) and allowed to bind.  
- Centre panel: Non-binding phages and weak binders are removed by stringent washing, leaving only phages with 
appropriate affinity behind.  Binders are eluted by conditions that interrupt the phage-target interaction (e.g. pH 
modulation).  
- Right panel: Bacterial host cells are infected with eluted phages which are thereby amplified.   
Successive rounds of panning leads to formation of a less and less diverse population of phages and enrichment for 
high affinity binders.  
 
After repeated rounds of panning, monoclonal phage populations or pools of phage may be selected and analysed.  
Eventually genes encoding the peptides with desired binding properties are recovered (i.e. by PCR based methods).        
Target binding     Elute Amplification Washing
 47
Two key parameters to keep in mind when screening phage display libraries are, stringency 
and yield.  Stringency is the degree to which peptides with higher affinity (or some other 
preferred ability) are favoured over peptides with lower affinity.  Yield is the fraction of 
peptide expressing phage within a given affinity window that survives the selection 
procedure.  The ultimate goal in affinity selection usually is to retrieve phages that express 
peptides with high affinity for the target of interest.   
 
Increased stringency (i.e. reduced target concentration, shorter target-library incubation period 
or excessive washing), may appear to do the trick.  However, the immense library diversity 
and low number of identical clones may cause loss of potential high affinity binders as the 
number of phage recovered after the first round of panning typically is in the 106 vicinity.  In 
the first round of panning good yield of high affinity peptides is of great importance, thus the 
stringency of the panning procedure must be sacrificed.  Prior to subsequent panning rounds, 
the survivors of the first panning are amplified to millions of identical clones.  At this stage 
high stringency can be applied as yield can safely be decreased.  The level of stringency 
applied is limited however.  Panning procedures are imperfect, causing an unavoidable 
background of phage binding to the solid support (reviewed in Smith and Petrenko, 1997; 
Willats, 2002).   
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3. Targeting pIgR: specific delivery to epithelia and mucosa  
Oral and systemic delivery of therapeutic macromolecules, gene therapy vectors and 
diagnostics to tissue may be hampered by endothelial or epithelial barriers.  In an effort to 
overcome this obstacle, delivery strategies exploiting innate trans-barrier transport 
mechanisms have been suggested.  Transport of phage particles across epithelial cells are 
facilitated by peptides selected from a random phage display peptide library, suggesting that 
small peptide carriers are capable of binding transcytosing receptors and mediate delivery of 
macromolecules, gene vectors or liposomes to epithelial cells and surfaces (Ivanenkov and 
Menon, 2000; Scherrmann, 2002, review).   
 
The pIgR-mediated transcytosis pathway for secretory Abs provides a transport mechanism 
that can potentially be exploited for the specific delivery of drugs, antibodies, antibody 
derivatives, viruses, and genes to epithelial cells and mucosal surfaces.  pIgR specific scFvs, 
conjugated to a therapeutically active protease inhibitor, have been shown to be specifically 
transcytosed across epithelial cells in an in vitro model (Eckman et al., 1999; Ferkol et al., 
2000).  Recently, an in vivo epithelial model provided further supportive evidence for the 
feasibility of utilizing pIgR for specific delivery of therapeutics to epithelial surfaces (Ferkol 
et al., 2003).  Furthermore, pIgR specific Fabs and scFvs have been developed for receptor 
mediated gene delivery to epithelial cells (Ferkol et al., 1993; Gupta et al., 2001).   
 
An alternative strategy, approached in parallel to scFv and Fab based targeting, is the use of 
short and simple peptides.  Small peptides with high affinity for the polymeric Ig receptor that 
are transported across epithelial cells by transcytosis may meet the criteria as ideal fusion 
partners for receptor mediated transfer to epithelia or mucosal surfaces.  Selection of viable 
small peptides candidates, preferably peptides that do not compete with sAbs for pIgR 
binding, may be achieved through phage display.  White and Capra (2002) recently reported 
selected peptides, both based on the IgA Cα3 sequence and candidates selected from random 
phage display libraries, that are specifically transcytosed across polarized, pIgR transfected, 
MDCK cells.  Their study supports evidence that small pIgR-binding peptide motifs may 
deliver therapeutics to mucosal sites. 
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Abbreviations  
 
A, Adenine 
A405, Absorption at 405nm 
ABTS, 2,2’-Azino-bis (3-ethylbenzthia-
zoline-6-sulfonic-acid) 
AMP, Adenosine monophosphate 
AP, Alkaline phosphatase 
Bio, Biotin 
BSA, Bovine serum albumin 
C, Cytosine 
C1q, Complement system factor 1 
subcomponent q 
C-terminal, COOH-terminal 
dH2O, Distilled water 
dNTP, deoxy-N-triphosphate (where 
N=adenine, guanine, thymine or cytosine)  
E, Eluate 
EA, Amplified eluate 
ELISA, Enzyme linked immunosorbent 
assay 
fSC, Free SC 
G, Guanine 
GFP, Green fluorescent protein 
h(rs), Hour(s) 
HRP, Horse radish peroxidase  
Ig, Immunogloublin 
IPTG, Isopropyl-β-D-thiogalactoside 
kDa, Kilo Daltons 
LB, Luria Bertani medium 
LB/amp, LB with 50µg/mL ampicilline 
LB/tetc, LB with 20µg/mL tetracycline 
 
 
mAb(s), Monoclonal antibody(s) 
MDCK, Madin-Darby canine kidney  
min, Minute(s) 
NEB, New England BioLabs 
N-terminal, NH2-terminal 
ON, Over night 
PBS, Phosphate buffer saline 
PBS/T, PBS with 0,05% Tween 20 
PCR, Polymerase chain reaction 
pIgA, Polymeric immunoglobulin A 
pIgM, Polymeric immunoglobulin M 
pIgR, Polymeric Immunoglobulin receptor 
RF, Replicative form 
RFU, Relative fluorescence units 
rpm, Rotations per minute 
RT, Room temperature 
SB, Super Broth medium 
SC, Secretory component  
scFv, Single chain fragment of variation 
SDS PAGE, Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis 
sec, Seconds 
sIgA, Secretory IgA 
sIgM, Secretory IgM 
SKM, Skimmed milk 
T, Thymine 
TAE, Tris-acetat EDTA 
TU, Transducing units 
U, Units 
wt, Wild type 
α, Anti 
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1.  Abstract 
 
Delivery of therapeutic macromolecules, gene therapy vectors and diagnostics to tissue may 
be hampered by endothelial or epithelial barriers.  In an effort to overcome this obstacle, 
delivery strategies exploiting innate trans-barrier transport mechanisms have been suggested.  
The polymeric immunoglobulin receptor (pIgR) directs formation and trans-epithelial 
transportation of secretory immunoglobulins that provides a first line of humoral defence at 
mucosal surfaces.  Consequently, the pIgR-mediated mucosal secretion system potentially 
represents a route for targeted delivery to epithelial cells and mucosal surfaces.  We aimed at 
identifying novel small peptides that bind to the extracellular domains of pIgR, known as the 
secretory component (SC), and that are specifically transcytosed across Madin Darby Canine 
Kidney (MDCK) cells transfected with human pIgR, by affinity selection from phage display 
libraries.  Assuming that one key to identifying peptides, with the sought after properties, is 
the number of screened phage single clones, semi-automated screening procedures were 
designed.  We have identified 5 novel SC binding phage displayed peptides by affinity 
selection using two libraries.  One of the identified clones, C9-4, bind immobilized SC in a 
SpsA-like manner and is specifically transcytosed across MDCK cells transfected with human 
pIgR.  Amino acid substitution mutation analysis revealed that all, but three, amino acids were 
indispensable to the selected peptide’s functionality as an SC binder.  Furthermore we 
constructed and expressed C9-4 as a fusion to green fluorescent protein (GFP).  Despite the 
successful affinity selection, transcytosis, and fusion protein construction and expression, 
interaction with immobilized SC could not be demonstrated in the new fusion format. 
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2.  Introduction 
Mucosal surfaces, constantly challenged with potential pathogens, are protected by innate and 
adaptive immune defense mechanisms.  Adaptive immunity at the mucosa is mediated mainly 
by the polymeric immunoglobulins (pIgs).  Polymeric IgA and IgM contain a small 
polypeptide called the "joining" (J) chain.  J chain-positive IgA primarily consists of dimers 
(dIgA), and some larger polymers, whereas only IgM pentamers (pIgM) incorporate the J 
chain (reviewed in  Johansen et al., 2000).  dIgA and pIgM bind to the polymeric 
immunoglobulin receptor (pIgR) expressed on the basolateral side of mucosal epithelial cells.  
The protective antibodies are transported across the epithelia by pIgR to mucosal surfaces 
(Norderhaug et al., 1999, review).   pIgR is a transmembrane type I receptor consisting of five 
Ig homologous domains a membrane spanning domain and a cytoplasmic tail.  Internalization 
signals in the cytoplasmic, C-terminal domain of pIgR causes the receptor to be sorted into 
coated pits and hence endocytosed.  In the endosomal compartment, pIgR is sorted into 
vesicles for transcytosis to the apical surface or recycled to the basolateral surface.  At the 
apical surface, a protease cleaves off the extracellular receptor domain, named secretory 
component (SC).  pIgR is constitutively transcytosed, regardless of ligand binding.  However, 
ligand binding increases the internalization rate (Luton et al., 1999).  Consequently, free 
secretory component (fSC) as well as SC associated pIgs is released into the extracellular 
secretions.  SC associated Abs are referred to as secretory Abs (sAb) i.e. secretory IgA (sIgA) 
and IgM (sIgM).   
 
sIgA, by far the dominating species of sAbs, remains covalently linked to SC in secretions.  
Pentameric IgM, on the other hand, remains non-covalently associated with SC in secretions 
after apical cleavage.  Anchored to the mucus layer by SC, secretory antibodies serve as an 
external barrier that performs immune exclusion at mucosal surfaces, thereby protecting the 
epithelium from pathogen colonization and invasion.  Furthermore, dIgA bound to pathogens 
located in the lamina propria are transported through the epithelia by pIgR and are excreted at 
the luminal face as complexes of sIgA and antigen.  En route to luminal secretion, pIgA 
bound to pIgR may counteract invading pathogens by intracellular neutralization and 
subsequent excretion (reviewed in Phalipon and Corthesy, 2003).  Uncleaved pIgR is 
internalized and recycled apically (Breitfeld et al., 1989).  pIgR, recycling at the apical face of 
the epithelia, is suggested to provide a mechanism for colonization and invasion of the 
epithelia.   
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SpsA (also known as CbpA) is a surface displayed protein virulence factor of Streptococcus 
pneumoniae.   S. pneumoniae is a potentially lethal bacterial pathogen that commonly 
colonizes the upper respiratory epithelium in an asymptomatic fashion.  To invade, the 
pathogen must cross the respiratory epithelial barrier, and it has been shown to bind human 
pIgR, fSC and sIgA (Hammerschmidt et al., 2000; Zhang et al., 2000).  Expression of pIgR in 
epithelial model systems has been shown to greatly enhance pneumococcal adherence and 
invasion, suggesting that pIgR recycling is one of several mechanisms utilized for invasion 
(Zhang et al., 2000).     
 
In light of the pIgR biology, the pIgR-mediated transcytosis pathway is a mechanism that 
might be exploited for the specific delivery of therapeutic payloads, diagnostic agents or gene 
delivery vectors to epithelial cells and mucosal surfaces.  Furthermore, pIgR binding peptides 
might have the potential to block ligand binding sites on the receptor, potentially leading to 
reduced transcytosis or entry of pathogens.    
 
Phage display libraries have successfully been the source of peptides with affinity for a large 
variety of targets.  Peptides used in detection of biological threats (Petrenko and Vodyanoy, 
2003, review), mapping of molecular markers of tumors (Zurita et al., 2003, review), mapping 
of enzyme specificity (Deperthes, 2002, review), vaccine development (Lesinski and 
Westerink, 2001, review) and targeted drug delivery, i.e. to tumors (Nilsson et al., 2000, 
review), have been performed using phage display libraries.  Functional mimicry of a protein 
hormone, by a peptide agonist that bind the EPO receptor (Livnah et al., 1996), demonstrates 
that small peptides without resemblance to the receptor’s native ligand, may be biologically 
active.  Phage displayed peptides have been demonstrated to block receptors.  Hetian et al., 
(2002) describe a peptide that block the vascular endothelial growth factor receptor and thus 
have potential in inhibition of angiogenesis and tumor growth.  Mucosae have been targeted 
both by integrin binding phage displayed peptides (Ivanenkov and Menon, 2000) and through 
pIgR binding peptides.  Recently, pIgR targeting peptides were identified from phage display 
libraries and demonstrated to be specifically transcytosed across an epithelial model system 
(White and Capra, 2002).   
 
Furthermore, four peptides that bind immobilized SC were isolated by affinity selection from 
two cysteine constrained phage display libraries (Lauvrak et al., 2003; Braathen et al., 
unpublished data).   
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Only one of the identified peptides, named C9-4, was specifically transported across MDCK 
cells transfected with human pIgR.  The peptide was shown to bind to SC at a site different 
from the interaction site utilized by IgA and IgM.  Interestingly, phages displaying the peptide 
were inhibited from target binding by SpsA.  Inhibition studies using a synthetic version of 
the C9-4 peptide interfered with the phage-receptor interaction at nM concentrations 
(Braathen et al., unpublished results).   
 
Assuming that one key to isolating more peptide candidates was to screen additional peptide 
displaying phage clones, semi-automated screening procedures to allow for high throughput 
sample handling and screening was set up.  Access to a robotic liquid handler and large 
amounts of human SC purified from colostrum, made SC a feasible target to use when 
designing an automation pilot project.  Furthermore, to study the interaction between the C9-4 
peptide and the receptor, the peptide sequence was analyzed by systematically substituting 
each amino acid.   
 
Phage displayed peptides affinity selected for various targets have been attempted fused to 
scFv- and Fab antibody fragments in our laboratory.  One of these peptides, a C1q binder, 
retained its target binding ability both as a C-terminal fusion to Fab, scFv and as an internal 
fusion to Fab (Lauvrak and Berntzen, unpublished).  A scFv antibody fragment with C9-4 as 
C-terminal fusion and a green fluorescent protein (GFP) with C9-4 as N-terminal fusion have 
previously been engineered and expressed in bacteria.  However, both constructs gave low 
yields and no SC binding was observed using ELISA assays (Lauvrak and Berntzen, 
unpublished).  Lack of binding in the new fusion protein context can be due to low 
accessibility, low affinity and/or improper folding of the peptide.  To investigate if the 
introduction of a flexible linker and dimerization of the C9-4 peptide would affect pIgR 
binding, through increased peptide accessibility and avidity, N-terminal GFP fusion proteins 
were constructed. 
 
The goal of the current study has been to identify and isolate small peptide motifs that would 
both bind to the pIgR and be specifically transcytosed by the receptor and thus offer the 
possibility of targeting mucosal sites.  We aimed at developing efficient screening methods for 
handling of large numbers of phage single clones.  Moreover, we have studied the C9-4 
peptide’s interaction with pIgR in further detail.    
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3. Materials and Methods 
3.1 Phage display libraries, phage clones, plasmids and bacterial strains  
The fUSE5 vector (Scott and Smith, 1990) was kindly provided by Dr. G.P. Smith, University 
of Missouri, USA.  The phage protein III fusion libraries Cys9 (Lauvrak et al., 2003), and 7-
mer (Lauvrak, unpublished) were both constructed in our lab using the fUSE5 vector.  The 
Cys9 library consisted of approximately 5 x 107 different clones and displays constrained 
peptides of nine random amino acids, flanked by cysteines.  The 7-mer library consisted of 
approximately 8 x 107 different clones and displays random unconstrained peptides, seven 
amino acids in length.  The libraries were constructed from degenerative synthetic 
oligonucleotides (NNK), where N represents an equal mix of the four natural DNA 
nucleotides; Adenine (A), guanine (G), cytosine (C) and thymine (T) and K represents an 
equal mix of G and T.  Phage clone C9-4 (CVVWMGFQQVC) was previously selected from the 
Cys9 library and shown to bind SC and demonstrated to be transcytosable (unpublished 
results, Braathen et al.).  The irrelevant phage clones T7 (LHVSQRG) and TCys9 
(CDLGWWMDVSC) were randomly chosen from the 7-mer and Cys9 libraries, respectively.      
 
The bacterial expression vector pET21d was obtained from Novagen.  The green fluorescent 
protein (GFP) encoding vector pHOG-GFP was kindly provided by Dr. O.H. Brekke, Affitech 
AS, Norway, and is a modified version of the bacterial expression vector pHOG (Kipriyanov 
et al., 1997) with a GFP encoding sequence inserted C-terminally of an scFv encoding 
sequence (Brekke, unpublished).  The bacterial strains E.coli BL21DE and E.coli XL-1 blue 
were obtained from Novagen and Stratagene, respectively.  E.coli K91K (Smith and Scott, 
1993) and E.coli MC1061 (Meissner et al., 1987) were both kind gifts from Dr. G.P. Smith, 
University of Missouri, USA. 
 
3.2 Preparation and transformation of electrocompetent E.coli cells 
10mL Super broth growth medium (SB) was inoculated with  E.coli MC1061, E.coli XL-1 
blue or E.coli BL21DE cells and incubated at 37oC, over night (ON), with agitation (220rpm) 
(InnovaTM 4000 incubator shaker, New Brunswick Scientific).   
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One litre of preheated SB with 5mL of glucose (2M), in a three litre shaking flask, was 
inoculated with 5mL of the starter culture.  The E.coli MC1061 cultures were grown in the 
presence of 100µg/mL streptomycin and E.coli XL-1 blue cultures were prepared using 
10µg/mL tetracycline.  The cultures were incubated at 37oC with agitation (220rpm) 
(Controlled environment incubator shaker, New Brunswick Scientific) until a density of 0.8 at 
OD600 was reached (PU 8750 UV/VIS scanning spectrophotometer).  Shaking flasks were 
cooled on ice for 15 minutes (min).  Next, cells were harvested by centrifugation at 5000rpm 
for 15min at 4oC (Sorvall® RC-5B Refrigerated superspeed centrifuge, DuPont Instruments).  
The cell pellet was washed 3x by gentle re-suspension in ice cold dH2O with 10% glycerol.  
The amount of washing reagent was reduced between each round of washing (500mL, 250mL 
and 50mL).  Each washing step was concluded with centrifugation as described above.   
After the last washing step, the pellet was gently resuspended in 2mL of ice cold dH2O with 
10% glycerol.  Aliquots of 40µL in cold tubes were immediately frozen in ethanol- dry ice 
bath and stored at -70oC. 
 
Electrocompetent bacteria were transformed by electroporation.  2µL of the vector DNA to be 
propagated or 2µL of seeDNATM (Amersham Bioscience) precipitated ligation mix, were 
mixed with 40µL electrocompetent cells on ice and transferred to ice cold cuvettes (1mm gap, 
BTX).  Subsequently, cells were pulsed (BioRad, 200Ω, 1.3V), recovered from the cuvette by 
adding 1mL 2xYT growth medium, transferred to an eppendorf tube and incubated at 37oC 
for 1hour (h).  E.coli MC1061 transformed with fUSE5 was recovered and incubated using 
2xYT growth medium containing tetracycline (0.2µL/mL).  The low concentration of 
antibiotic, does not affect sensitive cells, however it induce expression of the tetracycline 
resistance gene.  Cell dilutions were then plated on to LB plates with relevant antibiotic and 
incubated at 37oC ON.  E.coli MC1061 transformed with fUSE5 were plated onto tetracycline 
(20µg/mL) containing plates (LB/tetc), whereas E.coli XL-1 blue transformed with pHOG-
GFP and E.coli BL21DE transformed with pET21d were plated onto LB plates containing 
ampiciline (50µg/mL) (LB/amp). 
 
3.3 Phage titration, amplification and propagation of single clones 
The number of phage particles in a solution was determined by titration as E.coli K91K 
transducing units per millilitre (TU/mL), i.e. the number of phage particles that infect host 
cells, calculated as tetracycline resistant colonies.   
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fUSE5 phages have a reduced infectivity rate (the ratio of TU to the number of physical phage 
particles) of ~5-10%,  compared to ~50% infectivity in wild type phage (Smith, 1994).  Thus, 
the actual amount of phage particles in a sample may exceed the TU/mL value by a factor of 
10-20.   
 
Phage amplification was done by growing transduced E.coli K91K cells in liquid media and 
phage containing supernatants were obtained by removing the cells by centrifugation.  Due to 
a defect in minus strand synthesis, and consequently low copy number of RF-DNA, fUSE5 
can be propagated for an extended period of time without causing detrimental harm to the host 
cells (Smith, 1994).  
 
Fresh Terrific Broth (TB) cultures of E.coli K91K cells were prepared prior to each titration 
or amplification by inoculating 9mL TB medium added 1mL phosphate buffer (0.17M 
KH2PO4 and 0.72M K2HPO4) with a single colony of E.coli K91K.  Cells were incubated for 
4 hours (hrs) at 37oC with agitation (200rpm) (InnovaTM 4000 incubator shaker, New 
Brunswick Scientific) to yield a high density of living host cells (~109cells/mL).  The last 15 
minutes of the incubation time, the shaking rate was reduced to 50 rpm to allow for 
regeneration of F-pili.   
 
Dilutions of the phage suspensions to be titrated, was prepared in PBS.  10µL of diluted phage 
was mixed with 10µL of E.coli K91K TB culture prepared and incubated for 10min at RT.  
The ratio of phage TU versus host cells was always assured to be below 0.1.  Luria Bertani 
medium (LB) with tetracycline (0.2µg/mL) was added to a total of 200µL and the mixture 
was incubated for 45min at 37oC to allow for gene expression from the tetracycline resistance 
gene.  Subsequently, 100µL of the cultures were plated onto LB/tetc plates and incubated at 
37oC ON.  Colonies were counted to calculate TU/mL. 
 
Phages were amplified by mixing 100µL phage supernatant with 100µL of fresh E.coli K91K 
TB host cells and incubated as for the titration, using 1mL of LB medium with low 
tetracycline concentration.  Subsequently, the cultures were transferred to 20mL of 
tetracycline (20µg/mL) added LB medium (LB/tetc) in a 50mL tube.  Dilutions of the 20mL 
culture were plated onto LB/tetc plates and incubated at 37oC ON to determine output.  The 
20mL culture was incubated at 37oC ON with agitation.  Cells were removed by 
centrifugation at 4600rpm for 30min at 4oC (Centra CL3, International Equipment Company).  
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The phage supernatant was centrifuged once more to remove remaining cells and cell debris.  
Phage supernatants were stored at 4oC. 
 
Individual phage clones were propagated and screened for target binding capacity.  Fresh 
colonies of transduced E.coli K91K cells, prepared as described above, were transferred to 
15mL tubes containing 3mL LB/tetc or to 96 deep well plates containing 900µL of LB/tetc by 
standard sterile techniques and incubated at 37oC, ON with agitation.  Phage supernatants 
were recovered by two centrifugations as described above, or for 30min at 4000rpm at 4oC 
(AllegraTM25R Centrifuge, Beckman Coulter) for the 96 deep well cultures.  The phage 
supernatants were transferred to 15mL tubes or 96well V-bottom plates and stored at 4oC. 
 
3.4 Affinity selection for SC binding, peptide displaying, phages 
Novel SC binding peptides were isolated by performing two rounds of affinity selection using 
the 7-mer and Cys9 libraries.  SC purified from human colostrum was provided by Dr. F-E. 
Johansen, Laboratory for Immunohistochemistry and Immunopathology, Institute of 
Pathology, University of Oslo, Rikshospitalet.  Nunc-ImmunoTM MaxiSorpTM tubes, with 
“star” shaped bottom, or Nunc-ImmunoTM MaxiSorpTM strips were coated with 800µL or 
200µL of 30µg/mL human SC diluted in PBS, respectively by ON incubation at 4oC.  The 
tubes and strips were blocked using two coat volumes of either 1% skimmed milk (SKM) or 
1% bovine serum albumin (BSA) (Sigma-Aldrich) in PBS at room temperature (RT) for 1h 
followed by three times washing in PBS with 0.05% Tween20 (Sigma-Aldrich) (PBS/T).  
Input phage to the first round of affinity selection was 100µL of the Cys9 library 
(~1.4x1010TU) and 10µL of the 7-mer library (~1.5x109TU), diluted to 800µL or 200µL, 
respectively, in 1% SKM or 1% BSA and pre-incubated for 30min at RT before they were 
added to the coated and blocked tubes or wells.  Phages were allowed to interact with and 
bind to immobilized SC for 90min at RT.  Following washing, 8x PBS/T, bound phages were 
eluted by adding 800µL or 200µL 0.1M HCl/Glycine pH 2.2 to the tubes and wells of the 
strips, respectively.  The acidic buffer was incubated for 10min at RT before the phage 
containing eluates were neutralized by adding 120µL or 17µL of 1.5M Tris pH8.8 buffer, 
respectively.  200µL of the first eluates (E1) were amplified in 20mL cultures by infecting 
fresh E.coli K91K as described in section 3.3.  The output of phage from each selection was 
determined as the total number of TUs in the eluates.  100µL portions of the amplified eluates 
(EA1) served as input to the second round of affinity selection.   
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Phage supernatant nomenclature: 
Eluates from the first and second round of selection are referred to as E1 and E2, respectively. 
Amplified eluates from the first and second round of selection are referred to as EA1 and 
EA2, respectively.  The prefix 7-mer or Cys9 refers to the library of origin.  The applied 
blocking agent is included in the eluate/amplified eluate name via the suffix BSA or SKM.  
3.5 Phage ELISA  
Supernatants, originating from pools of phage or single clones, were analyzed for the presence 
of SC binding particles by ELISA assays with immobilized SC as target.  NuncTM MaxiSorpTM 
96 well plates were coated with 100µL or 200µL of 5µg/mL SC by incubation at 4oC, ON.  
Wells were blocked, using two coat volumes of 1% SKM or 1% BSA, for 1h at RT, and 
subsequently washed 3x in PBS/T.  Phage supernatants, 50µL or 100µL, were pre-incubated 
in blocking solution (1:1) for 30min at RT.  Pre-incubated phages (100µL or 200µL) were 
allowed to interact with, and bind to immobilized SC for 90min at RT.  Following extensive 
washing, 8x PBS/T, bound phages were incubated with one coat volume of M13 specific 
mAbs (from mouse) conjugated to horse raddish peroxidase (αM13-HRP) (Amersham 
Pharmacia Biotech, 5000x), diluted (1:4000) in blocking solution, for 1h at RT.  The washing 
step was repeated before bound phages were visualized.  One coat volume of ABTS (Sigma-
Aldrich), dissolved in sterile filtrated 0,05M citric acid buffer and added H2O2 (Aldrich, 
30%), was applied as HRP substrate.  Readout was absorbance at 405nm (A405) as measured 
(Tecan Sunrise Spectrophotometer, with Magellan 3.0 software) after 30-60 minutes of 
incubation at RT.       
 
3.6 Phage elution-titration study 
The number of phages bound to SC was determined by elution-titration studies carried out in 
parallel to ELISA analysis.  NuncTM MaxiSorpTM 96 well plates were coated with 200µL of 
20µg/mL SC by incubation at 4oC, ON.  Subsequently, wells were blocked and washed and 
phages were incubated as described for the ELISA assay in 3.5.  Washing, elution with 200µL 
of  0.1M HCl/Glycine pH 2.2 and neutralization using 30µL of  1.5M Tris pH8,8 buffer were 
performed essentially as described for affinity selection in 3.4.  Output of recovered phages 
was determined by infecting fresh E.coli K91K cells, as described in 3.3., to validate 
enrichment for SC binding clones.   
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3.7 Phage sequencing 
gpIII displayed fusion peptides, of ELISA positive phages, were characterized by recovering 
the DNA sequences by PCR.  A large number of sequencing templates were prepared in a 96 
well format, using a Biomek 2000 liquid handling robot. 
 
Each PCR reaction contained: 10µL phage supernatant as template, primers fUSE5 
(TCGAAAGCAAGCTGATAAACCG) and fUSE5-for (GTACAAACCACAACGCCTGTAG) 
(20pmol) (Eurogenetic), dNTP (200µM, Amersham Pharmacia Biotech), 10µL Thermopol 
polymerase buffer (10x, NEB), 0.5µL Vent DNA polymerase (2000U/mL, New England 
BioLabs (NEB)) and dH2O to a total of 90µL.  Templates and PCR reaction mix were 
transferred to 96well V-bottom PCR plates using an automated liquid handler, Biomek 2000, 
(Beckman Coulter) (see appendix 1 for robotic scripts) or manually.  The sequencing 
templates were amplified by the following cycles: 94oC for 5min, then 30 cycles of 1min 
94oC, 55oC for 30 seconds (sec) and 72oC for 30sec using a Techne Genius thermocycler 
(Techne).  PCR products were purified (QIAquick® PCR Purification Kit, Qiagen) as 
described in the protocol provided with the kit.  Purified PCR products were analysed by gel 
electrophoresis (BioRad powerpac 300 and Pharmacia electrophoresis power supply 500/400, 
90-100V) (2% agarose gel, Sigma-Aldrich, in TAE buffer), to confirm generation of 
sequencing templates.  Agarose gels were prepared with casting combs designed to 
accommodate sample application using multi-channel pipettes, consequently leading to 
enhanced throughput. 
 
Purified templates were shipped to GATC Biotech AG for sequencing using primer sekP 
(CCCTCATAGTTAGCGTAACG), complementary to the fUSE5 + strand.  The sequencing 
results were provided electronically as abi files and analysed by Chromas software 
(McCarthy). 
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3.8 Inhibition of phage binding to SC 
Phage binding to SC was further examined by the addition of competing target binding 
molecules in an SC binding ELISA.  The native ligands of human SC, pIgA and pIgM plus 
fragments of pneumococcal surface protein SpsA (Streptococcus pneumoniae) that bind 
human SC species specifically were applied as inhibitors.  pIgA and pIgM was prepared and 
purified as described by Braathen et al., (2002).  SpsA fragments SH2, SM1 (SC positive) and 
SH3 (SC negative) (Hammerschmidt et al., 1997; Hammerschmidt et al., 2000) were obtained 
from S. Hammerschmidt.  NuncTM MaxiSorpTM 96 well plates were coated with 50µL of 
30µg/mL SC by incubation at 4oC, ON.  Subsequently, wells were blocked, using two coat 
volumes of 1% BSA, for 1h at RT and washed in PBS/T (4x using a Tecan Columbus washer, 
Tecan).  60µL of inhibitor dilutions (end concentration 100, 50, 25, 12.5 and 0nM) were 
added to 60µL phage supernatant.  50µL  samples were incubated against immobilized SC of 
for 90min at RT.  The washing step was repeated prior to incubation with one coat volume of 
mouse anti-M13 antibody (Amersham Pharmacia Biotech) diluted 1:1000 in PBS/T for 90 
minutes at RT.  Following repeated washing, 50µL of the secondary antibody reagent, rabbit 
anti-mouse conjugated to alkaline phosphatase (AP) (DAKO) diluted 1:1000 in PBS/T was 
added for 90 min at RT.  Finally, following washing, the plates were incubated with p-
nitrophenyl phosphate (Sigma) in diethanolamine buffer at RT for 10-60 min.  Absorbance at 
405 nm was measured as described in 3.5. 
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3.9 Transcytosis of phage across pIgR transfected MDCK cells  
Madin-Darby canine kidney (MDCK) cells, a commonly used epithelia model system, were 
used to investigate if SC binding phage, identified by affinity selection, could be transported 
across epithelia by pIgR mediated transcytosis. 
MDCK cells, untransfected or stably transfected with human or murine pIgR (Natvig et al., 
1997; Roe et al., 1999) were used to study transcytosis.  Approximately 5.0 × 105 cells were 
seeded on 1-cm2, 3.0-µm collagen-coated PTFE filters (Transwell-COL 3494; Costar)  The 
cells were incubated for 3 days at 37 °C with 5% CO2 in Dulbecco's modified Eagle's medium 
containing 10% fetal calf serum, 50 µg/ml gentamicin, and 1 mM L-glutamine.  At that time, 
the transepithelial resistance was about 150-200 ohms.   
10 µl of phage supernatant were added to the basolateral chamber and the filters were 
incubated for 20 h at 37°C in fresh medium.  Irrelevant phage, was used as a control together 
with 100 nM (15µg/mL) human IgG (to control for unspecific transport and leakage).  The 
apical medium was harvested, and the number of phage particles, transported by pIgR, was 
calculated by standard titration studies as described in section 3.3.  IgG leakage to the apical 
medium was detected by ELISA essentially as described in Braathen et al., (2002).  
 
3.10 Amino acid substitution mutation analysis  
The contribution of each individual amino acid side chain on C9-4’s (CVVWMGFQQVC) ability 
to bind SC was determined by performing an alanine / serine scan on the phage displayed 
peptide.   
3.10.1 Production of inserts encoding amino acid substituted peptides   
Synthetic oligonucleotides (Eurogenetic) comprising systematic substitutions of wild type 
amino acids with alanine or serine were designed with SfiI (highlighted in yellow) restriction 
sites.  The sequences of the mutagenic oligonucleotides are given in table 1.  All templates 
differed only in one codon, except the double mutant AS-C1SC11S that differed from the 
wild type in two codons.   
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5’- CTA TTC TCA CTC GGC CGA CGG GGC C- Peptide insert -GG GGC CGC TGG GGC CGA AAC TGT TGA A- 3’ 
 
Table 1.  Synthetic oligonucleotides encoding alanine (GCA) or serine (AGC) substitutions 
Oligo name Oligonucleotide sequence 
C9-4  * TGT GTG GTT TGG ATG GGT TTT CAG CAG GTG TGT 
AS-C1S AGC GTG GTT TGG ATG GGT TTT CAG CAG GTG TGT 
AS-V2A TGT GCA GTT TGG ATG GGT TTT CAG CAG GTG TGT 
AS-V3A TGT GTG GCA TGG ATG GGT TTT CAG CAG GTG TGT 
AS-W4A TGT GTG GTT GCA ATG GGT TTT CAG CAG GTG TGT 
AS-M5A TGT GTG GTT TGG GCA GGT TTT CAG CAG GTG TGT 
AS-G6A TGT GTG GTT TGG ATG GCA TTT CAG CAG GTG TGT 
AS-F7A TGT GTG GTT TGG ATG GGT GCA  CAG CAG GTG TGT 
AS-Q8A TGT GTG GTT TGG ATG GGT TTT GCA CAG GTG TGT 
AS-Q9A TGT GTG GTT TGG ATG GGT TTT CAG GCA GTG TGT 
AS-V10A TGT GTG GTT TGG ATG GGT TTT CAG CAG GCA TGT 
AS-C11S TGT GTG GTT TGG ATG GGT TTT CAG CAG GTG AGC 
AS-C1SC11S AGC GTG GTT TGG ATG GGT TTT CAG CAG GTG AGC 
 
 
 
Peptide encoding inserts were produced by PCR amplification of the synthetic 
oligonucleotides.  Each reaction contained:  Oligonucleotide template (40pmol), 5’-
biotinylated primers P1-bio (CTATTCTCACTCGGCCGACG) and P2-bio 
(TTCAACAGTTTCGGCCCCAG) (200pmol) (Eurogenetic), dNTP (200µM) and dH2O to a total 
of 100µL.  Inserts coding for mutations AS-C1S, AS-V2A and AS-W4A were obtained using 
0.5µLVent polymerase and 10µL Thermopol polymerase buffer (10x), whereas inserts 
encoding the remaining substitutions, were acquired using 0.5µL HerculaseTM Enriched DNA 
polymerase (5000U/µL)(Stratagene) and 10µL HerculaseTM reaction buffer (10x) 
(Stratagene).   
 
The reaction was run under the following conditions: 94oC for 5min, then 20 cycles of 94oC 
for 1min, 50oC for 30 seconds (sec) and 72oC for 30sec on a Techne Genius thermocycler.  
The PCR products were purified with CentriflexTM protein removal cartridges (Advanced 
Genetic Technologies Corp.), seeDNATM precipitated as described in the protocol provided 
with the kit using a microcentrifuge (Heraeus, Biofuge pico), and resuspended in 10µL dH2O.  
sfiI sfiI 
*C9-4 is included in the table for comparison only.   
This template was recovered from a SC binding, phage displayed peptide.  
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Samples of the seeDNATM precipitated PCR products (2µL) were analysed by gel 
electrophoresis using 4% NuSieve®3:1 agarose (BMA products) in TAE buffer. 
 
The double stranded products were restricted with SfiI to generate fUSE5 compatible inserts.  
Each digestion reaction contained: seeDNATM precipitated PCR product aliquot, 10µL NEB2 
buffer (10x), 5µL SfiI (20000U/mL, NEB) and dH2O to a total of 100µL.  The restriction 
reactions were carried out at 50oC for 4h using a Techne Genius thermocycler.  Subsequently, 
10µL of the restriction reactions were analysed by gel electrophoresis (4% NuSieve®3:1 
agarose). 
 
Biotinylated ends and undigested PCR products were removed by incubating two volumes of 
restriction mix with one volume of Streptavidin (Promega, 1mg/mL) for 30min at RT and 
subsequent capture by CentriflexTM protein removal cartridges (Ihle and Michaelsen, 2000).  
fUSE5 compatible, peptide encoding inserts were recovered using a micro centrifuge 
(Heraeus, Biofuge pico), seeDNATM precipitated, resuspended in 20µL dH2O and analyzed on 
a 4% NuSieve®3:1 agarose gel by electrophoresis to determine DNA concentration. 
3.10.2 Generation of phage expressing amino acid substituted peptides  
fUSE5 RF DNA was propagated by transforming electrocompetent E.coli MC1061 cells 
(competency: ~2x1010Trf/µg pUC DNA) with 2µL RF DNA (~300ng/µL) (diluted 1:1000 in 
dH2O) as described in section 3.2.  Single clones of the transformants were transferred to 
10mL LB/tetc growth medium in 50mL tubes and incubated at 37oC ON with agitation.  The 
following day RF-DNA was isolated from the ON cultures by Wizard® Plus SV Miniprep 
(Promega) as described in the protocol provided in the DNA isolation kit.  
 
fUSE5 RF-DNA was restricted with SfiI to release a 15bp stuffer fragment.  Each restriction 
reaction contained: RF-DNA aliquot (90µL), 20µL NEB2 buffer (10x), 2µL BSA (100x), 
2,5µL SfiI and dH2O to a total of 200µL.  The restriction reactions were carried out at 50oC 
for 4h using a thermocycler (Techne Genius).  5µL additional SfiI diluted in NEB2 buffer 
(1:20) was added to each reaction tube and the incubation was continued for one hour at the 
same temperature conditions.  Restricted and uncut RF-DNA were quality checked by gel 
electrophoresis (0.8% agarose), seeDNATM precipitated and concentration evaluated by gel 
electrophoresis.   
 
 68
Peptide encoding inserts were ligated to restriction digested fUSE5 RF-DNA in a 1:1 molar 
ratio.  Approximately 100ng of fUSE5 vector DNA and 1ng of the various inserts, as 
determined by gel electrophoresis band intensity, were added to a ligation mix containing 
0.5µL T4 DNA ligase (1000U/mL) (Roche), 2µL ligase reaction buffer(10x)(NEB) and dH2O 
to a total of 20µL.  The ligation reactions were carried out at RT ON, seeDNATM precipitated 
and resuspended in 5µL dH2O.  All DNA was stored at -20oC.     
 
Phage particles expressing alanine or serine substituted gpIII fusion peptides were generated 
by transforming E.coli MC1061 cells using 2µL of each seeDNATM precipitated ligation mix 
as described in section 3.2.  The transformation cultures (1mL) were transferred to 50mL 
tubes containing 25mL LB/tetc medium and incubated at 37oC ON with agitation.  The 
following day phage containing supernatants were recovered by centrifugation as described in 
and single clone supernatants were prepared by infecting fresh E.coli K91K cells as described 
in section 3.3. 
 
The single clone supernatants were used as templates in a PCR reaction identical to the one 
described in section 3.7.  The PCR products were analysed by gel elctrophoresis (2% agarose) 
to confirm insertion of peptide encoding fragments.  Furthermore the PCR products were 
purified (QIAquick® PCR Purification Kit, Qiagen) and shipped to GATC Biotech AB for 
sequencing using primer sekP (see 3.7).  Sequencing of mutants AS-V3A and AS-F7A was 
carried out at the Laboratory for Immunohistochemistry and Immunopathology, Institute of 
Pathology, University of Oslo, Rikshospitalet. 
3.10.3 Effect of amino acid substitutions on SC binding capacity 
Single clone phage supernatants, confirmed to contain phage displayed alanine or serine 
substituted peptides, were screened for their ability to bind to immobilized SC in vitro by 
ELISA and elution-titration studies as described in section 3.5 and 3.6, respectively.   
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3.11 Construction of GFP fusion proteins 
Auto fluorescent GFP fusion proteins were constructed to asses the pIgR binding properties of 
the phage displayed peptide C9-4 (CVVWMGFQQVC) when taken out of the gpIII fusion 
context.  To ensure flexibility, the fusion proteins were constructed with a linker sequence.  
To examine the role of avidity on pIgR binding, a peptide-dimer fusion to GFP was designed.  
Another peptide, also selected by phage display, with affinity for complement subcomponent 
C1q was applied as control (CYWVGTWGEAVC).  This peptide has previously been shown to 
retain target binding capacity when shifted from the phage context to alternative fusion 
partners (Lunde et al., 2002).      
3.11.1 Production of GFP-fusion encoding inserts 
The pHOG-GFP plasmid was propagated by transforming E.coli XL-1 blue cells as described 
in section 3.2.  Single clones of the transformants were transferred to 3mL LB/amp growth 
medium in 15mL tubes and incubated at 37oC ON with agitation.  The following day pHOG-
GFP was isolated from the ON cultures by Wizard®Plus SV Miniprep (Promega) as described 
in the protocol provided in the DNA isolation kit.  
  
PCR was used to recover the GFP gene from the pHOG-GFP vector.  Biotinylated primers, 
GFP-Start and GFP-End (Eurogenetic) were designed as described in table 2.  GFP-Start 
carried an NcoI restriction site, whereas GFP-End carried an XhoI site, producing inserts 
compatible with directional cloning in pET21d (Novagen) (Figure 1A).  Three fusion protein 
encoding fragments, carrying NcoI restriction sites, were constructed using specific, 
mutagenic oligonucleotides (DNA Technologies) (Table 2).  
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Table 2.  GFP fusion primer sequences 
Primer name Oligonucleotide sequence * 
GFP-Start Bio-ATATATTATTCCATGGTGAGCAAGGGCGAGGAGCTG 
GFP-End Bio-ATAATAATACTCGAGTTACTTGTACAGCTCGTCCATGCCG 
C9-4-Mono-GFP ATAATATCCATGGGAGCCTGTGTGGTTTGGATGGGTTTTCAGCAGGTGTGT 
GGAGGACCAGGAGTGAGCAAGGGCGAGGAGCTG 
C9-4-Dimer-GFP ATAATATCCATGGGAGCCTGTGTGGTTTGGATGGGTTTTCAGCAGGTGTGT 
GGAGGAGGACCAGGATGTGTGGTTTGGATGGGTTTTCAGCAGGTGTGT 
GGAGGACCAGGAGTGAGCAAGGGCGAGGAGCTG 
C1qC10-Mono-GFP ATAATATCCATGGGAGCCTGTTATTGGGTGGGTACGTGGGGTGAGGCTGTTTGT 
GGAGGACCAGGAGTGAGCAAGGGCGAGGAGCTG 
 
*All sequences are given in 5’ - 3’ direction.   
Legend:  - NcoI (CCATG) and XhoI (CTCGAG) restriction sites are highlighted in yellow 
- GFP annealing primer regions are highlighted in turquoise.   
- Sequences highlighted in red represent fusion peptide encoding DNA.   
- A spacer region, connecting the two peptides of the dimer fusion peptide, is given in pink.   
- The linker region, connecting the peptide to GFP, is given in blue.   
- DNA highlighted in grey separates the restriction sites from the peptide encoding DNA.  . 
 
GFP was recovered by PCR as in the Vent polymerase based reaction described in 3.7 using 
primers GFP-Start (40pmol) and GFP-End (40pmol) and 10µL pHOG-GFP miniprep 
(10ng/µL) as template.  Mutagenic primers (~40pmol) and GFP-End (40pmol) were 
employed to produce fusion protein encoding PCR products using 0.5µL HerculaseTM 
Enriched DNA polymerase (5000U/µL) and 10µL HerculaseTM reaction buffer (10x), in a 
reaction otherwise identical to the one described in 3.7.   
 
The PCR products were analysed by gel electrophoresis (1% agarose), purified with 
CentriflexTM protein removal cartridges, seeDNATM precipitated, resuspended in 20µL dH2O 
and concentration determined by gel electrophoresis (1% agarose).  2µL of the purified DNA 
was restriction digested by 1µL XhoI (20000U/mL, NEB), 1µL NcoI (10000U/mL, NEB), 
3µL 10x NEB2 buffer and dH2O to a total volume of 30µL.  Following incubation for 2h at 
37oC, the restriction reaction was analysed by gel electrophoresis (1% agarose).   
 
Biotinylated ends and uncut DNA were removed from the fusion free GFP PCR product with 
Streptavidine as described in section 3.10.1.  Restriction digested fusion protein inserts were 
seeDNATM precipitated and extracted from gels (1% agarose) using QIAquick® Gel Extraction 
Kit (Promega).  Finally, the DNA inserts were seeDNATM precipitated and analysed by 
electrophoresis (2% NuSieve®3:1 agarose) to determine the DNA concentration. 
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3.11.2 Ligation into pET21d, and transformation of E.coli BL21DE 
10µL pET21d plasmid DNA was restricted, analysed, seeDNATM precipitated and 
resuspended in 20µL dH2O as described in 3.11.1.  Furthermore linearized vector DNA was 
purified using QIAquick® Gel Extraction Kit, seeDNATM precipitated and concentration 
determined by gel electrophoresis (2%NuSieve®3:1 agarose).   
 
GFP encoding inserts with and without peptide fusions were ligated into linearized pET21d, 
using approximately 100ng of pET21d vector DNA and 1ng of the various inserts, as 
determined by gel electrophoresis band intensity, and seeDNATM precipitated as described in 
3.10.2. 
 
GFP-Start 
 
3’-CACTCGTTCCCGCTCCTCGACAAGTGCCCC//TAGTGAGAGCCGTACCTGCTCGACATGTTC-5’ 
5’-GTGAGCAAGGGCGAGGAGCTGTTCACCGGG//ACTCTCGGCATGGACGAGCTGTACAAGTAA-3’ 
pHOG-GFP 
GFP-End
GCCGTACCTGCTCGACATGTTCATTGAGCTCATAATAATA-Bio-5’
XhoI 
5’-Bio-TATATTATTCCATGGTGAGCAAGGGCGAGGAGCTG
NcoI 
A 
B 
GFP-EndXhoI 
 
3’-CACTCGTTCCCGCTCCTCGACAAGTGCCCC//TAGTGAGAGCCGTACCTGCTCGACATGTTC-5’ 
5’-GTGAGCAAGGGCGAGGAGCTGTTCACCGGG//ACTCTCGGCATGGACGAGCTGTACAAGTAA-3’ 
GCCGTACCTGCTCGACATGTTCATTGAGCTCATAATAATA-Bio-5’
5’-xxxxxxxxxxxC9-4xxxxxxxxxxxxx       
5’-xxxxxxxxxxxC9-4xxxxxxxxxxxxC9-4xxx xxxxxxxxxx        
5-xx xxxxxxxxxC1qC10xxxxxxxxxxxxx   
C9-4-Mono-GFP 
C9-4-Dimer-GFP 
C1qC10-Mono-GFP 
Legend: 
Xxx  Restriction sites  
Xxx  GFP gene 
Xxx  GFP annealing  primer region 
Xxx  Fusion peptide  
Xxx  Spacer region (GGAGGACCAGGA) 
Xxx  Linker region (GGAGGAGGACCAGGA) 
pHOG-GFP 
Figure 1.  Overview of the GFP fusion protein cloning strategy 
A-The GFP gene was recovered from a pHOG-GFP plasmid in a PCR, using biotinylated primers GFP-Start and GFP-End 
comprising NcoI and XhoI restriction sites respectively, to produce a pET21d compatible cloning insert.   
B-GFP fusion protein encoding inserts were constructed using three different mutagenic primers carrying peptide encoding 
sequences (sequences given in table 2) and an NcoI restriction site.  The PCR reactions were carried out using pHOG-GFP as 
template and the additional primer GFP-End to produce pET21d compatible fusion protein encoding inserts. 
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Electrocompetent E.coli BL21DE cells were transformed with pET21d carrying GFP and 
GFP fusion protein encoding inserts by electroporation as described in 3.2.  Transformed 
single clones were transferred to 3mL LB/amp and incubated ON at 37oC with agitation.   
850µL of the ON cultures were transferred to 1.5mL tubes containing 150µL Glycerol and 
stored at -70oC. 
3.11.3 Plasmid isolation, restriction analysis and sequencing 
pET21d DNA was isolated from the ON cultures using a Wizard® Plus SV Miniprep kit.  
10µL plasmid aliquots were restriction digested with NcoI and XhoI as described in 3.11.1.  
The restriction reactions were analysed by gel electrophoresis (1% agarose) to confirm vector 
linearization and insert excision.  30µL plasmid prep was shipped to GATC Biotech AG for 
sequencing.  The GFP-peptide encoding inserts were sequenced using primers T7 and pET-
RP (GATC in-house primers).     
3.11.4 Correction of deletion in peptide dimer fusion to GFP  
Two guanine (G) deletions in the C9-4-Dimer-GFP construct were attempted corrected by 
design of an additional primer. The mega primer, C9-4-Dimer-G-correction-GFP 
(AGATATACCATGGGAGCCTGTGTGGTTTGGATGGGTTTTCAGCAGGTGTGTGGAGGAGGACCAGG
ATGTGTGGTTTGGATGGG) (DNA Technologies), was designed to anneal to the pET21d 
template carrying the deletions.  The PCR reaction was carried out essentially as described in 
3.11.1, with the following alterations: 10µL pET21d miniprep (~10ng/µL) carrying the 
deletions were used as template, 1µL of HerculaseTM DNA polymerase was added and the 
annealing temperature was adjusted to 60oC.  The PCR product was prepared for cloning as 
described in 3.11.1 and 3.11.2.   
 
3.12 Bacterial expression of GFP fusion proteins 
Crude cell lysates were prepared from E.coli BL21DE cells, confirmed to be transformed with 
pET21d carrying the GFP constructs.  GFP expression was verified by fluorescence 
microscopy, SDS PAGE and Western blotting.  The feasibility of using ammonium sulphate 
precipitation as a purification method for bacterially produced GFP was investigated. 
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3.12.1 Bacterial cell growth and induction of protein expression  
pET21d transformed E.coli BL21DE cells were plated onto ampicilline (50µg/mL) / glucose 
(100µL, 2M) plates and incubated at 37oC ON to yield fresh single colonies.  Single colonies 
were transferred to 2mL ampicilline (100µg/mL) added LB growth medium and incubated for 
approximately 3h at 37oC with agitation.  Subsequently the starter cultures were transferred to 
Erlenmeyer shaking flasks containing 100mL of ampicilline added (100µg/mL) LB and 
incubated at 37oC with agitation for good aeration until a density at A600 of ~1 was reached 
(PU 8750 UV/VIS scanning spectrophotometer).  Pre-induction-samples of the cultures were 
recovered (T0).  Protein expression was induced by adding 100µL IPTG (100mM) to the 
cultures and the incubation at 37oC was continued for three hours (T180).  The cells were 
harvested by centrifugation at 4600rpm for 10 minutes at 4oC (Centra CL3, International 
Equipment Company) and resuspended in 10mL PBS per 100mL culture volume. 
3.12.2 Fluorescence microscopy and cell lysis 
Auto fluorescent GFP was detected by fluorescence microscopy (Axioplan 2 Imaging, Zeiss).  
Resuspended cells were frozen and thawn prior to ultrasonic disruption in 50mL tubes on ice 
for 4x 10 seconds at max power (Soniprep 150, MSE Scientific Instruments).  Cell debris and 
unlyzed cells were removed by centrifugation 2x 30min at 4600rpm (Centra CL3, 
International Equipment Company).  The lysates were stored at -70oC.           
3.12.3 SDS PAGE 
Cells and crude lysates were analyzed by SDS PAGE.  12µL of the samples to be analysed 
and dilutions of GFP (BD Biosciences) were mixed with 4µL of 4xSDS loading buffer, 
incubated for 5 minutes at 95oC and loaded on to 12% Tris-HCl pre-casted gels (BioRad).  
Molecular weight standards RainbowTM (Amersham Biosciences) and SDS PAGE broad range 
standard (BioRad) were used.   
 
Following electrophoresis (BioRad Mini PROTEAN® II Cell, BioRad powerpac, 90-100V), 
the gels were CoomassieTM (PhastGel Blue R., Amersham Pharmacia Biotech) stained for 
15minutes, fixated and washed ON in a methanol (30%), acetic acid (10%) added fixing 
solution.  Images of the stained gels were obtained using a BioDoc-ItTM UV Transluminator 
(UVP). 
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3.12.4 Western Blotting 
GFP in the lysates diluted 1:10 in PBS and dilutions of commercially available GFP were 
detected in a western blott alongside biotinylated SDS PAGE broad range molecular weight 
standard (BioRad).  The proteins were separated as described 3.12.3 and electro transferred to 
an ImmobilonTM-P PVDF membrane (Millipore) by blotting at 4oC for 1hour (BioRad minigel 
blotting cassette, BioRad powerpac, 100V).  The membrane was allowed to air dry for a 
minute prior to blocking in 1% SKM, at 4oC, ON in a rotating 50mL tube.  The membrane 
blocking was continued for 30min at RT.  Subsequently, the membrane was washed 
thoroughly in PBS/T.  The membrane was incubated with goat polyclonal biotinylated 
antibody against GFP (1mg/mL) (Abcam) diluted 1:2000 in PBS/T for 1hour at RT.  The 
washing step was repeated before the membrane was incubated with Streptavidine-HRP 
conjugate (Amersham LIFE SCIENCES) diluted 1:5000 in PBS/T for 1hour at RT.  
Following repeated washing, the membrane was incubated in ECLTM western blotting 
detection reagent (Amersham Pharmacia Biotech) for 1minute at RT.  Biomax MR- film 
(Kodak) was exposed to the membrane and developed using an Optimax processor (Protec).  
3.12.5 Ammonium sulphate precipitation  
Cell lysate from E.coli BL21DE cells expressing GFP without fusion peptide (GFP) was 
ammonium sulphate precipitated.  Increasing amounts of ammonium sulphate ((NH4)2SO4, 
Merck), 5, 10, 20, 30, 40 and 50 % (1g/100mL = 1%), were added to 1.5 mL aliquots of 
lysate.  The samples were kept cool and agitated until all of the salt had dissolved.  The 
samples were incubated for one hour on ice prior to centrifugation at 10000rpm for 30min at 
4oC (Biofuge A, Heraeus sepatech).  Supernatants were discarded and the pellets were 
dissolved in 1mL PBS.  Subsequently the samples were analysed by SDS PAGE as described 
in 3.12.3.        
 
3.13 Target binding capacity of GFP fusion proteins 
Crude cell lysates, containing GFP and GFP fusion proteins, were screened for their ability to 
bind immobilized SC and C1q by direct measurement of fluorescence and by ELISA.  The 
lysates were standardized by measurement of the relative fluorescence (485nm/535nm, 1sec, 
VictorTM fluorometer, Perkin Elmer) in black FluoroNuncTM MaxisorpTM plates and 
subsequent dilution in PBS to ensure consistent in-put levels of GFP.   
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3.13.1 Target binding determined by fluorescence measurement 
Black FluoroNuncTM MaxisorpTM plates were coated with 100µL SC (10µg/mL) or 100µL 
C1q (10µg/mL) (Calbiochem) in separate wells by ON incubation at 4oC.  Following 1hour of 
blocking in 1% SKM, dilutions of lysates in PBS (GFP-no fusion, C9-4-Mono-GFP, C1qC10-
Mono-GFP and GFP negative lysate) were added to the wells and incubated for 90minutes.  
Subsequently, the wells were washed in PBS/T (5x using a Tecan Columbus washer, Tecan).  
100µL of PBS was added to the wells prior to fluorescence measurement to confirm target 
binding (485nm/535nm, 1sec, VictorTM fluorometer, Perkin Elmer).  Dilutions of 
commercially available GFP (BD Biosciences) were measured alongside the lysates for 
comparison and concentration determination. 
3.13.2 Target binding determined by ELISA 
NuncTMMaxisorpTM plates were coated with SC and C1q as described in 3.13.1, blocked in 1% 
SKM and washed as described 3.5.  Standardized lysates (~20000RFU, corresponding to 
~10µg/mL of commercially obtained GFP) were pre-incubated (1:1) in blocking solution 
prior to 90minutes incubation with the target at RT.  Following washing, as described in 3.5, 
100µL of biotinylated goat polyclonal anti-GFP antibody (Abcam) diluted 1:1000 in blocking 
solution was added to the wells and incubated for 1h at RT.  The washing procedure was 
repeated.  Next, 100µL of Streptavidine-HRP conjugate (Amersham LIFE SCIENCES) 
diluted 1:4000 in blocking solution was added and incubated for 1h at RT.  Following 
repeated washing, bound GFP fusions were visualized by adding ABTS.  Absorbance at 
405nm (A405) were measured (Tecan Sunrise Spectrophotometer, with Magellan 3.0 software) 
after 30-60 minutes incubation at RT.  The integrity of the SC coat was confirmed by the use 
of a SC binding phage detected essentially as described in 3.5.  The C1q coat quality was 
assessed using a rabbit anti-C1q antibody (3.7mg/mL, DAKO) diluted 1:1000 in 1% SKM 
and an anti-rabbit antibody conjugated to HRP (Amersham Biosciences) diluted 1:4000 in 1% 
SKM essentially as in the lysate ELISA described above.  
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4.  Results 
The objective of this work has been to screen for, and isolate phage displayed peptides with 
affinity for SC and potential for use in mucosal targeting.  A semi-automated screening 
procedure has been developed to increase sample throughput and allow for efficient screening 
of large numbers of phage clones.   
4.1 Affinity selection  
To isolate novel peptides with high affinity for human SC, two rounds of affinity selection 
from the random phage display libraries Cys9 and 7-mer, were performed.  To reduce 
unspecific background binding, the solid phase was blocked, and phages were pre-incubated, 
using 1% SKM or 1% BSA. 
 
1.5 x 109 TUs of the 7-mer library were added to wells of Nunc-ImmunoTM MaxiSorpTM strips 
coated with 200µL of SC at 30µg/mL.  The 7-mer library contained approximately 8 x 107 
different clones.  Thus, on average only ~20 particles of each clone were represented in the 
first round of affinity selection.  To the second round of selection 1.0 x 109 TUs from the 7-
mer amplified eluate 1 obtained using BSA as blocking agent (7-mer EA1BSA) were added.  
The same amount of phage from the first 7-mer amplified eluate, obtained using SKM (7-mer 
EA1SKM), were added to the second selection round.   
 
1.4 x 1010 TUs of the Cys9 library were added to Nunc-ImmunoTM MaxiSorpTM tubes coated 
with 800µL of SC at 30µg/mL.  The library contained roughly 5 x 107 different clones, thus 
~280 copies of each clone was represented in the first round of selection.  4.5 x 109 TUs from 
the Cys9 amplified eluate 1, obtained using BSA as blocking agent, (Cys9EA1BSA) was 
added to the second round of selection.  3.0 x 109 TUs from the Cys9 amplified eluate 1, 
obtained using SKM as blocking agent (Cys9EA1SKM), were added to the second round of 
selection using SKM as blocking agent. 
 
Recovery of 7-mer phage from the first- and second round of selection using BSA as blocking 
agent (7-mer E1BSA) 7.7 x 10-3 % and (7-mer E2BSA) 6.0 x 10-3 %, respectively, gave no 
indication of enrichment for SC binding phages.  Recovery of 7-mer phage from the first- and 
second round of selection using SKM as blocking agent (7-mer E1SKM) 1,2 x 10-3 % and (7-
mer E2SKM) 2.1 x 10-4 % , respectively showed a slight increase of phage yield. 
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After the first- and second round of selection using the Cys9 library with BSA as blocking 
agent (Cys9 E1BSA) and (Cys9 E2BSA) recovery rates of 2.1 x 10-3 % and 1.2 x 10-3 %, 
respectively, were seen.  SKM blocking after the first- (Cys9 E1SKM) and second (Cys9 
E2SKM) round returned 2.3 x 10-3 % and 6.0 x 10-4 % phage yield, respectively.  Thus, no 
enrichment of SC binding phages was seen after two rounds of selection using Cys9 
regardless of the blocking agent applied.  The results after two rounds of affinity selection are 
summarized in table 3.  
 
    Table 3.  Affinity selection for SC binding peptides phage display libraries 
Library. eluate and blocking agent Input (TU) a Output (TU)b Yield (%)C 
7-mer E1 BSA 1.5 x 109 115000 7.7 x 10-3 
7-mer E2 BSA 1.0 x 109 60000 6.0 x 10-3 
7-mer E1 SKM 1.5 x 109 3200 2.1 x 10-4 
7-mer E2 SKM 1.0 x 109 12000 1.2 x 10-3 
Cys9 E1 BSA 1.4 x 1010 300000 2.1 x 10-3 
Cys9 E2 BSA 4.5 x 109 52000 1.2 x 10-3 
Cys9 E1 SKM 1.4 x 1010 320000 2.3 x 10-3 
Cys9 E2 SKM 3.0 x 109 18000 6.0 x 10-4 
 
 
 
 
 
 
 
 
a) 10µL of the 7-mer library (titer 1.5x1011TU/mL) and 100µL of the Cys9 library (titer 
1.4x1011TU/mL) served as input to the first round of affinity selection.  100µL of 7-
mer EA1BSA/SKM (titre 1.0x1010TU/mL) served as input to the second panning 
round as did 100µL of Cys9EA1BSA (titre 3.0x1010TU/mL) and Cys9EA1SKM (titre 
4.5x1010TU/mL).   
 
b)    Output phages were calculated as the total number of E.coli K91K TUs in the eluates.   
 
c)    Yield = (output TU/input TU) x 100%  
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4.1.1 Screening the amplified eluates for SC binding phages by ELISA 
To disclose whether the pool of amplified phages after the second round of selection 
contained detectable amounts of SC binding phages, an ELISA was performed.   
Nunc-ImmunoTM MaxiSorpTM 96 well plates coated with 100µL of SC at 5µg/mL were used as 
solid phase and 50µL of each amplified eluate was added to the wells diluted 1:1 in blocking 
solution.  The phage clones C9-4 and T7 were used as positive and irrelevant control phages, 
respectively. 
 
The amplified eluates from the 7-mer library selection, namely 7-mer EA1BSA, 7-mer 
EA2BSA, 7-mer EA1SKM and 7-mer EA2SKM, were assayed for SC binding and binding to 
blocking solutions or the solid phase.  No difference was seen between binding to wells with- 
or without SC coat.  Thus, despite the increased recovery of phage that was observed between 
rounds of selection, using SKM as blocking agent, none of the phage pools contained 
detectable amounts of SC binding phage (data not shown).   
 
Likewise, the phage pools obtained after Cys9 library selection, namely Cys9EA1BSA, 
Cys9EA2BSA, Cys9EA1SKM and Cys9EA2SKM, were assayed for SC binding and binding 
to blocking solutions or the solid phase.  The ELISA assay included cross-blocking where 
eluates obtained using a SKM blocking procedure were blocked using BSA and vice versa to 
disclose the role of the blocking agent.  From wells coated with SC and blocked with SKM a 
small increase in readout value A405 between Cys9EA1SKM and Cys9EA2SKM was 
obtained.  No such increase in binding to SKM blocked wells alone was seen, indicating the 
presence of SC binding phages in the pool.  The Cys9EA2SKM A405 value was clearly above 
background level.  When the same amplified eluates were screened for SC binding in wells 
blocked with BSA, the same trend occurred only this time the absorbance values were higher 
and both Cys9EA1SKM and Cys9EA2SKM values exceeded the background level.   
 
An increase in absorbance values was also seen between Cys9EA1BSA and Cys9EA2BSA.  
However, the same increase was seen for phage binding to BSA blocked wells as well.  When 
subjected to cross blocking with SKM, the increase in A405 value between Cys9EA1BSA and 
Cys9EA2BSA is preserved.  The results of the Cys9 phage pool ELISA are summarized in 
figure 2.  
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The ELISA results indicate that Cys9EA1SKM and Cys9EA2SKM contain detectable 
amounts of SC binding phages.      
4.2 Screening for single clones displaying SC binding peptides 
To screen for single clones expressing SC binding peptides, randomly picked clones 
originating from E.coli K91K cells transduced with phage from all four Cys9 amplified 
eluates were grown in 96 deep well plates compatible with semi-automated sample handling.  
Single clone phage supernatants were screened for SC binding and background binding by 
ELISA to identify those specifically binding to SC.  SC specific clones, selected by A405 
readout values, were further investigated in subsequent ELISAs.  Finally, the sequences of the 
SC binding peptides were determined.  
4.2.1 Initial high throughput screening for SC binding single clone phages 
Scripts for use of the automated liquid handler, Biomek2000, were designed to allow for 
efficient ELISA screening (see Appendix 1).  The semi-automated procedure was never 
implemented due to technical difficulties with the robotic washing tool.  88 transductants 
originating from Cys9EA1SKM Cys9EA2SKM, Cys9EA1BSA and Cys9EA2BSA (88 x 
4=352 clones) were propagated in 96 deep well plates.  Nunc-ImmunoTM MaxiSorpTM 96 well 
plates coated with 100µL of SC at 5µg/mL were used as solid phase and 100µL of each single 
clone supernatant diluted 1:1 in blocking solution was added to the wells.  The phage clones 
C9-4 and T7 were used as positive and irrelevant control phages, respectively. 
Figure 2.  Cys9 phage pool SC binding and enrichment after two rounds of panning 
Amplified eluates after two rounds of panning were screened for SC binding (light blue) and 
background binding (purple) detected in an ELISA as absorbance at 405nm.  Furthermore, the role of 
the blocking agent in the ELISA was revealed in an x-blocking assay.  Background binding was not 
determined in the x-blocking experiment.  Nunc-ImmunoTM MaxiSorpTM 96 well plates coated with 
100µL of SC at 5µg/mL were used as solid phase.   
 80
6 of the 88 clones from Cys9EA1SKM were positive for SC binding.  As many as 75 clones 
out of the 88 from Cys9EA2SKM were also able to bind immobilized SC specifically.  63 of 
the 88 Cys9EA1BSA clones appeared to be positive for SC binding.  However, all came back 
as non-specific binders.  9 out of the 88 Cys9EA2BSA clones showed specific SC binding, 
whereas 68 clones proved to be background binders in the primary binding assay (data not 
shown).  The results of the initial screening for SC binding single clone phages are 
summarized in table 4.  
 
Table 4.  Initial screening for SC binding single clone phages 
EA of origin Number of screened 
clones 
Number of SC binding 
clones 
Number of background 
binding clones  
EA1SKM 88 6 0 
EA2SKM 88 75 0 
EA1BSA 88 0 63 
EA2BSA 88 9 68 
 
4.2.2 Screening of selected positive individual clones in a confirmative ELISA 
To confirm the SC binding capacity of selected single clones, identified in the large scale 
screening described above, additional ELISA assays were performed.  The confirmative 
ELISAs were identical to the initial high throughput assay.   
 
All 6 of the identified EA1SKM single clones were confirmed to bind SC.  No background 
binding was identified (Figure 3A).  Furthermore, of the 75 EA2SKM positives initially 
identified, the ten clones with the highest A405 values in the ELISA were picked, accompanied 
by 20 more with varying A405 readout values.  All of the top ten A405 clones and 18 of the 
other 20 clones came back positive for SC binding in the confirmation ELISA (Figure 3B).  
Also, all of the 9 selected EA2BSA single clones returned A405 values above the negative 
control.  One of the clones, 6C, gave high readout values for background binding and was not 
sequenced (Figure 3C).   
 
The results of the confirmative single clone ELISAs are recapitulated in figure 3.   
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Figure 3A.  EA1SKM single clone binding to immobilized SC as determined by ELISA 
Single clones, obtained from host cells infected with EA1SKM, were examined for their ability to bind 
immobilized SC.  6 out of 88 clones proved to bind SC specifically.  The clones are named after their 
matrix position in the 96-well growth plate in which they were propagated.  Binding to SC and 
background binding is depicted in light blue and in purple, respectively.    
Note:  This ELISA was prepared with single samples of each clone only, and it has not been repeated. 
Figure 3B.  EA2SKM single clone binding to immobilized SC as determined by ELISA 
Single clones, obtained from host cells infected with EA2SKM, were examined for their ability to bind immobilized SC.  
10 clones selected for their top ten A405 readout values in an initial ELISA (5A-6E) and 20 clones (2D-8G) with varying 
A405 readout value in the same experiment were selected to undergo further investigation.  The clones are named after 
their matrix position in the 96-well growth plate in which they were propagated.  Binding to immobilized SC and 
background binding, depicted in light blue and in purple, respectively, were determined with samples in triplicates.    
EA2 SKM single clone ELISA 
0
0,5
1
1,5
2
5A 4A 3B 1A 3A 9H 11
A 7F 3F 6E 2D 10
G 1B 6G 6H 9G 10
C 9B 8D 8H 6C 6D 6A 1G 2F 7A 8A 9A 10
H 8G
Po
sit
ive
 co
ntr
ol
Irre
lev
an
t p
ha
ge
No
 ph
ag
e
Selected clones
A
40
5
Binding to immobilized SC
Binding to SKM / Solid phase
Figure 3C.  EA2BSA single clone binding to immobilized SC as determined by ELISA 
Single clones, obtained from host cells infected with EA2BSA, were examined for their ability to bind 
immobilized SC.  9 clones selected for their apparent SC binding in an initial ELISA were selected to 
undergo further investigation.  The clones are named after their matrix position in the 96-well growth 
plate in which they were propagated.  Binding to immobilized SC and background binding, depicted in 
light blue and in purple respectively, were determined with samples in duplicates.    
EA2 BSA single clone ELISA 
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4.2.3 Sequencing of selected SC binding phage  
To produce sequencing templates of the DNA encoding the peptides fused to gpIII, 
supernatants from selected, ELISA positive, single clones were used as template in a PCR.   
A total of 44 sequencing templates from Cys9EA1SKM (6), Cys9EA2SKM (30) and 
Cys9EA2BSA (8) were shipped to GATC Biotech AG, and 43 sequences were obtained (all 
but Cys9EA2SKM clone 10G).   
 
7 different sequences were isolated in the screening procedure.  Only two of these encoded 
cysteine constrained 9-mer peptides.  6 clones displayed peptide CIIVPHAYAWC, all of which 
originated from Cys9EA2SKM.  13 clones with sequence CVVWMGFQQVC were identified, 
one from Cys9EA1 SKM and 12 from Cys9EA2 SKM.  This peptide is identical to the one 
displayed by the positive control phage C9-4 that had previously been selected and 
characterized as a SC binder (Braathen et al., unpublished). 
 
The sequence CALVSEAGCLVWAA was found to be displayed by a total of 20 selected single 
clones, including all 8 Cys9EA2 BSA clones, 4 Cys9EA1 SKM clones and 8 Cys9EA2 SKM 
clones.  This dominating 14-mer peptide sequence is in-frame without cysteine (TGT) as the 
C-terminal amino acid.  Thus, it deviates from the expected cysteine flanked random 9-mer.  
In the following, this peptide/phage is referred to as ASR.  
 
Four 7-mer peptides were also identified.  Three of them were isolated from phage originating 
from Cys9EA2SKM (RGPFVYM, RFWWGWY and GWAGWLG), whereas the last one (PFVVLLV) 
was obtained from an EA1 SKM clone.  It should be noted that Cys9EA2SKM clones 6A 
(RGPFVYM) and 8G (GWAGWLG) tested negative for SC binding in the confirmation ELISA.  
However, at that time they were already shipped of to sequencing.  The recovered 7-mers are 
likely to be contaminants from the affinity selection performed in parallel to the Cys9 library 
using a 7-mer library.  ASR and C9-4, represented approximately 45% and 30% of the 
recovered sequences, respectively. 
 
Abi files, representing all of the 7 recovered peptides, describing the detailed sequencing data 
are enclosed in appendix 2.  The single clone phage sequencing results are summarized in 
table 5.  
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Table 5.  Recovered sequences from SC affinity selection  
 
DNA 
 sequence 
Amino acid 
sequence 
Eluate of origin, selected clone and frequency * 
TGT GCG TTG GTG AGT GAG GCT 
GGC TGC TTA GTG TGG GCC GCT 
CALVSEAGCLVWAA EA2 BSA    1G, 2C, 2F, 4F, 6H, 8A, 8C, 11G                         8/8 
EA1 SKM   7C,10C, 10F, 10H                                            4/6 
EA2 SKM   1B, 6G, 10C, 9B, 8D, 8H, 6C, 3F                         8/29 
TGT GTG GTT TGG ATG GGT TTT 
CAG CAG GTG TGT 
CVVWMGFQQVC EA1 SKM   8F                                                                 1/6  
EA2 SKM   5A, 4A, 3B, 1A, 3A, 9H, 11A, 7F, 6E, 2D, 6H, 9G 12/29 
TGT ATT ATT GTG CCG CAT GCG 
TAT GCT TGG TGT  
CIIVPHAYAWC EA2 SKM   6D, 1G, 2F, 7A, 8A, 9A                                      6/29 
CGT GGT CCG TTT GTG TAT ATG  RGPFVYM EA2 SKM   6A                                                                 1/29 
AGG TTT TGG TGG GGG TGG TAT RFWWGWY EA2 SKM   10H                                                                               1/29 
GGG TGG GCT GTG TGG CTG GGG GWAGWLG EA2 SKM   8G                                                                 1/29 
CCG TTT GTG GTG TTG TGG GTG PFVVLLV EA1 SKM   11H                                                                1/6 
 
 
 
 
 
 
4.3 Inhibition of phage binding to SC by pIgA, pIgM and SpsA fragments 
C9-4 and ASR were tested for interaction with immobilized SC in a competition ELISA in the 
presence of IgA, IgM or SpsA.  Nunc-ImmunoTM MaxiSorpTM 96 well plates coated with 50µL 
of SC at 30µg/mL were used as solid phase.  Phage supernatant was added to the wells diluted 
1:1 in dilutions of the inhibitors.   
 
C9-4 binding to immobilized SC is not inhibited by pIgA or pIgM.  SpsA fragment SH2 and 
SM1 on the other hand, knock out detectable C9-4 binding to immobilized SC (see figure 
4A).  A SC-negative control fragment of SpsA, SH3, did not interfere with the C9-4 SC 
interaction.  In conclusion, C9-4 binds SC at a location different from the binding site used by 
pIgA and pIgM.  Moreover, the interaction site is likely to overlap a contact area also used by 
SpsA.  ASR binding to SC is not affected by the polymeric Igs or by SC binding SpsA 
fragments.  Thus, ASR is likely to bind an area of the receptor not utilized by any of the other 
ligands applied (see figure 4B).  The results of the inhibition study are summed up in figure 4. 
 
 
 
 
 
* Cys9 eluates from which the sequences are derived, each individual clone representing this sequence 
(bold) and finally, the frequency of each recovered sequence in relation to their eluate of origin.    
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4.4 Transcytosis of SC binding phage across pIgR transfected MDCK cells 
To elucidate whether C9-4 and ASR retain binding to SC when the target is presented in its 
native configuration and to reveal if the phage can be transported across epithelia by pIgR 
mediated transcytosis, phages were allowed to react with polarized MDCK cells transfected 
with pIgR.  Untransfected cells were applied as control.  Motivated by the inhibition studies, 
the ability of both C9-4 and ASR phages to discriminate between murine and human SC was 
investigated by using MDCK cells transfected with murine or human pIgR in the transcytosis 
experiments.  Basolateral to apical transport was measured as phage recovered apically. 
Phages with irrelevant specificity (TCys9) as well as IgG were used to control for unspecific 
transport and leakage. 
 
Basolateral inputs of C9-4, ASR and control phage were 8.2x109 TU, 4.4x108 TU and 
2.7x1010 TU, respectively.  5 x10-2 % of C9-4 was recovered apically of MDCK cells 
transfected with human pIgR.  Cells transfected with the murine receptor returned only  
2 x10-5 %, the same as untransfected cells.  In conclusion, it appears that C9-4 is transported 
across MDCK cell monolayers by pIgR mediated transcytosis.  Evidently C9-4 also 
discriminates between murine and human pIgR, showing affinity for the human receptor only 
as SpsA does.  Thus, C9-4 meet valuable criteria for peptide candidates intended for use in 
pIgR mediated mucosal targeting. 
 
 
Inhibition of C9-4  binding to immobilized SC
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Figure 4.  Inhibition of phage binding to immobilized SC 
A: pIgA (blue) does not inhibit C9-4 binding to hSC, neither does pIgM (pink) nor SpsA fragment SH3 
(turquoise).  SH2 (yellow) and SM1 (purple), on the other hand, clearly inhibit C9-4 binding to the SC coat. 
B: None of the added inhibitors hamper the interaction between ASR and immobilized SC. 
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MDCK cells transfected with the human receptor, returned 4.7 x 10-4 % of the added ASR 
phage.  Cells transfected with the murine receptor returned 7.2 x 10-4 %, whereas 
untransfected cells returned 5.4 x 10-4 % ASR phages.  In conclusion, the ASR phage is not 
transported across the epithelial model system by pIgR mediated transcytosis.  Whether this is 
due to lack of receptor binding on the cell surface or not has not been established.   
 
The recovery figures for the irrelevant phage were as follows:  2.9 x 10-4 % for the human 
receptor; 1.2 x 10-4 % for the murine receptor and 1.3 x 10-3 % for untransfected cells.   
15µg/mL IgG at 100nM was added in the basolateral medium.  Less than ~30ng/mL IgG was 
recovered apically, confirming no system leakage (data not shown).   
The results of the transcytosis experiment are summarized in figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 Determination of the contribution of each C9-4 amino acid on SC binding  
To determine the contribution of each individual amino acid on the functionality of the 
peptide each amino acid of C9-4 was systematically substituted with alanine.  The flanking 
cysteines of the constrained peptide were substituted with serine.  The mutants were 
sequenced to confirm substitutions before SC binding capacity was assessed by ELISA and 
elution-titration.   
Figure 5.  Transcytosis across MDCK cells 
 
C9-4 phages (left) are specifically trancytosed 
across MDCK cells transfected with human pIgR 
(light yellow column).  Untransfected cells (blue 
column) or cells bearing the murine receptor (purple 
column) are not capable of relocating the phage 
from the basolateral- to the apical side.  ASR 
(centre) and the irrelevant control phage (right) are 
not able to utelize pIgR mediated transcytosis for 
transport.  Basolateral inputs of C9-4, ASR and 
control phage were 8,2x109 TU, 4,4x108 TU and 
2,7x1010 TU, respectively. 
 
Apical medium was harvested and titrated as E.coli 
K91K TUs to calculate the yield of recovered 
phages.   
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4.5.1 Sequencing of alanine/serine substitution mutated C9-4   
Sequencing of the mutated DNA, confirmed the presence of the alanine/serine substitutions in 
the appropriate positions.  The sequencing results are summarized in table 6.  Abi files, 
representing C9-4 and all of the 12 substituted peptides, describing the detailed sequencing 
data are enclosed in appendix 2 and 3, respectively. 
 
Table 6.  Confirmed alanine / serine substitution sequences  
Mutant Peptide encoding inserts Amino acid sequence 
C9-4  * TGT GTG GTT TGG ATG GGT TTT CAG CAG GTG TGT C V V W M G F Q Q V C 
AS-C1S AGC GTG GTT TGG ATG GGT TTT CAG CAG GTG TGT S V V W M G F Q Q V C 
AS-V2A TGT GCA GTT TGG ATG GGT TTT CAG CAG GTG TGT C A V W M G F Q Q V C 
AS-V3A TGT GTG GCA TGG ATG GGT TTT CAG CAG GTG TGT C V A W M G F Q Q V C 
AS-W4A TGT GTG GTT GCA ATG GGT TTT CAG CAG GTG TGT C V V A M G F Q Q V C 
AS-M5A TGT GTG GTT TGG GCA GGT TTT CAG CAG GTG TGT C V V W A G F Q Q V C 
AS-G6A TGT GTG GTT TGG ATG GCA TTT CAG CAG GTG TGT C V V W M A F Q Q V C 
AS-F7A TGT GTG GTT TGG ATG GGT GCA  CAG CAG GTG TGT C V V W M G A Q Q V C 
AS-Q8A TGT GTG GTT TGG ATG GGT TTT GCA CAG GTG TGT C V V W M G F A Q V C 
AS-Q9A TGT GTG GTT TGG ATG GGT TTT CAG GCA GTG TGT C V V W M G F Q A V C 
AS-V10A TGT GTG GTT TGG ATG GGT TTT CAG CAG GCA TGT C V V W M G F Q Q A C 
AS-C11S TGT GTG GTT TGG ATG GGT TTT CAG CAG GTG AGC C V V W M G F Q Q V S 
AS-C1SC11S AGC GTG GTT TGG ATG GGT TTT CAG CAG GTG AGC S V V W M G F Q Q V S 
 
 
 
4.5.2 Effect of amino acid substitutions on binding to SC as determined by ELISA  
To examine the effect of systematic alanine substitution and removal of flanking cysteines on 
target binding capacity, phages expressing mutated peptides were screened for SC binding 
using ELISA.  C9-4 was used as positive control and TCys9, with irrelevant specificity, was 
used as negative control.  Nunc-ImmunoTM MaxiSorpTM 96 well plates coated with 200µL of 
SC at 5µg/mL, were used as solid phase and 100µL of each mutant supernatant was added to 
the wells diluted 1:1 in blocking solution.  The amount of input phage in the ELISA varied 
from 2 x 109 TU to 7 x 109 TU.  The lowest supernatant titre was seen for AS-C11S, whereas 
the highest was seen for the double mutant, AS-C1SC11S. 
 
The ELISA reveals that all, but three, amino acids are essential to C9-4’s ability to bind SC.  
Mutants AS-Q9A, and to a lesser extent AS-V3A and AS-G6A, bind SC.  Substitutions of 
valine (V), glycine (G) and glutamine (Q) in positions 3, 6 and 9, respectively, are tolerated 
and SC binding are detected by ELISA.  In conclusion, glutamine in position 9, valine in 
position 3 and glycine in position 6 appears not to be indispensable to the functionality of C9-
4.  The variation in phage input, does not explain the observed binding pattern.  ELISA results 
from the substitution mutant binding to SC are summarized in figure 6.   
*C9-4 is included in the table for comparison only.   
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4.5.3 Effect of amino acid substitution on SC binding as determined by elution-titration 
ELISA and elution-titration studies are alternative methods to investigate binding of phage 
clones to immobilized target.  An elution-titration experiment was carried out to determine the 
number of phages added and recovered from each well.  The yield of eluted phages was 
calculated, to determine the contribution of each individual amino acid. 
 
Nunc-ImmunoTM MaxiSorpTM 96 well plates coated with 200µL of SC at 20µg/mL were used 
as solid phase and 50µL of each mutant supernatant was diluted to a total volume of 200µL in 
SKM and added to the wells.  Included controls were as in the ELISA described above.  The 
amount of input phage to the elution-titration assay varied from 1 x 109 TU to 3.5 x 109 TU.   
 
AS-Q9A clearly binds immobilized SC.  The yield of AS-Q9A phage recovered from the 
procedure is approximately 60% of that seen for the positive control.  As for the ELISA, AS-
V3A and AS-G6A stand out from the remaining mutants.   
 
 
Figure 6.  Amino acid substituted C9-4 peptide mutant binding to immobilized SC  
The C9-4 substitution mutant phage presented peptides were screened in an ELISA to disclose amino acids 
essential to C9-4’s SC binding capacity.  Mutants AS-Q9A, and to a lesser extent AS-V3A and AS-G6A, bind SC.  
Valine (V), glycine (G) and glutamine (Q) in positions 3, 6 and 9, respectively, may be substituted.  The remaining 
amino acids, cysteines included, appear to be critical to for SC binding.  SC binding and binding to SKM or the 
solid phase are given in light blue and purple, respectively.   
 
* AS-V3A and AS-C1SC11S were examined for SC binding in separate experiments with internal controls 
reaching the same A405 levels as shown here. 
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Although AS-V3A and AS-G6A recovery only make up approximately 1,5% and 2% of the 
positive control, respectively, they return ~30-100 times more phage that do the other mutants 
and ~500-600 times more phage than do the irrelevant control phage.  The recovery rate for 
all mutants, even the ones considered to be SC binding negatives (1.5 x10-4 % - 9.0 x10-5 % 
recovery), were higher than the number seen for the irrelevant phage (7.5 x10-6 % recovery), 
this matter of fact was not revealed by ELISA.  The results of the elution-titration study are 
summarized in table 7. 
 
In conclusion, glutamine in position 9, valine in position 3 and glycine in position 6 appears 
not to be of critical importance to the functionality of C9-4.  The elution and titration assay, 
confirms the data obtained in the ELISA and gives an estimate of the actual amount of phages 
bound to the target, thus the method return high resolution data.   
   
Table 7.  Effect of C9-4 amino acid substitution on SC binding as determined by elution / titration  
 
Phage Titre (TU/mL) Input (TU) Output (TU) Yield (%) 
AS-C1S 4.0 x 1010 2.0 x 109 600 3.0 x10-5 
AS-V2A 4.0 x 1010 2.0 x 109 1300 6.5 x10-5 
  AS-V3A* 5.0 x 1010 2.5 x 109 75000 3.0 x10-3 
AS-W4A 5.0 x 1010 2.5 x 109 900 3.6 x10-5 
AS-M5A 5.0 x 1010 2.5 x 109 3750 1.5 x10-4 
AS-G6A 4.0 x 1010 2.0 x 109 80000 4.0 x10-3 
AS-F7A 5.0 x 1010 2.5 x 109 1550 6.2 x10-5 
AS-Q8A 4.0 x 1010 20 x 109 1400 7.0 x10-5 
AS-Q9A 4.0 x 1010 2.0 x 109 2500000 1.3 x10-1 
AS-V10A 5.0 x 1010 2.5 x 109 2250 9.0 x10-5 
AS-C11S 2.0 x 1010 1.0 x 109 200 2.0 x10-5 
AS-C1SC11S* 7.0 x 1010 3.5 x 109 4000 1.1 x10-4 
C9-4 5.0 x 1010 2.5 x 109 5250000 2.1 x10-1 
Irrel. 4.0 x 1010 2.0 x 109 150 7.5 x10-6 
  
 
 
 
 
 
* AS-V3A and AS-C1SC11S were examined for SC binding in separate experiments with internal controls 
reaching the same yields as presented here.  
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4.6 Construction and expression of GFP fusion proteins with target binding capacity  
An objective of this work has been to select short peptides with high affinity for SC that can 
mediate transcytosis.  Thus, successful candidates have potential as fusion partners to 
therapeutically active molecules or diagnostics targeted to the mucosae.  To reveal whether 
the characterized phage displayed peptide, C9-4, retain its SC binding capacity when taken 
out of the phage format, GFP fusion proteins were constructed.   
 
Three, N-terminal, GFP fusion proteins were engineered alongside GFP without any fusion 
peptide.  C9-4-Mono-GFP comprised one SC binding C9-4 peptide, selected by phage 
display, linked to GFP using a short spacer region.  C9-4-Dimer-GFP was constructed as two 
C9-4 peptides connected by a linker and then coupled to GFP using a spacer region.  The 
dimer was constructed to mimic the multimeric presentation of peptides seen on phage, 
consequently giving rise to increased avidity for SC.  C1qC10-Mono-GFP contained a C1q 
binding peptide, selected by phage display, attached to GFP via a spacer region.  The fusion 
free GFP is referred to as GFP only in the following.  The GFP fusions were expressed in a 
prokaryotic system and screened for target binding. 
4.6.1 Confirmation of fusion peptide sequences 
Sequencing of the GFP-fusion peptide encoding inserts showed that GFP, C9-4-Mono-GFP 
and C1qC10-Mono-GFP matched the expected sequence.  The C9-4-Dimer-GFP sequence, 
however, had two guanine (G) deletions, consequently leading to a frame shift mutation.  The 
deletions were unsuccessfully attempted corrected.  As a result the C9-4-Dimer-GFP was not 
expressed and excluded from further testing.  The sequencing results are summarized in table 
8.  Detailed sequencing information is enclosed as Abi files in appendix 4. 
 
Table 8.  Confirmed sequences of peptides genetically fused to GFP  
Fusion peptide DNA sequence a 
C9-4-Mono- CCATGGGAGCCTGTGTGGTTTGGATGGGTTTTCAGCAGGTGTGTGGAGGACCAGGA-GFP 
C9-4-Dimer- CCATGGGAGCCTGTGTGGTTTGGATGGGTTTTCAGCAGGTGTGTXGAGGAGGACCAGGA   b 
TGTXTGGTTTGGATGGGTTTTCAGCAGGTGTGTGGAGGACCAGGA-GFP 
C1qC10-Mono- CCATGGGAGCCTGTTATTGGGTGGGTACGTGGGGTGAGGCTGTTTGTGGAGGACCAGGA-GFP 
 
 a) The sequences are given in 5’-3’ direction.  Legend as in table 2.   
b) The C9-4-Dimer was constructed with two C9-4 peptides genetically connected by a linker sequence 
(GGGPG).  However, as indicated with X, the sequencing revealed a G deletion in the linker as well as in 
the repeated C9-4 monomer.  Consequently a frame shift mutation arises.   
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4.6.2 Prokaryotic expression of GFP fusion proteins 
C9-4-Mono-GFP, C1qC10-Mono-GFP and GFP, expressed in the prokaryotic pET system 
alongside GFP negative cells, were harvested three hours after induction and studied by 
fluorescence microscopy.  C9-4-Mono-GFP, C1qC10-Mono-GFP and GFP cells were 
confirmed to express auto fluorescent GFP.  Growth BL21DE expression host cells 
transformed with pET21d vector DNA without GFP encoding inserts (GFPneg) were 
confirmed by phase contrast microscopy.  Microscopy photographs are presented in figure 7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additionally, to confirm the presence of a protein the size of GFP, harvested cells and cell 
lysates were further analysed by SDS PAGE.  Commercially available, recombinant, GFP 
(kDa 27) was applied to the gel to estimate the amount of GFP in the cells and lysates 
respectively.  SDS PAGE disclosed the presence of a protein the size of GFP (figure 8, line 2) 
and the somewhat larger proteins corresponding to C9-4-Mono-GFP (figure 8, line 3) and 
C1qC10-Mono-GFP (figure 8, line 4) respectively.  Cells and lysate known to be GFP 
negative (figure 8, line 5) does not CoomassieTM stain for proteins the size of GFP.  The SDS 
PAGE results are shown in figure 8. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.  Detection of GFP expression by fluorescence microscopy  
Cells harvested three hours after induction were screened for GFP expression using a fluorescence microscope (40x). 
A: GFPneg (phase contrast reveals actual cell growth).  B: GFP.  C: Cells expressing C9-4-Mono-GFP.  D: Cells 
expressing C1qC10-Mono-GFP. 
A B C D 
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Samples (12µL) of cells expressing GFP without peptide fusion (line A2) and  cells 
expressing C9-4-Mono-GFP (line A3) holds approximately 1µg GFP (~80µg/mL), whereas 
the C1qC10-Mono-GFP (line A4) cell sample indicates approximately 5µg GFP 
(~400µg/mL).  The concentration was determined by band intensity comparison with 
dilutions of commercial GFP (line A6-9).  Samples (12µL) of lysates containing GFP without 
fusion peptide (line B2), C9-4-Mono-GFP (line B3) and C1qC10-Mono-GFP (line B4) all   
correspond roughly to 0.1µg commercially obtained GFP (8µg/mL) or a bit more.  The 
expression level of C9-4-Mono-GFP appears to be somewhat lower than for the two other 
constructs.  The GFP content of each individual lysate was determined as for the cells. 
 
Finally, to confirm the presence of GFP, the lysates were investigated by western blotting 
using a GFP specific primary antibody.  Dilutions of commercially obtained GFP were 
included as positive control and to estimate the amount of GFP in the lysates.   
 
Western blotting confirmed the presence of GFP in the lysates from fusion free GFP (figure 9, 
line 2), C9-4-Mono-GFP (figure 9, line 3) and C1qC10-Mono-GFP (figure 9, line 4).  Lysate 
from GFPneg cells gave no signal in the western blott (figure 9, line 6).  The blotting results 
are presented in figure 9. 
 
 
Figure 8.  Expression of GFP fusion proteins  
12% SDS PAGE gels prepared with resuspended 
cells (A) and lysates (B) respectively, were 
coomassie stained to verify expression of GFP 
and GFP fusions.   
A/B1 MW 
A/B2 GFP 
A/B3 C9-4-Mono-GFP 
A/B4 C1qC10-Mono-GFP 
A/B5 GFPneg  
A/B6 5µg rGFP (27kDa ) 
A/B7 1µg rGFP 
A/B8 0.1µg rGFP 
A/B9 0.01µg rGFP  
A/B10 Empty. 
B A 
97 kDa
20 kDa
66 kDa
220 kDa
45 kDa
30 kDa
14 kDa
1     2     3     4     5     6     7     8     9    10 1     2     3     4     5     6     7     8     9    10 
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12µL aliquots of GFP positive lysates, diluted 1:10 in PBS, correspond to the signal from 
12µL of 1µg/mL commercial GFP (line 9).  Thus the lysate concentration is calculated to 
~10µg/mL GFP, concurring with the lysate concentration determined by CoomassieTM 
staining.  Western blotting confirms lower expression of C9-4-Mono-GFP compared to the 
two other constructs.  In conclusion, C9-4-Mono-GFP, C1qC10-Mono-GFP and fusion free 
GFP cells all express auto fluorescent GFP.   
4.6.3 Ammonium sulphate precipitation of GFP lysate 
Lysate from BL21DE cells, expressing GFP without a fusion peptide, was ammonium 
sulphate precipitated to examine whether this method was a feasible purification procedure 
for the GFP lysates.  Increasing amounts of ammonium sulphate were added to aliquots of 
lysate.  Subsequently, the samples were examined by SDS PAGE and CoomassieTM stained. 
 
The precipitation study demonstrated that hardly any protein precipitate until 30% (1g/100mL 
=1%) of ammonium sulphate was added (figure 10, line 5).  At this concentration however, 
essentially all proteins in the lysate precipitate.   The results of the ammonium sulphate 
precipitation are presented in figure 10. 
 
 
 
 
 
 
 
220 kDa 
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 1     2     3      4     5    6    7      8     9    10 Figure 9.  Detection of GFP in cell lysates by western blotting 
Cell lysates, diluted 1:10 in PBS, were separated by SDS PAGE 
alongside dilutions of commercially available rGFP and transferred 
to a blotting membrane prior to detection using an anti GFP primary 
antibody.    
1 MW 
2 GFP 
3 C9-4-Mono-GFP 
4 C1qC10-Mono-GFP 
5 Empty 
6 GFPneg 
7 Empty 
8 10µg/mL rGFP 
9 1µg/mL rGFP 
10  0.1µg/mL rGFP 
Figure 10.  Ammonium sulphate precipitation  
Lysate, containing GFP without fusion peptide 
(GFP), was Ammonium sulphate precipitated by 
adding increasing amounts of the salt 
(1g/100mL=1%).  The precipitates were assayed by 
SDS PAGE and Coomassi staining. 
1  MW 
2   5% 
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5  30% 
6  40% 
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Note: The molecular weight ladder has been added digitally  
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Evidently, this system requires fine tuning to play a practical role in lysate purification.  The 
reported non- or all precipitation renders the system ineffective for the intended application, 
thus it was not implemented for the other lysates. 
 
4.7 Target binding capacity of GFP fusion proteins 
To examine the fusion peptides’ target binding capability when removed from the phage 
format in which they had been initially selected, C9-4-Mono-GFP and C1qC10-Mono-GFP 
were screened for their capacity to bind immobilized SC and C1q, respectively.  C1qC10-
Mono-GFP lysate was used as negative control in the SC biding studies whereas C9-4-Mono-
GFP was used in the C1q binding assays.  GFP lysate and GFPneg lysates were applied as 
controls in both binding assays.   
4.7.1 Standardization of lysate fluorescence intensity  
The concentration of GFP in the lysates was standardized by fluorescence measurement and 
subsequent dilution to ensure consistent GFP input levels.  Fluorescence from undiluted C9-4-
Mono-GFP lysate was measured to ~20000 RFU, corresponding to ~10µg/mL of 
commercially obtained GFP. Undiluted C1qC10-Mono-GFP lysate and GFP-lysate were 
measured to approximately 200000 RFU.  According to RFU values from a dilution series, 
these lysates were diluted 1:7 and 1:12, respectively, to match the level of fluorescence 
measured for C9-4-Mono-GFP.  The results of the lysate standardization are summarized in 
figure 11. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  Standardization of lysates  
 
Fluorescence in 100µL of dilutions of 
lysates (lines) and commercially available 
GFP (columns) were determined as relative 
fluorescence units (RFU) using a 
fluorometer.  Undiluted C9-4-Mono-GFP 
lysate (pink line), ~20000RFU corresponds 
to 10µg/mL commercially available control 
GFP (purple column).  Undiluted GFP 
(blue line) and C1qC10-Mono-GFP 
(yellow line) lysates were measured to 
~200000RFU.  1:12 and 1:7 dilutions of 
GFP and C1qC10-Mono-GFP lysates, 
respectively, correspond to ~20000RFU 
(10µg/mL commercially obtained GFP).  
Background fluorescence from GFP 
negative lysate (GFPneg) is represented by 
the turquoise line. 
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Fluorescence measurement of the lysates revealed the presence of functional auto fluorescent 
GFP.  Consistent with the SDS PAGE and Western blotting findings, C9-4-Mono-GFP 
contains less functional GFP than the two other GFP positive lysates.  Lysates diluted to 
~20000RFU, corresponding to approximately 10µg/mL of commercially obtained control 
GFP, were used as starting concentrations in target binding assays. 
4.7.2 Binding to SC as determined by ELISA and fluorescence measurement  
To determine whether C9-4 binds its target when shifted from the phage display context to the 
GFP fusion format, C9-4-Mono-GFP was screened for binding to immobilized SC using 
ELISA and fluorescence measurement.  Nunc-ImmunoTM MaxiSorpTM 96 well plates coated 
with 100µL of SC at 10µg/mL were used as solid phase in the ELISA.  100µL of each 
standardized lysate (~20000 RFU) were pre-incubated in 100µL SKM and added to two SC 
coated wells (10000 RFU/ reaction).  Black FluoroNuncTM MaxiSorpTM 96 well plates coated 
with 100µL of SC at 10µg/mL were used as solid phase in the fluorescence measurement 
study.  100µL standardized lysate (20000 RFU) were added to each well in duplets.   
 
No SC binding above background levels was detected in either of the assays.  Accordingly, 
C9-4 does not appear to bind to SC in a detectable manner in this system when shifted from 
the phage display format to a monomeric GFP fusion.  The results of C9-4-Mono-GFP 
binding to immobilized SC are presented in figure 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Fusion peptide binding to immobilized SC 
A: Binding to immobilized SC was investigated by ELISA using an anti-GFP antibody.  Standardized GFP positive 
lysates (~20000RFU/100µL) were preincubated (1:1) in blocking solution, thus 100µL input to each well correspond 
to ~10000RFU.  The integrity of the coat was confirmed using a SC binding phage displaying C9-4.   
SC binding and background binding is indicated in light blue and purple respectively.   
B: Fusion peptide binding to SC (light blue) as determined by fluorescence.  100µL standardized GFP positive 
lysates and GFP negative lysate were incubated with immobilized SC.  Following washing fluorescence was 
measured to reveal bound GFP fusion proteins.  Dilutions of commercially obtained GFP (red) were included as 
positive control.     
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4.7.3 Binding to C1q as determined by ELISA and fluorescence measurement 
A C1q binding peptide, selected by phage display, was fused to GFP to serve as a negative 
control in the SC binding studies.  The peptide has previously been shown to bind C1q with 
high affinity when shifted from the phage display context to alternative fusion partners 
(Lunde et al., 2002).  Consequently, we expected the C1qC10-Mono-GFP to bind its 
immobilized target.  This construct would reveal whether target binding of GFP-fusion 
proteins, expressed bacterially, could be detected at all by fluorescence measurement in the 
concentrations we were obtaining.    
 
To determine whether the C1q binding peptide, binds its target when presented in the GFP 
fusion format, C1qC10-Mono-GFP was screened for binding to immobilized C1q using 
ELISA and fluorescence measurement.  Nunc-ImmunoTM MaxiSorpTM 96 well plates coated 
with 100µL of C1q at 10µg/mL were used as solid phase in the ELISA.  100µL of each 
standardized lysate (~20000 RFU) were pre-incubated in 100µL SKM and added to two C1q 
coated wells (10000 RFU/ reaction).  Black FluoroNuncTM MaxiSorpTM 96 well plates coated 
with 100µL of C1q at 10µg/mL were used as solid phase in the fluorescence measurement 
study.  100µL standardized lysate (20000 RFU) were added to each well in duplets. 
 
Both the ELISA and fluorescence assay shows that C1qC10-Mono-GFP binds its target above 
background binding levels.  Fluorescence readout suggests binding of GFP corresponding to 
approximately 0,3µg/mL of commercially obtained GFP.  Thus, the phage display selected 
C1q binding peptide appears to bind its target also when displayed in an alternative fusion 
context.  The results of the C1q binding assays are summarized in figure 13. 
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In conclusion, the selected C1q binding control peptide binds its target and the interaction can 
be detected both by ELISA and by fluorescence measurement of bound GFP-fusion protein.  
Accordingly, it should be possible to detect target-fusion protein interactions using direct 
measurement of target bound auto-fluorescent fusion proteins, provided that the interaction is 
strong enough.   
Figure 13. Fusion peptide binding to immobilized C1q 
A: Binding to immobilized C1q (light blue) and background binding (purple) was investigated by ELISA using 
an anti-GFP antibody.  Standardized GFP positive lysates (~20000RFU/100µL) were preincubated (1:1) in 
blocking solution, thus 100µL input to each well correspond to ~10000RFU.  The integrity of the coat was 
confirmed using an anti-C1q antibody.    
B: Fusion peptide binding to C1q was determined by fluorescence measurement.  100µL standardized GFP 
positive lysates and GFP negative lysate were incubated with immobilized C1q.  Following washing 
fluorescence was measured to reveal bound GFP fusion proteins.  Dilutions of commercially obtained GFP (red) 
were included as positive control.     
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5. Discussion  
Delivery of therapeutic macromolecules, gene therapy vectors and diagnostics to tissue may 
be hampered by endothelial or epithelial barriers.  In an effort to overcome this obstacle, 
delivery strategies exploiting innate trans-barrier transport mechanisms have been suggested.   
To explore the possibility of selecting peptides targeting human pIgR a selection procedure 
for isolating human SC binding phages was developed and phages binding to SC were 
investigated for pIgR dependent transcytosis.   
 
The isolated phage clone C9-4 was specifically transcytosed across MDCK cells expressing 
human pIgR.  This is comparable to what has recently been reported by others on peptide 
targeted transport of intact phage particles across receptor expressing MDCK cells.  A 9-mer 
phage peptide with an integrin binding motif has been demonstrated to yield 1000 to 10,000-
fold improved transport compared to a control phage without the fusion peptide in basolateral 
to apical transport across MDCK cells (Ivanenkov and Menon, 2000).  Likewise, peptides 
selected from a 20-mer and a 40-mer peptide phage display library by in vitro transcytosis 
across rabbit pIgR transfected MDCK cells, revealed increased transcytosis across receptor 
transfected cells compared to untransfected cells (White and Capra, 2002).  One of the 
selected phages, displaying a peptide of 40 amino acids, was shown to be transported in vivo 
in a rat model measuring hepatic bile transport (White and Capra, 2002).  Furthermore, GFP 
fusion proteins comprising peptides selected for pIgR binding from a IgA gene fragment 
library (Hexham et al., 1999) were shown to be specifically transcytosed across pIgR 
transfected MDCK cells (White and Capra, 2002).    
 
To identify short novel peptides with capacity to target human pIgR, a 7-mer and Cys9 phage 
display library were subjected to two rounds of affinity selection and single clone screening 
for binding to human SC purified from colostrum.  For the 7-mer library a SC specific 5-fold 
increase in recovery from the first round of selection to the second selection round was seen 
when using SKM as blocking agent, indicating enrichment in the phage pool for SC binding 
clones.  However, as an ELISA assay failed to confirm the presence of SC binding phages in 
the amplified second eluates, no attempt were made to screen for individual target binding 
clones.   
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Considering that only ~20 copies of each phage were added to the first round of selection, it 
would be of interest to investigate whether consecutive rounds of selection and / or altered 
selection conditions (i.e. stringency) would have given a clearer trend of enrichment.   
 
Regarding the Cys9 library, approximately 280 copies of each phage clone were present in the 
initial round of affinity selection. The peptides are expected to fold into a more rigid 
conformation due to disulfide bridge formation.  This has proven to be advantageous when 
screening for high affinity target binding peptides (McLafferty et al., 1993, review; O'Neil et 
al., 1992).  Despite the fact that no enrichment was indicated by the recovery rate after two 
rounds of selection, an ELISA assay revealed the presence of detectable amounts of SC 
binding phage in the amplified Cys9 second round eluates.  When using BSA as blocking 
agent, significant background binding was observed indicating enrichment of BSA or plastic 
binding phage particles.  No such background binding was observed for eluates derived from 
selections using SKM as blocking reagent.  Cross-blocking with SKM demonstrated that the 
amplified Cys9 eluates, derived from selections using BSA as blocking agent, in fact contain 
some specific SC binding phages.  Although, SKM reduced the signal for specific target 
binding, SKM seemed to be the better choice of blocking agent with regard to recovery of 
specific binders.  
 
Automation of phage display library selection and high throughput screening has proven 
useful in the study of receptor ligand interactions and has resulted in the identification of a 
broad array of novel peptides and engineered proteins (Hallborn and Carlsson, 2002, review; 
Krebs et al., 2001; Sidhu et al., 2003).  Single clones were successfully propagated in high 
throughput compatible deep well growth plates.  Increased evaporation from the outermost 
wells was observed, but all wells appeared to produce cultures of approximately equal 
density.  A BioWorks script (Appendix 1) designed to direct the Biomek2000 robot to aliquot 
phage supernatants was tested and could be further developed to be included in a high 
throughput phage display screening protocol.   
 
352 single clones were screened for binding to immobilized SC by ELISA.  Clones, positive 
in the initial high throughput screening were re-screened to confirm specific target binding.  
The confirmative ELISA revealed that all, but two, of the 43 clones selected for re-screening 
bound specifically to SC rather than the background.  7 different sequences were identified 
amongst the SC specific clones.   
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Only two of these, CIIVPHAYAWC and CVVWMGFQQVC, encoded 9-mer peptides flanked by 
cysteins.  CIIVPHAYAWC was recovered six times from individual clones originating from the 
second round of selection using SKM as blocking reagent.  CVVWMGFQQVC, isolated 13 
times from separate clones, was found amongst positive clones after both the first and second 
round of selection using SKM as blocking agent.  Interestingly, this dominating sequence 
turned out to be identical to clone C9-4, previously identified by Braathen et al., (unpublished 
data) using the same Cys9 library.  C9-4 was used as a positive control phage in the screening 
procedures.  Thus, it can not be excluded that its re-occurrence may be due to contamination.  
However, the re-isolation may also indicate that the sequence is one of the better SC binders 
in the library, if not the best, thus it should be expected to dominate.   
 
A 14-mer peptide CALVSEAGCLVWAA named ASR, deviating from the expected cystein 
constrained 9-mer sequence, was identified 20 times amongst phages originating from all 
amplified eluates.  All of the three described sequences contain two cysteins.  The four 
different 7-mer peptides RFWWGWY, PFVVLLV, RGPFVYM and GWAGWLG each isolated only 
once are likely to be contaminants originating from the 7-mer library used in parallel to the 
Cys9 library.  Two selected clones were negative for SC binding in the confirmative SC 
binding ELISA; these were identified to be the latter two of the 7-mer contaminants. 
 
The Cys9 library  (Lauvrak et al., 2003) has previously been the source of a number of 
different peptides with clear consensus motifs covering a stretch of four to six amino acids 
when using monoclonal antibodies as target in selection (Lauvrak et al., 2003).  However, 
when using SC (this work and Braathen et al., unpublished) and FcγRI (Berntzen et.al, 
unpublished) as target no consensus motifs were found among the target binding clones.  The 
library size was estimated to 5 x 107 different clones, which represents only a fraction of all 
theoretically possible 9-mer peptides.  A Cys6 library of the same size gave consensus motifs 
involving more than five different peptides and five out of the six amino acids for peptides 
binding to FcγRI and FcγRIIa (Berntzen et al., unpublished).  No SC binding sequence with 
consensus motifs of only six amino acids could be isolated from the same Cys6 library 
(Braathen et al., unpublished).  Instead longer peptides, assumingly representing duplicates of 
inserts, were identified to have SC binding ability.  Thus, it seems likely that a SC binding 
consensus motif would involve stretches of more than four to six amino acids.  Notably, no 
consensus was observed amongst the 20-mer and 40-mer peptides isolated by White and 
Capra (2002) when targeting rabbit pIgR.   
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Approximately 109 different clones would be necessary to cover a complete presentation of all 
possible 6-mer sequences involving a NNK codon, as used for the libraries in this work. 
Considering the fact that random libraries can be constructed with diversities exceeding 109 
different sequences (Noren and Noren, 2001), our Cys9 library is relatively small.  This may 
potentially explain why not additional SC binding peptides were identified.  Screening of 
larger libraries might yield additional SC binding peptides with consensus motifs.      
 
Notably, IgA binds covalently to SC involving cysteines (Weicker and Underdown, 1975).  
The presence of cysteins in SC and the library may potentially lead to covalent disulfide 
interaction during the affinity selection procedure.  Thus, potentially strong SC binders may 
never have been recovered by acidic elution.  The presence of such peptides has not been 
confirmed.  However, infection by adding fresh host cells directly to the selection wells, as an 
alternative to acidic elution, might lead to the identification of such SC binding candidates.    
 
Alternative strategies to obtain SC binding peptides may include randomization between 
rounds of affinity selection.  This process mimics the affinity maturation seen for antibodies 
(Hawkins et al., 1992).  Based on the observation that no short, consensus motif containing 
peptides were not selected, the binding sites on SC might be very different from the hyper 
variable regions of an antibody with its protruding CDR loops.  Thus, to increase affinity the 
surface area available for receptor interaction can be expanded by adding randomized NNK 
codons both N- and /or C-terminally to a promising peptide candidate.  Another approach 
could be the use of cells transfected with pIgR as solid phase in the affinity selection.  
Selection directly on cells allows for a native presentation of the receptor, thus additional 
binding sites may occur.  Subsequent labeling for bound phage particles, cell sorting and host 
cell infection may lead to the identification of additional pIgR binding peptides not identified 
by means of classical selection in plastic wells.  Yet another potential method is the selection 
of pIgR binding peptides, and screening of such, by transcytosis across pIgR transfected 
polarized cells.  This allows for direct recovery of receptor binding phage from the apical side 
of the cell growth chamber.  Selection by transcytosis would be highly relevant in our work, 
as our aim is to select peptides that are transported across epithelia.  This method was 
successfully used by White and Capra (2002) to obtain SC binding peptides, 20 and 40 amino 
acids of length, from random libraries.    
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The SC binding capacity of the two most dominating phages, in terms of number of identical 
clones isolated, C9-4 (CVVWMGFQQVC) and ASR (CALVSEAGCLVWAA), were investigated in 
a target binding inhibition assay (figure 4).  The dIgA and pIgM interaction with SC has been 
characterized in detail and the N-terminal domain 1 of pIgR has been demonstrated to be the 
dIgA and pIgM binding domain (Bakos et al., 1994).  Furthermore, amino acids 402-410 
(QEPSQGTTT) of domain Cα3 of IgA has been suggested to be critical for pIgR binding 
(Hexham et al., 1999).  In addition, the J-chain has been confirmed to be of importance in the 
binding of pIgs to their receptor and thus formation of secretory Abs (Johansen et al., 2001).  
Accordingly, to map whether C9-4 and ASR interact with SC at a binding site utilized by 
pIgs, phage binding was attempted hampered by addition of dIgA and pIgM.  Binding of C9-4 
or ASR to immobilized SC is not affected by polymeric Igs, indicating that the selected 
phages do not bind to SC at the same site or at overlapping sites as those utilized by pIgM or 
sIgA.   
 
The virulence factor SpsA of S. pneumonia, has been demonstrated to bind sIgA and fSC 
(Hammerschmidt et al., 1997).  The interaction has been demonstrated to be specific for the 
human pIgR (Hammerschmidt et al., 2000) and recent work has demonstrated that domains 
D3 and D4 of human pIgR together are necessary and sufficient for SpsA binding (Elm et al., 
accepted for publication; Lu et al., 2003).  SpsA hexapeptide (YRNYPT), located between 
amino acids 198 and 203, and in particular the highly conserved YPT motif, has been 
demonstrated to be of critical importance for pIgR binding.  However, the recent results from 
Lu et al., strongly suggests that the SpsA binding motif(s) on pIgR is of conformational 
nature, indicating the involvement of more than the YPT motif in the receptor-ligand 
interaction.  Three fragments of SpsA were applied as inhibitors.  Approximately 10 nM of 
the SpsA fragments SH2 and SM1 reduced SC binding by 50% (A405 value reduction), 
whereas the SC negative SpsA fragment, SH3, did not interfere with the binding, suggesting 
that C9-4 binds SC in a SpsA like manner.  C9-4 does not contain an YPT motif, indicating 
that the binding site utilized by SpsA and C9-4 is not identical.  However, the observation that 
C9-4 binding to SC clearly is inhibited by SpsA suggests that the binding sites overlap to 
some extent or potentially that occupation of one of the bindings sites renders the other 
unavailable due to sterical hindrance or conformational change.  C9-4 binding to series of 
human/murine chimeras of pIgR may further elucidate how and where C9-4 binds to SC 
(work in progress).  ASR binding to SC was not affected by any of the applied inhibitors, 
indicating that the phage binds SC at a site not utilized by polymeric Igs or by SpsA.   
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C9-4 and ASR’s ability to bind SC, when presented in a more native configuration 
basolaterally on MDCK cells, and their ability to be transcytosed across this in vitro epithelial 
model was examined to asses their prospects for use in mucosal targeting.  To reveal whether 
the phage-receptor interaction, like the SpsA-pIgR interaction, is species specific both murine 
and human SC were included in the transcytosis experiments.  We demonstrate that C9-4 is 
specifically transcytosed across MDCK cells transfected with the human pIgR only.  
Accordingly, C9-4 interacts with SC in a species dependent manner despite considerable 
amino acid homology (55%) between the human and murine receptor (Hammerschmidt et al., 
2000; Zhang et al., 2000), adding further similarities to the list of traits shared with SpsA.  
The fact that untransfected MDCK cells are unable to mediate C9-4 transcytosis strongly 
suggests that the pIgR mediated transcytosis is the actual transport mechanism in action.  No 
receptor specific transfer of ASR across polarized MDCK cells was seen.  Whether this is due 
to lack of SC binding in the cellular assay or is caused by some other unknown limitation has 
not been examined.   
 
The contribution of each individual amino acid on peptide binding to SC was examined by 
substitution mutation analysis.  Flanking cysteins were substituted with serine whereas the 
remaining amino acids were systematically substituted with alanine.  Alanine substitution 
does not interfere with the protein backbone, making it a suitable tool for studying receptor-
ligand interaction, protein function and protein stability (reviewed in Morrison and Weiss, 
2001).  Serine substitution of cysteine implicates the loss of ability to form disulfide bridges, 
thus the mutants are expected to lack a rigid conformation, potentially of importance for 
binding capacity.  All mutants, but three, completely lost their ability to bind SC in an ELISA 
detectable manner.  Mutant AS-V3A provided an A405 readout signal approximately 40% of 
the signal seen for the positive control, C9-4.  Furthermore, mutant AS-G6A binding to SC 
gave a signal approximately 70% of the signal seen for the positive control and AS-Q9A gave 
a SC binding signal identical to that of C9-4.  Elution-titration, performed in parallel to the 
ELISA, revealed the same tendency.  However, this assay revealed that all C9-4 amino acid 
substitution mutants did bind SC slightly better than an irrelevant phage.  Furthermore a 
difference between C9-4 and AS-Q9A not observed with the ELISA assay was uncovered, as 
recovery for AS-Q9A was only 60% of the yield seen for C9-4 wild type phage.  A larger 
difference in recovery rates for AS-V3A and AS-G6A was seen than would have been 
expected from the ELISA results.  Only 1.5% and 2% of the recovery seen for C9-4 was 
observed for AS-V3A and AS-G6A, respectively.   
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Thus, the elution-titration study has higher resolution than the ELISA assay.  The reported 
variation in ELISA signal and phage recovery can not be accounted for by considering a slight 
difference of amount of input phage only, thus the variation is likely to be due to the 
functionality of the peptides.  Alanine for valine substitution as in AS-V3A implicates the 
substitution of CH(CH3)2 for a CH3 side chain.  These are both nonpolar, hydrophobic side 
chains and both amino acids are likely to cluster together on the inside of a structurally 
constrained polypeptide.  Consequently, the reported substitution was likely not to affect the 
overall structure of the peptide.  Notably, a substitution of V in position 2 and 9 was not 
tolerated, indicating that the more hydrophobic nature of V relative to A at these positions 
might be of more importance than in position 3.  Alanine for glycine substitution implies the 
removal of a CH3 group in favour of a simple H atom.  Glycine lacks a functional side chain 
group and is not expected to energetically contribute to the interaction, but might be of great 
importance for the structure.  Substitution of the uncharged, polar side chain of glutamine 
(CH)2CONH2 with a non-polar CH3 group implicates the removal of a charged protruding, 
slightly hydrophilic amino acid in exchange for a small hydrophobic one.  Consequently, 
when such a mutation does not affect the peptides ability to bind SC in a serious manner, the 
amino acid can not be directly involved in the interaction.  Mutants AS-C1S, AS-C11S and 
the double mutant AS-C1SC11S did not bind SC, suggests an important role of disulphide 
bridge formation on C9-4 binding to SC.  The apparent requirement for cysteines suggests 
that C9-4 folds into a restrained tertiary structure and that this cysteine constrained 
conformation is essential for target binding. 
 
A synthetic version of the gpIII presented C9-4 peptide inhibits binding of C9-4 phage to 
immobilized SC.  20nM (0.3µg/mL) of synthetic C9-4 reduced phage binding to SC by 50%,    
indicating that the peptide binds its target with remarkably high affinity (Braathen et al., 
unpublished).  It should be noted that the nature of the inhibitor, in terms of whether it is 
present as monomeric peptide or multimeric aggregate, has not been established.  Thus, the 
results must be interpreted with this in mind.   
 
To investigate whether C9-4 retained its SC binding capacity when shifted from the 
multimeric gpIII phage fusion format to a different fusion context, N-terminal GFP fusions 
were constructed and the fusion proteins ability to bind SC was examined.  We aimed at 
constructing a monomeric fusion protein and a C9-4 dimer-GFP fusion.  The dimer was 
included as a dimerization might potentially cause increased avidity for the target.   
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GFP fusions are frequently constructed with a spacer sequence between the auto fluorescent 
protein and its fusion partner (Cubitt et al., 1995).  We opted for a flexible spacer with ability 
to form kinks to make sure C9-4 was protruding away from its much bigger fusion partner 
(238aa), thus a spacer based on the GGGGGGPG-sequence used by White and Capra (2002) 
was chosen.  The two C9-4 peptides making up the dimmer fusion protein were inter-
connected by a linker sequence almost identical to the applied spacer sequence.  The choice of 
linker and spacer length was limited by the chosen cloning strategy.  To limit the length of the 
synthetic oligonucleotides, a GGPG sequence was inserted between GFP and C9-4 whereas 
GGGPG was inserted between the two C9-4 monomers.  We did not succeed in producing a 
C9-4 dimer fusion to GFP.  The C9-4-Dimer-GFP fusion construct was confirmed to carry 
two deletion mutations, consequently leading to a frame shift mutation.  Although we initially 
feared the formation of secondary structures on the very long mutagenic oligonucleotides, 
such a structure can not explain the deletion of two single nucleotides separated by 17 
perfectly incorporated nucleotides.  Alternative mutagenesis in one or more steps would most 
certainly correct the reported errors.  However, such an approach was not attempted and the 
construction of a C9-4 dimer fusion was put to an end.    
 
Crude lysates containing C9-4-Mono-GFP and control GFP fusion proteins was successfully 
obtained (figures 7, 8 and 9).  In an effort to purify the GFP containing lysates, the use of 
ammonium sulphate precipitation was examined.  At 30% E.coli proteins started to 
precipitate.  Increasingly higher Coomassie staining intensity was seen for lysate aliquots 
added 40% and 50% of ammonium sulphate, respectively.  Although no specific precipitation 
of the 27kDa sized GFP was observed, it may be possible to fine tune the precipitation 
conditions in order to obtain a GFP enriched fraction to be further purified by other means 
such as gel filtration.  Alternatively, other approaches, such as heat denaturation and removal 
of coagulated E.coli proteins, can be tried as GFP is reported to tolerate heating to 78oC 
before a 50% loss of fluorescence is seen (Tsien, 1998, review).  Thus, E.coli proteins that 
denatures and coagulates at temperatures lower than that of GFP might be removed from the 
cell lysates by centrifugation.  Yet another possibility lies in the unique structure of GFP that 
allows for isolation of the active fluorescent protein directly from the crude cellular sources 
by extraction with organic solvents (Skosyrev et al., 2003).  White and Capra (2002), reported 
to use crude cell lystate with GFP fusion proteins in their pIgR targeting study.   
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To estimate the amount of functional GFP in the lysates, dilutions of fusion protein lysate was 
compared with dilutions of commercially obtained GFP of known concentration.  The 
concentration determination was hampered by the prize of GFP.  Consequently an insufficient 
amount of GFP with known concentration was obtained.  As a result the standard dilution 
failed to reach a linear phase.  As C9-4-Mono-GFP reached the lowest fluorescence intensity 
level (~20,000 RFU), corresponding to approximately 10µg/mL of commercial GFP), control 
lysates were adjusted accordingly (figure 11).   
 
We were unable to detect C9-4-Mono-GFP binding to immobilized SC by ELISA or direct 
fluorescence measurement (figure 12).  It is reasonable to speculate that the lack of binding 
may be caused by too low affinity for the target.  It should be noted that GFP tend to form 
dimers spontaneously (Tsien, 1998, review).  The contribution of this property on multivalent 
peptide display has not been studied, neither has the potential presence of GFP dimers in the 
lysates been examined.  The lack of target binding may also be caused by improper peptide 
folding or accessibility.  The integrity of the fusion peptide was not inspected, thus it is not 
known whether the C9-4 peptide is actually present on the larger GFP molecule that we 
screened for.  This could have been analyzed by N-terminal protein sequencing, which would 
have required a purification step.  Yet another concern is the concentration of functional GFP-
fusion peptide.  The highest available concentration of the fusion protein was applied, thus 
purification and up concentration would potentially reveal the answer to this question.   
 
A C1q binding peptide, identified by phage display (Bremnes et al., 1998), was applied as a 
negative control in the SC binding experiments.  In elution-titration studies, phage particles 
displaying the control peptide were shown to yield recovery rates for C1q binding 
approximately 10-fold higher than what we observed for C9-4 (results not shown).  Thus the 
avidity of the peptide on phage for its target seems to be higher for this peptide than observed 
for C9-4 and SC.  Moreover, this peptide had previously been demonstrated to retain C1q 
binding capacity as Fab- and scFv fusions (Lunde et al., 2002).  Accordingly, the chosen 
peptide was selected to serve as an overall system control to reveal the possibility of shifting 
peptides to GFP and still see target binding.  As we successfully demonstrated that the control 
GFP fusion, C1qC10-Mono-GFP, did bind immobilized C1q in a manner detectable by both 
ELISA and fluorescence measurement the system worked.  Thus the lack of C9-4 binding to 
SC could be due to low affinity, low availability or both.   
 
 106
A synthetic version of C9-4 conjugated to biotin was made.  This version of the peptide did 
not dissolve in water (not shown).  Solubilisation at high concentration in DMSO and 
subsequent dilutions in an adequate buffer might solve the problem.  Specific transcytosis of 
the biotinylated peptide, or multimers thereof (e.g. aggregation by streptavidin binding), 
across pIgR transfected MDCK cells might reveal whether the identified sequence has the 
potential to target mucosa when removed from the phage display context.     
 
In conclusion:  Five phage display peptides binding to human SC were isolated.  One of these 
peptides was shown to specifically bind human SC in a SpsA like manner.  Phages displaying 
this peptide are specifically transcytosed across MDCK cells expressing human pIgR.  This 
demonstrates that the scenario of using phage display derived peptides in mucosal targeting is 
achievable.  However, as a GFP fusion of the peptide did not lead to detectable SC binding, 
further work needs to be done to identify a general pIgR targeting peptide.  
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7.  Appendix   
 
• Appendix 1  
BioWorks scripts for Biomek 2000 liquid handler designed for semi-automated 
sample handling and enhanced throughput.   
• Appendix 2  
Abi files, presenting the sequences of peptides recovered from Cys9 affinity 
selection for SC binders. 
• Appendix 3  
Abi files, confirming the systematic alanine- and serine substitution of amino acids 
of peptide C9-4. 
• Appendix 4  
Abi files, presenting the sequences of the constructed GFP fusion peptides 
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Appendix 1 
 
Three scripts, instructing Biomek 2000 (Beckman Coulter) to set up a PCR reaction, to 
aliqoute phage supernatnat and to run an ELISA, repectively, were designed for semi-
automated sample handling and incrased throughput. 
 
Script 1 
BioWorks script giving Biomek 2000 instructions to pipete phage supernatant and a  PCR mix 
to a PCR reaction plate.  The figure also include the configuration of the Biomek 2000 
workbench surface.  This program was designed and used to set up the PCR reaction applied 
for production of sequencing templates of affinity selected phage single clones in a semi-
automated fashion. 
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Script 2 
BioWorks script giving Biomek 2000 instructions to pipete phage supernatant from a deep 
well culture growth plate and aliqoute it to 200µL V-bottom storage plates.  The figure also 
include the configuration of the Biomek 2000 workbench surface.  This program was 
designed to allow for semi automated handeling of supernatant from large numbers of 
selected phage single clones.  The procedure was not implemented byond test runnings. 
 
 114
Script 3 
BioWorks script giving Biomek 2000 instructions to set up a phage single clone ELISA.  The 
figure also include the configuration of the Biomek 2000 workbench surface.  This program 
was designed for robotic pipeting aid when screening phage single cones for target binding.  
ELISA plates were precoated. Only half of the actual script is shown her.  The procedure was 
not implemented due to technical difficulties with the whashing tool. 
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Appendix 2 
 
Abi files showing the sequence of the peptides displayed by phage recovered from the affinity 
selection procedure as presented in table 5.  The sequence of interest is flanked by SfiI 
restriction sites (GGGGCC).  
 
 
Amino acid sequence:  CALVSEAGCLVWAA 
Comment:  The sequence has some unexpected features.  G829 is represented by a somewhat 
low peak.  If this is a “false” nucleotide, the sequence will harbor a TAG (Stop) codon prior to 
the expected final amino acid, TGT (Cystein).  This appears to be unlikely.  However the 
phage is clearly infectious, thus the peptide seems to be a 14-mer inframe without the cystein 
constriction.  This sequence was given the name ASR.      
 
 
 
Amino acid sequence:  CVVWMGFQQVC   
Comment:  This sequence is identical to the previously identified clone named C9-4. 
 
 
 
Amino acid sequence:   PFVVLLV 
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Comment:  This is an unconstrained 7-mer peptide.  Most likely a contaminant from the 
library screened in parallel to the Cys9 library. 
 
Amino acid sequence:  RGPFVYM   
Comment:  This is an unconstrained 7-mer peptide.  Most likely a contaminant from the 
library screened in parallel to the Cys9 library.  This phage tested negative for SC binding in a 
confirmative ELISA. 
 
 
Amino acid sequence:  RFWWGWY 
Comment:  This is an unconstrained 7-mer peptide.  Most likely a contaminant from the 
library screened in parallel to the Cys9 library.   
 
 
Amino acid sequence: CIIVPHAYAWC  
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Amino acid sequence:  GWAGWLG 
Comment:  This is an unconstrained 7-mer peptide.  Most likely a contaminant from the 
library screened in parallel to the Cys9 library. This phage tested negative for SC binding in a 
confirmative ELISA. 
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Appendix 3 
 
Abi files confirming the sequences of the peptide encoding inserts in the amino acid 
substitution mutation analysis.  The sequence of interest is flanked by SfiI restriction sites 
(GGGGCC).  Serine substitutions are given in blue, whereas alanine substitutions are 
highlighted in red.   
 
The prefix “AS” of the mutant’s name conveniently means both “Amino acid Substitution” 
and “Anders Sandvik”.   
 
AS-C1S  
 
AGC GTG GTT TGG ATG GGT TTT CAG CAG GTG TGT  
 
 
AS-V2A  
 
TGT GCA GTT TGG ATG GGT TTT CAG CAG GTG TGT  
 
 
AS-V3A  
 
TGT GTG GCA TGG ATG GGT TTT CAG CAG GTG TGT 
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AS-W4A 
 
TGT GTG GTT GCA ATG GGT TTT CAG CAG GTG TGT  
 
 
 
AS-M5A 
 
TGT GTG GTT TGG GCA GGT TTT CAG CAG GTG TGT  
 
 
 
AS-G6A 
 
TGT GTG GTT TGG ATG GCA TTT CAG CAG GTG TGT 
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AS-F7A  
 
TGT GTG GTT TGG ATG GGT GCA CAG CAG GTG TGT  
 
 
AS-Q8A  
 
TGT GTG GTT TGG ATG GGT TTT GCA CAG GTG TGT 
 
 
AS-Q9A  
 
TGT GTG GTT TGG ATG GGT TTT CAG GCA GTG TGT  
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AS-V10A  
 
TGT GTG GTT TGG ATG GGT TTT CAG CAG GCA TGT  
 
 
AS-C11S  
 
TGT GTG GTT TGG ATG GGT TTT CAG CAG GTG AGC  
 
 
AS-C1SC11S  
 
AGC GTG GTT TGG ATG GGT TTT CAG CAG GTG AGC  
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Appendix 4 
 
Abi files presenting the detailed sequencing data from the GFP fusion work. 
The sequences of interest are limited by NcoI (CˇCATGG) and XhoI (CˇTCGAG) restriction 
sites N-terminally and C-terminally, respectively. 
 
 
GFP without fusion peptide (GFP) 
Comment:  NcoI cuts at position 60 and the first codon of GFP (GTG) starts at position 64.  
The GFP gene is terminated at position 787 with the XhoI restriction site.  
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C9-4-Mono-GFP 
Comment:  NcoI cuts at position 58 and the first codon of the SC binding peptide (TGT) starts 
at position 69.  The GFP gene starts at (GTG) position 114 and is terminated at position 
834with the XhoI restriction site.   
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C9-4-Dimer-GFP 
Comment: NcoI cuts at position 19 and the first codon of the first monomer of the SC binding 
peptide (TGT) starts at position 28.  At positions 61 and 68, the sequence diverges from the 
expected one by lacking a G in each position.  Consequently a frame shift mutation arises.  
Note that this insert was sequenced from both ends using primers T7 and pET-RP.  The 
sequence obtained using pET-RP has been inverted to enable 5’ to 3’ reading for the complete 
sequence.  The GFP gene starts at (GTG) position 119 on the T7 sequence.  The GFP gene is 
terminated at position 876 on the pET-RP sequence with the XhoI restriction site.  The 
sequences overlap to produce the complete C9-4-Dimer-GFP sequence.  The thymine (T) at 
position 700 on the T7 sequence corresponds to the thymine in position 739 of the pET-RP 
sequence. 
 
T7 sequencing: 
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 129
 
 
 
pET-RP sequencing: 
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C1qC10-Mono-GFP 
Comment:  NcoI cuts at position 43 and the first codon of the C1q binding peptide (TGT) 
starts at position 53.  The GFP gene starts at (GTG) position 101 and is terminated at position 
820 with the XhoI restriction site.    
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